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Patients, especially those older than 65-years-old, do not receive adequate 
assessment or management of atrial fibrillation, resulting in higher ischemic stroke rates 
and worse outcomes related to strokes.  Oral anticoagulation is recommended indefinitely 
for patients with atrial fibrillation and a moderate to high risk of stroke; yet this 
population is not receiving oral anticoagulation consistently.  Factors such as 
overexaggerated bleeding risk in the elderly, the lack of head-to-head studies comparing 
anticoagulants, cost, patient compliance, safety, lab monitoring, and reversal agents 
convolute the process of prescribing anticoagulation for atrial fibrillation.  Variations 
exist with assessing bleeding risk and stroke risk for every patient through reliable tools 
such as HAS-BLED and CHA2DS2-VASc scores, respectively, and translating these 
scores into practice.  Due to these inconsistencies and the lack of a comprehensive, 
universal guideline for assessment and management of atrial fibrillation, this topic was 
selected for a capstone project.   
A retrospective chart review was completed on 100 patients to assess the current 
practice of diagnosing atrial fibrillation and treating with anticoagulation in the primary 
care setting.  Through utilization of two rounds of the Delphi method, expert opinion, and 
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the recommendations of national and international guidelines, an evidence-based 
anticoagulation toolkit was created and modified to guide primary care providers on 
improving diagnosis of atrial fibrillation and enhanced initiation and maintenance of oral 
anticoagulation to reduce the incidence of stroke in elderly patients with atrial fibrillation.  
The Anticoagulation for Atrial Fibrillation Toolkit is a four-step, simplified guideline to 
guide providers on improved diagnosis and treatment of AF; it is supported by four 
algorithms: CHA2DS-VASc score, HAS-BLED score, comparison of anticoagulants, and 
patient specific factors influencing selection of anticoagulant.  Additionally, this toolkit 
offers in one document a summary of additional information and resources for providers 
to improve the overall management of atrial fibrillation.  The chart reviews demonstrated 
gaps between evidence and practice, predominantly a lack of utilization of CHA2DS2-
VASc and HAS-BLED scores to assess for stroke and bleeding risk, respectively, in 
patients with atrial fibrillation, poor continued monitoring of AF in the primary care 
setting, a disconnect between the treatment plan and providers, and the absence of 
consistently diagnosing an irregular pulse as AF through an EKG.    
Round 1 of the Delphi survey assessed providers’ comfort level and expertise 
with prescribing anticoagulants and diagnosing and managing AF and Round 2 evaluated 
the anticoagulation toolkit and how its incorporation could influence practice.  Results 
from Round 1 were utilized to revise the evidence-based anticoagulation toolkit; data 
analysis concluded 70% consensus was achieved on at least 6 of the 10 questions.  Even 
without 70% consensus, the researcher incorporated provider expertise, suggestions, and 
requests into the anticoagulation toolkit.  In Round 2, data analysis of greater than 70% 
consensus suggested the Anticoagulation for Atrial Fibrillation Toolkit was evidence-
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based, user-friendly, promoted safety and efficacy of anticoagulation, and could 
positively impact practice; however, the toolkit was too extensive and lengthy.  
A thorough evaluation concluded this capstone project successfully addressed the 
following problem statement: In adult patients with atrial fibrillation older than 65 years 
old and a moderate to high risk of stroke, how effective is an anticoagulation toolkit in 
guiding primary care providers on (a) diagnosing atrial fibrillation and (b) initiating and 
maintaining oral anticoagulation safely, to reduce the incidence of ischemic stroke?  The 
comprehensive literature review not only provided extensive background information on 
atrial fibrillation and anticoagulation but also highlighted key references to first compare 
evidence to practice (analyze patient chart reviews) and then utilize these identified gaps 
to translate evidence into practice (create the anticoagulation toolkit).  Furthermore, the 
PARIHS framework and RE-AIM model evaluated the ability to effectively facilitate the 
results from this research project into practice.  Additionally, this capstone project met all 
five criteria of the EC as PIE model, concluding this was a successful Doctor of Nursing 
Practice capstone project.  A future extension of this project suggests evaluation of 
patient outcomes with AF, predominantly stroke incidence, subsequent to implementation 
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Background and Significance of Project 
Background 
Atrial fibrillation (AF) is the most frequent cardiac arrhythmia, affecting 
approximately 2.7 to 6.1 million people in the United States (Centers for Disease Control 
and Prevention [CDC], 2015).  The American Heart Association (AHA) in 2015 released 
the alarming estimate of the incidence of this disease increasing to 5.6 to 12 million 
people by the year 2050, influenced by the large aging population and its expanding 
cardiovascular risk factors and comorbidities (Desai, El-Chami, Leon, & Merchant, 
2017).  Atrial fibrillation is present in 0.5% of Americans less than 40 years old, 5% of 
the population older than age 65, and 10% in persons 80 years of age or older (Desai et 
al., 2017).  Likewise, the American College of Cardiology (ACC; Doherty et al., 2017) 
predicted AF prevalence in 18% of the population older than 85 years old.  One in four 
patients age 40 or older will develop atrial fibrillation with an estimated 16 million 
Americans diagnosed with AF by 2050 (You et al., 2012).  Internationally, stroke caused 
by AF is most prevalent within the United States and Europe and least prevalent within 
Latin America, revealing a higher incidence in persons older than 75 years old and 
female.  Globally, AF is predominantly diagnosed through a health history or captured on 
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an electrocardiogram with few patients receiving cardiac monitoring post stroke to assess 
for AF (Perera et al., 2016).   
Negative Outcomes of Atrial  
Fibrillation 
Negative outcomes with AF are related to a decrease in cardiac output, resulting 
in the symptoms experienced in patients as well as the formation of thrombi in the atria 
and atrial appendages.  Thrombi substantially increase the risk of strokes and 
embolization in the periphery (Kumar, 2016b).  Atrial fibrillation results in 750,000 
hospitalizations annually and 130,000 deaths in the United States with death rates 
increasing exponentially for the past 20 years.  In Colorado alone, as many as 77.12 per 
1,000 people ages 65 and older were hospitalized from 2007 to 2012 related to AF (CDC, 
2015).  Overall costs for this chronic disease are greater than $6 billion annually in the 
United States with healthcare costs attributed solely to atrial fibrillation costing an extra 
$8,705 per patient annually (CDC, 2015).  According to the cost of clot model (Janssen, 
2014d), in a hypothetical situation of 1,000 patients with AF at a high risk of stroke, 
increasing prescription of anticoagulation by 10% would decrease the cost of strokes by 
$258,554 and increase the cost of extracranial bleeds by $1,732 and intracranial bleeds by 
$21,157, overall reducing healthcare costs by $235,666. 
Stroke risk. The stroke rate increases four to five times with AF as well as the 
severity of stroke complications as AF is the predominant cause of 15-20% of ischemic 
strokes (CDC, 2015).  Of significance, patients are unaware of the devastating effects of 
AF; only 50% believe they are at risk for a stroke with AF with 43% voicing concerns of 
developing heart disease as the predominant negative outcome of AF rather the 8% with 
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stroke.  Approximately 86% of patients feel they can explain the definition a stroke but 
only 61% correctly comprehend the disease implications (AHA, n.d.).  
Women diagnosed with atrial fibrillation have a two-fold increased risk of 
mortality compared to a 1.5-fold increased risk in men, predominantly as a cause of 
stroke, sudden cardiac death, or heart failure.  Furthermore, left ventricular dysfunction is 
present in 20-30% of patients with atrial fibrillation.  Atrial fibrillation is a contributing 
factor to 20-30% of ischemic strokes.  Quality of life is diminished with AF even when 
cardiovascular components are removed as these patients suffer from increased 
depression, brain white matter lesions, cognitive decline, and vascular dementia 
compared to patients without AF.  Resulting from the aforementioned complications with 
AF, 10-40% of these patients are hospitalized annually.  This diagnosis is financially 
devastating for the economy, contributing to 1% of total healthcare costs within the 
United Kingdom and $6.0-26.0 billion dollars in the United States in 2008 alone 
(Kirchhof et al., 2016).  Atrial fibrillation is correlated with a five-fold enhanced risk of 
ischemic stroke with a 5% risk of stroke even in patients who are properly anticoagulated 
(You et al, 2012).  
Recommendations.  To reduce unnecessary healthcare costs and hospitalizations 
as well as improve quality of life, atrial fibrillation treatment focuses on stroke risk 
minimization and symptom management.  Guidelines and clinical recommendations for 
atrial fibrillation treatment are vast; yet the elderly population is not adequately included 
in research studies.  The primary cause of thromboembolic stroke is atrial fibrillation, 
demonstrating escalating prevalence and worse outcomes in correlation with increasing 
age.  In fact, the stroke risk with AF is heightened five-fold and is the culprit of 25% of 
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strokes in the older population (Desai et al., 2017).  The mortality rate is doubled with the 
combination of ischemic strokes and atrial fibrillation and the neurological sequelae tend 
to be more severe.  The American College of Cardiology and American Heart Associated 
have recommended atrial fibrillation patients with a CHA2DS2-VASc of 1 be treated 
prophylactically with anticoagulation to prevent ischemic strokes; a systematic review of 
evidence concluded all patients 65 years of age and older should be treated with 
anticoagulation to prevent strokes regardless of risk factors (Desai et al., 2017).   
Patients might require hospitalization for new onset atrial fibrillation, treatment 
for heart failure or hypotension after rate or rhythm control, starting antiarrhythmic drugs, 
symptomatic atrial fibrillation, or management of concurrent medical issues resulting in 
arrhythmia such as infection, chronic obstructive pulmonary disease exacerbation, 
hypertension, thyroid storm, or pulmonary embolism (Kumar, 2016b).  
Classification of Recommendations and 
Levels of Evidence 
The American Heart Association (AHA) and American Stroke Association (ASA; 
2016) evaluated the certainty of evidence-based recommendations upon the following 
taxonomies: Level A evidence is obtained from numerous meta-analyses and randomized 
clinical trials; Level B evidence is obtained from nonrandomized studies or one 
randomized study; and Level C evidence is based upon expert opinion, case studies, or 
standards of care.  The treatment effect size is classified by the following: the benefits of 
Class I evidence greatly outweigh the risks and treatment is recommended; the benefits of 
Class IIa evidence outweigh the risks and with reason treatment should be implemented; 
the benefits of Class IIb evidence outweigh the risks and treatment may be implemented; 
and the harms of Class III (harm) or Class III (no benefit) evidence outweigh the benefits 
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and treatment is not recommended.  These classifications and recommendations of 
evidence are illustrated in Figure 1 (January et al., 2014).  These same criteria to evaluate 
evidence are utilized by the European Society of Cardiology (ESC; Kirchhof et al., 2016) 
and the Heart Rhythm Society (HRS; January et al., 2014).  The American College of 
Chest Physicians (CHEST) evaluates the quality of evidence as follows: Grade A 
(strong), Grade B (moderate), and Grade C (low).  The evidence quality is incorporated 
into the overall recommendation for the evidence: Grade 1 (strong) and Grade 2 (weak; 
Kearon, et al., 2016).  The CHEST criteria to measure the quality of evidence is depicted 







Figure 1.  Classification of recommendations and levels of evidence.  
Adapted from January et al. (2014, p. 2249). Copyright 2014 by the American Heart 
Association Inc., the American College of Cardiology Foundation, and the Heart Rhythm 
Society. 
 
A recommendation with Level of Evidence B or C does not imply that the 
recommendation is weak. Many important clinical questions addressed  in the  guidelines  
do  not  lend  themselves to clinical trials. Although randomized trials are unavailable, 
there may be a very clear clinical consensus that a particular test or therapy is useful or 
effective. 
*Data available from clinical trials or registries about the usefulness/efficacy in different 
subpopulations, such as sex, age, history of diabetes mellitus, history of prior myocardial 
infarction, history of heart failure, and prior aspirin use. 
†For comparative-effectiveness recommendations (Class I and IIa; Level of Evidence A 
and B only), studies that support the use of comparator verbs should involve direct 




American College of Chest Physicians Guideline Classifications for Evaluating the 
Strength and Quality of Evidence  
 
Classification Strength of Evidence 
Grade 1 Strong 
Grade 2 Weak 
 Quality of Evidence 
Grade A High 
Grade B Moderate 
Grade C Low  
Note. Adapted from Kearon et al. (2016). Copyright 2016 by The American College of 




In 2010, an estimated 20.9 million men and 12.6 million women had atrial 
fibrillation with higher rates evident in developed countries.  Increasing incidence and 
prevalence of atrial fibrillation are attributed to improved diagnosis of the disease as well 
as rises in both the aging population and the following risk factors: heart failure, coronary 
artery disease, hypertension, diabetes mellitus, chronic kidney disease, obesity, and 
valvular heart disease.  In Europe, the incidence of AF is one in four adults with an 
estimated 120,000-215,000 new diagnoses by the year 2030 (Kirchhof et. al., 2016).   
In the Framingham Heart Study of 5,209 subjects, a 10-year follow-up 
demonstrated the mortality rate was higher in both men and women age 55- to 74-years- 
old with atrial fibrillation (Kumar, 2016b).  The incidence of AF is 9% in the elderly 
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above 65-years-old compared to 2% in people less than 65-years-old.  Atrial fibrillation is 
more prevalent in older women of European heritage (CDC, 2015); however, 
independent of age, the disease is generally more common in men (Kumar, 2016b).  The 
risk of death from AF in women is comparable to men; yet women exhibit more risk 
factors to stroke than men (especially increasing age) regardless of anticoagulation status. 
Furthermore, women tend to be more symptomatic with AF and utilize less rhythm 
control treatment.  Men and women both display similar bleeding risks from 
anticoagulation (Class IIa, Level of Evidence B; Kirchhof et al., 2016).   
Risk Factors 
Other than increasing age and sex, risk factors for AF include obesity, heart 
failure, diabetes, chronic kidney disease, hyperthyroidism, alcohol abuse, and left 
ventricular hypertrophy.  Additionally, hypertension is a prevalent factor in the etiology 
of 14 to 22% of atrial fibrillation patients (CDC, 2015) with coronary heart disease as 
another predominant contributing factor to disease onset (Ganz & Spragg, 2016).  The 
strongest predictive factor of an ischemic stroke is a prior stroke or transient ischemic 
attack (TIA) in addition to increasing age (65 years of age or older), diabetes mellitus, 
sex (women), and hypertension.  One-third of patients with AF have concurrent coronary 
artery disease (You et al., 2012).  Abnormal laboratory results increasing an AF patient’s 
risk of stroke include labile international normalized ratio (INR) levels, low time in 
therapeutic range (TTR) while on warfarin, anemia, prior hemorrhage, alcoholism, 
chronic kidney disease, elevated N-terminal pro-B-type natriuretic peptide, and high 
troponin T or I (Kirchhof et al., 2016).  Post coronary artery bypass graft or cardiac valve 




Atrial fibrillation can be asymptomatic, “silent” (Kirchhof et al., 2016), or can 
present with the following clinical manifestations: heart palpitations, dizziness, fatigue, 
shortness of breath (dyspnea), irregular heart rate, weakness, presyncope, chest pain 
(CDC, 2015; Kumar, 2016b), difficulty sleeping, or psychosocial distress (Kirchhof et al., 
2016).  Approximately 30% of AF patients present without symptoms; yet this population 
demonstrates a higher CHA2DS2-VASc score and thus a higher risk of stroke.  Of 
significance, over 20% of people with silent AF are not diagnosed until after their first 
stroke (Shahid, Shantsila, & Lip, 2016).   
Classifications of Atrial Fibrillation 
Atrial fibrillation can be paroxysmal (terminating in less than seven days 
spontaneously or with electrical cardioversion or medications); persistent (episodes 
lasting longer than seven days including those terminated through cardioversion); or 
long-standing persistent (episodes lasting up to one year, often indefinitely despite 
rhythm control; Kirchhof et al., 2016; Olshansky & Arora, 2016; Spragg & Kumar, 
2017).  Non-valvular atrial fibrillation (NVAF) includes patients with moderate to severe 
mitral stenosis and/or a prosthetic heart valve (Guimaraes, Kaatz, & Lopes, 2015).  Long-
standing persistent AF is synonymous with permanent AF according to other sources 
(You et al., 2012) or can be classified as long-standing persistent if the arrhythmia is 
controlled with a rhythm control strategy (Kirchhof et al., 2016).  With paroxysmal AF, 
the risk of stroke is smaller than with persistent or permanent AF (patients are typically 
younger with less risk factors); yet the risk is enhanced with the conversion of AF back to 
normal sinus rhythm (cardioversion; You et al., 2012).   
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As a result of the heightened risk of stroke regardless of the classification of atrial 
fibrillation, the same prevention strategies utilizing anticoagulation are recommended, 
especially since only 1 of 12 paroxysmal AF occurrences are symptomatic (You et al., 
2012).  In a patient with AF risk factors, the risk of stroke is comparable with a duration 
of AF greater than one year, independent of the type of AF.  Other data suggest patients 
with permanent AF have a heightened risk of stroke and mortality (4.2%) compared to 
paroxysmal AF (2.1%) and persistent AF (3.0%; Shahid et al., 2016).   
Severity of Atrial Fibrillation Scale 
The Severity of Atrial Fibrillation scale (SAF), adopted from the Canadian 
Cardiovascular Society Severity of Atrial Fibrillation Scale (CCS-SAF), accurately 
assesses patient symptoms, association of symptoms with atrial fibrillation, and the 
patient’s functionality (quality of life) by assigning the patient a score of 0 (asymptomatic 
Afib) to 4 (severe Afib; American College of Cardiology, 2012).  The CCS-SAF has 
proven validity in quantifying quality of life related to a diagnosis of AF (Dorian et al., 
2006, 2009).  The SAF can be found within the Anticoagulation for Atrial Fibrillation 
Toolkit in Appendix A.  Approximately 25-40% of atrial fibrillation patients display mild 
symptoms or are asymptomatic while 15-30% display severe symptoms.  The ESC also 
has a similar scale named Modified European Heart Rhythm Association (EHRA) 
symptom scale to assess for AF symptom severity (Class I, Level of Evidence C; 








Research has suggested early-onset AF is heritable with one-third of these 
patients exhibiting one or more of 14 genetic variants, better known as single nucleotide 
polymorphisms (SNPs), which increase the risk of disease.  The most well-known genetic 
variant is the Pitx2 (paired-like homeodomain transcription factor 2) on chromosome 
4q25, increasing the risk of AF seven-fold.  Carrying these genetic variants in the genome 
has also been associated with an augmented risk of ischemic stroke.  Theories on how 
these genetic variants influence the onset of AF include atrial remodeling, penetration of 
genetic defects, and transforming the action potential of the atrial cells (Shehab, Sperling, 
Kegler, & Budnitz, 2010).    
Clinical Pharmacogenetics Implementation  
Consortium 
As warfarin has a narrow therapeutic index and a vast inter-patient dosing 
variability to achieve a therapeutic INR, four genetic variants have been identified that 
contribute to 50% of the variability in warfarin dosing: CYP2C9, VKORC1, CYP4F2, 
and CYP2C cluster (rs12777823).  In 2016 The Clinical Pharmacogenetics 
Implementation Consortium (CPIC), part of the National Institute of Health’s 
Pharmacogenomics Research Network, examined peer-reviewed genetic and medication 
guidelines and updated the 2011 guideline on pharmacogenetics-guided warfarin dosing 
(Johnson et al., 2017).  Literature discovered negative sequelae from incorrect warfarin 
dosages was one of the most common adverse drug effects reported to the Food and Drug 
Administration (FDA; Johnson et. al., 2017), not to mention the cause of acute 
hemorrhage in 2.5 per 1,000 emergency room visits (Shehab et al., 2010).  Based upon 
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this systematic review of data, CPIC recommended pharmacogenetic warfarin dosing 
through an algorithm focusing on VKORC1 and CYP2C9 alleles and started loading 
doses of warfarin based on genetic calculations and ancestry (Johnson et al., 2017).   
The mechanism of action of warfarin is inhibition of the vitamin K epoxide 
reductase complex; when administered, warfarin is a racemic mixture composed of S-
warfarin (more potent) and R-warfarin (less potent).  Gene CYP2C9 is an enzyme within 
the cytochrome P450 family and metabolizes S-warfarin.  The normal allele, CYP2C9*1, 
results in normal metabolism of S-warfarin.  In patients with alleles CYP2C9*2 and 
CYP2C9*3, the metabolism of S-warfarin is decreased; thus, these patients display an 
increased risk of bleeding while on warfarin and should be prescribed a lower dose.  
Alleles CYP2C9*5, *6, *8, and *11 are more common in African Americans and are 
more prominent in the general population, also influencing the dosing variability of 
warfarin (Johnson et al., 2017).  The VKORC1 allele encodes the vitamin K epoxide 
reductase protein, inducing the change from vitamin-K epoxidase to vitamin K.  The 
genetic variant VKORC1 c-1639G>A is responsible for warfarin sensitivity and suggests 
a lower dose of warfarin is needed compared to the variant 1639G/G.  The VKORC1 
genetic variant influences the dosing of warfarin amongst those of Asian, Caucasian, and 
African American ancestry (Johnson et al., 2017).   
Benefits and Risks of Pharmacogenetic  
Testing for Warfarin  
Benefits of pharmacogenetic warfarin testing include reaching a stable INR within 
a shorter time frame and more consistently, which could potentially decrease the risk of 
hemorrhage from inappropriate warfarin dosing and the risk of thromboembolism.  Risks 
of this genetic testing include calculation of the wrong dose of warfarin based upon these 
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recommendations and calculating the incorrect genotype, which is a permanent 
component of the patient’s medical record, especially if not following recommendations 
specific to ancestry.  The cost-benefit ratio of warfarin genetic testing is controversial as 
stable international normalized ratios (INRs) can reduce costs related to INR testing itself 
and decrease negative sequalae of poorly managed warfarin dosing; yet the majority of 
insurance companies do not cover the costs of this testing.  Furthermore, randomized 
clinical trials of CYP2C9 and VKORC1 alleles have not demonstrated reliable results and 
do not support the definitive benefits of genetic warfarin testing (Johnson et al., 2017).  
Consensus of Major Organization 
According to the CDC (2016a), routine pharmacogenomic screening of genetic 
variants CYP2C9 and VKORC1 to prevent myocardial infarctions, venous thrombosis, 
pulmonary embolism, or thromboembolic events related to AF or valve replacements is 
ranked a Tier 2.  More specifically, to obtain a Tier 2 recommendation, an FDA label 
indicates genetic biomarkers.  The clinical practice guideline supports the use of this 
genetic test but does not include a systematic review; refuting evidence is available but 
the use of this test is still encouraged.  Conversely, only a systematic review recommends 
the use of this genetic test or discovers inadequate evidence but still suggests use of this 
test.  For a Tier 2, the clinical practice guideline addresses individualized medication 
dosing for the patient yet does not indicate specific genetic testing (CDC, 2016b).   
The Centers for Medicaid and Medicare Services (CMS; 2009) covered this test 
for eligible patients based upon evidence.  More specifically, for CMS to cover 
pharmacogenetic testing for warfarin, the patient must meet the following criteria: (a) no 
prior genetic testing of markers CYP2C9 and VKORC1 alleles, (b) the patient has been 
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administered less than five days of warfarin, and (c) the patient is currently participating 
in a prospective, randomized, controlled clinical study for warfarin response and patient 
outcomes.  Unless the aforementioned measures are met, CMS does not routinely 
recommend screening Medicare patients for pharmacogenomic testing for warfarin.  In 
the presence of familial AF with multiple generations involved, genetic counseling and 
testing is an option (Class IIb, Level of Evidence C; January et al., 2014).  
 A systematic literature review of genetic variants for warfarin, specifically 
VKORC1 and CYP2C9, concluded all patients with a bleeding event while on warfarin 
should be tested within two weeks for VKORC1, CYP2C9*2 and CYP2C9*3 alleles 
including the pediatric population.  Additional recommendations for pharmacogenomic 
testing while on warfarin include difficulties obtaining therapeutic INRs or adverse drug 
events while on warfarin.  Evidence endorsed utilization of a specific pharmacogenetic 
dosing algorithm to accurately analyze the genotypes (Shaw et al., 2015).  According to 
the ESC, genetic testing for warfarin is not recommended as evidence has failed to 
demonstrate an influence on time in therapeutic regimen or decreased bleeding risk 
(Class III, Level B; Kirchhof et al., 2016).  
Pathophysiology 
With AF, the two upper heart chambers called atria beat irregularly, affecting the 
blood flow down to the two ventricles (CDC, 2015).  The rate of blood flow decreases 
and allows blood to pool within the atria, enhancing the risk of thrombi (blood clots) and 
thus stroke if a clot is expelled into the bloodstream and reaches the brain (AHA, n.d.).  
Regarding the mechanism, a trigger, predominantly rapid firing from the pulmonary 
veins, results in atrial fibrillation.  Other triggers include reentry circuits, atrial stretch, 
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inflammation, dilatation, fibrosis, repolarization abnormalities, autonomic imbalance, and 
conduction disturbances.  Early in the disease process, the atrium is fully functioning and 
can spontaneously return to sinus rhythm more easily.  Persistent AF occurs from cardiac 
remodeling (electrical and structural) over time, inhibiting the ability of the fibrillation to 
resolve spontaneously.  Thus, paroxysmal AF often precedes persistent atrial fibrillation 
(Olshansky & Arora, 2016).  The complex and poorly understood mechanism of Afib is 
summarized in Figure 2.  Predominant mechanisms for ectopy and conduction 
disturbances in the atria, which ultimately result in atrial fibrillation, include calcium 
instability, ischemia, vascular remodeling, atrial fibrosis, hypocontractility, fatty 
infiltration, and inflammation (Kirchhof et al., 2016).   
Risk factors for AF such as hypertension and diabetes contribute to atrial 
remodeling in the heart, ultimately resulting in fibrosis.  This fibrosis contributes to 
changes in atrial electrical conduction pathways to a reentry circuit, which further 
potentiates the risk of arrhythmias such as atrial fibrillation.  Research suggested 
prevention of cardiac remodeling could minimize the onset of AF (Shahid et al., 2016).  
The increased risk of blood clot or thrombus (prothrombotic) resulted not only from the 
irregular rhythm associated with AF but also the remodeling in predominantly the left 
atrial appendage.  Even brief periods of AF could contribute to stroke as this irregular 
rhythm harms the atrial heart muscle (myocardium), releasing inflammatory factors 
within the endothelium that accumulate platelets at the site of injury and increase the risk 
of thrombosis.  Furthermore, with atrial remodeling, changes in the calcium balance 
within cells influences the heart rate variability (autonomic tone) and thus precipitates AF 









History and Comparison of Anticoagulation 
 Derived in 1930, subcutaneous unfractionated heparin was the first anticoagulant 
(Bayer HealthCare, 2010).  Other than the route of administration through injection, 
additional concerns with this anticoagulant included the risk of heparin-induced 
thrombocytopenia (HIT) and osteopenia.  In the 1940s, vitamin K antagonists warfarin 
and acenocoumarol were released to the market (Bayer HealthCare, 2010).  Prior to this 
time, the natural form of warfarin, dicumarol, was noted to cause hemorrhages in cattle in 
the 1920s and warfarin was used as rat poison in the 1950s (Williams, Riley, & Tidwell, 
n.d.).  In the 1980s, injectable low molecular weight heparins were created; this drug does 
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not require the lab monitoring needed for unfractionated heparin and has a decreased risk 
of HIT yet should be used cautiously in patients with renal insufficiency.  The first oral 
direct thrombin inhibitor, ximelagatran was released in Europe in the 1990s yet was 
removed from the market due to liver impairment.  In the 2000s, the first injectable factor 
Xa inhibitor, fondaparinux, was released on the market.  The next direct thrombin 
inhibitor, dabigatran, was released in Europe in 2006 (Bayer HealthCare, 2010).  
Rivaroxaban, the first oral direct factor Xa inhibitor, was released on the market in 2008 
(Drugs.com, 2015b), followed by apixaban in 2012 (Drugs.com, 2016), and Edoxaban in 
2015 (Daiichi Sankyo, 2015).  A new factor Xa inhibitor, Betrixaban (Beyvxxa©), is 
currently under study, demonstrating a longer half-life and reduced effects on renal 
excretion and hepatic metabolism compared to other non-vitamin K oral anticoagulants 
(NOACs) on the market (Hu, Vaidya, & Asirvatham, 2016).  The first reversal drug for 
dabigatran, idarucizumab, was released in 2015 (Boehringer Ingelheim, 2015b).  
Currently, no specific reversal agents for the factor Xa inhibitors have been approved for 
use; yet andexant alpha (a factor Xa inhibitor antidote) and ciraparantag (a universal 
NOAC reversal agent) are currently in the development stages.  The mechanism of how 







Figure 3.  Coagulation cascade and the effects of oral anticoagulants. 
Note.  Vitamin K antagonists, such as warfarin, inhibit factors II, VII, IX, and X. 
Dabigatran directly inhibits factor IIa (thrombin). Apixaban, betrixaban, edoxaban, and 
rivaroxaban inhibit factor Xa. Abbreviation: TF, tissue factor. Adapted from Makaryus, 
Halperin, and Lau (2013). Copyright 2013, Macmillan Publishers Limited. 
 
 
Prevention of Stroke Through Anticoagulation 
The consensus of guidelines for atrial fibrillation suggests patients with risk 
factors for stroke should be given the opportunity to start oral anticoagulants for 
thromboprophylaxis unless they are low risk or have other contraindications (Shahid et 
al., 2016).  Oral anticoagulation is recommended indefinitely to prevent 
thromboembolism in patients with atrial fibrillation and a moderate to high risk of stroke 
(Wigle, Hein, Bloomfield, Tubbe, & Doherty, 2013).  Oral anticoagulation through 
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vitamin K antagonists (VKAs) or NOACs has demonstrated a reduction in overall 
mortality in patients with atrial fibrillation, predominantly strokes (Kirchhof et al., 2016).  
By increasing anticoagulant prophylaxis in 10% of 1,000 high-risk patients with atrial 
fibrillation, the stroke rate could be reduced by 8.4% as 33% of patients with low 
bleeding risk and high stroke risk are not treated appropriately with anticoagulation 
(Janssen Pharmaceuticals, 2014d).  Newer studies are using the term direct oral 
anticoagulants (DOACs; Samuelson, Cuker, Siegal, Crowther, & Garcia, 2017); thus, 
DOAC and NOAC are used interchangeably in this paper.   
Warfarin reduces stroke risk by two-thirds compared to aspirin or no 
anticoagulation.  Limitations of warfarin include the narrow therapeutic index, multiple 
drug interactions, and frequent lab monitoring of INRs requiring dose adjustments.  If 
warfarin requires temporary interruption, bridging with unfractionated heparin or low 
molecular weight heparin is initiated to decrease stroke risk in the interim (Class I, Level 
of Evidence C; January et al., 2014).  In comparison, the effects of NOACs are 
predictable without necessitating lab monitoring.  None of the NOACs (apixaban, 
edoxaban, rivaroxaban, or dabigatran) thus far have demonstrated safety for use with 
valvular AF (mitral stenosis) or artificial valves (Class III Harm, Level of Evidence B or 
C; Kirchhof et al., 2016).   
Ischemic stroke can be the initial manifestation of atrial fibrillation in patients, 
occurring predominantly as an embolus from the left atrial appendage.  In patients with 
AF, ischemic stroke severity tends to be more severe including longer durations of 
transient ischemic attacks (TIAs) because of larger emboli.  Even with anticoagulant 
prophylaxis, strokes of lesser severity can still occur in patients with AF.  Chronic 
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anticoagulation through warfarin or an NOAC (Dabigatran, Rivaroxaban, Apixaban or 
Edoxaban) displays the best efficacy in the long-term prevention of stroke and recurrent 
stroke in patients with nonvalvular atrial fibrillation (Manning, 2016).  The annual risk of 
stroke in patients with AF is ~1.5%, with a death rate of 3% even in anticoagulated 
patients, attributed to either stroke, heart failure, or sudden cardiac death (Kirchhof et al., 
2016).  Anticoagulants have demonstrated a 70% decreased risk of systemic embolism in 
non-valvular AF patients; yet the risk of bleeding risk must be considered when 
prescribing these medications (Manning, Singer, & Lip, 2016).  However, without risk 
factors, prophylaxis with anticoagulants or antiplatelets is contraindicated (Class III 
Harm, Level of Evidence B; Kirchhof et al., 2016).   
Assessing Stroke and Bleeding Risk 
Stroke Risk 
Evaluating for stroke risk with nonvalvular (nonrheumatic) AF is evaluated 
through the CHADS2 or CHA2DS2VASc scoring tools. The CHADS2 tool is 
recommended by the chest guidelines through validation of evidence and ease of use 
(You et al., 2012).  The CHA2DS2VASc tool is recommended by the ESC (Class I, Level 
of Evidence A; Kirchhof et al., 2016); AHA/ACC/HRS (Class I, Level of Evidence B; 
January et al., 2014); and the ASA (Meschia et al., 2014) to assess stroke risk and 
necessity of anticoagulation with AF.  The CHA2DS2VASc tool is recommended over the 
CHADS2 to assess for stroke risk as the former highlights more risk factors and 
demonstrates a better ability to predict patients with low, moderate, or high stroke risks.  
More specifically, the CHADS2 does not always accurately predict if a patient is at low 
stroke risk, thus increasing the incidence of thromboembolism in AF patients who do not 
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receive anticoagulation.  Risk stratifying patients with atrial fibrillation is essential as 
only 70% of patients necessitating oral anticoagulation receive this treatment.  
Furthermore, in high-risk patients with AF who suffered from a stroke, 29% were not 
prescribed any anticoagulation, 31% were prescribed antiplatelets, and 39% were 
prescribed warfarin, yet only 10% had therapeutic INR levels.  Prescribing 
anticoagulation adequately for AF patients is a predominant means to decrease stroke risk 
in this population (Lane & Lip, 2012).  Interpretation of CHADS2 and CHA2DS2VASc 
scoring is explained within the Anticoagulation for Atrial Fibrillation Toolkit in 
Appendix A. 
CHADS2 or CHA2DS2VASc score of zero.  Vitamin K antagonists (VKAs) have 
been proven to decrease all-cause mortality with atrial fibrillation diagnoses except in 
patients at low risk of stroke (CHADS2 score of 0) attributed to the increased risk of 
intracranial bleeds from anticoagulation.  Thus, treating patients with a CHADS2 score of 
0 with aspirin for one year could decrease two nonfatal strokes in a population of 1,000 
people with the caveat of three extracranial bleeds.  More specifically, monotherapy with 
aspirin could decrease the risk of stroke by 21% compared to no treatment; yet the risk of 
bleeding increases by 50-60%.  Treatment with a VKA could decrease the risk of stroke 
by one-half compared to aspirin, yet increases the bleeding risk by 50% (2.5-fold 
increased risk; You et al., 2012).  In nonvalvular AF (NVAF) and a CHA2DS2VASc 
score of 0, anticoagulation is not recommended (Class IIa, Level of Evidence C [January 
et al., 2014; Manning et al., 2016]; Class IIa, Level of Evidence B--Meschia et al., 2014).  
The American College of Chest Physicians (CHEST guidelines) made the same 
recommendation of no treatment with a CHADS2 score of 0 (Grade 2B), proposing 
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aspirin (Grade 2B) or aspirin with clopidogrel (Grade 2B) if the patient requested 
anticoagulation for AF (You et al., 2012).  In patients desiring an oral anticoagulant for a 
CHA2DS2-VASc score of 0 but with a high risk of bleeding, apixaban and dabigatran are 
suitable options.  Consensus suggests aspirin is not recommended to prevent stroke in 
patients with atrial fibrillation (Lane & Lip, 2012).  
CHADS2 or CHA2DS2VASc score of one.  The CHEST guidelines 
recommended oral anticoagulation with a CHADS2 score of 1 (Grade 1B), proposing the 
combination of aspirin and clopidogrel if the patient is unable to take oral anticoagulation 
(Grade 2B; You et al., 2012).  Dual treatment with aspirin and clopidogrel demonstrates 
an increased risk of bleeding 1.5-2 times compared to warfarin (You et al., 2012).  With a 
CHA2DS2-VASc score of 1, dabigatran, rivaroxaban, and apixaban have demonstrated 
superiority to warfarin with no increased bleeding risk (Lane & Lip, 2012).  With 
nonvalvular AF, a low risk for bleeding, and a CHA2DS2VASc score of 1, multiple 
treatment options are appropriate depending on patient preference including no 
anticoagulant, aspirin, or an oral anticoagulant (Class IIb, Level of Evidence C--January 
et al., 2014; Class IIb, Level of Evidence C--Meschia et al., 2014).  Anticoagulant 
therapy for a CHA2DS2VASc score of 1 is generally prescribed based on clinical 
judgment, with age 65-74 years old, hypertension, and diabetes as more significant risk 
factors contributing to disease onset compared to female sex and vascular disease 
(Manning et al., 2016).   
CHADS2 or CHA2DS2VASc score of greater than or equal to two.  With a 
CHA2DS2VASc score ≥ 2, chronic anticoagulation is suggested to decrease the risk of 
stroke (Grade 1a; Manning et al., 2016).  Without other risk factors, sex alone is not a 
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strong indicator of increased stroke risk, yet age greater than 65-years-old heightens the 
influence of other risk factors such as sex and heart failure (You et al., 2012).  With a 
CHA2DS2-VASc score ≥ 2 (regardless of bleeding risk) and with elevated bleeding and 
stroke risk, dabigatran, rivaroxaban, or apixaban have demonstrated superiority to 
warfarin (Lane & Lip, 2012).  
The AHA, ACC, and HRS (2014) proposed oral anticoagulation with a 
CHA2DS2VASc score ≥ 2, history of prior stroke, or history of TIA and recommended 
warfarin (Class I, Level of Evidence A), dabigatran, rivaroxaban, or apixaban as suitable 
anticoagulants (Class I, Level of Evidence B--January et al., 2014; Class I, Level of 
Evidence B--Meschia et al., 2014).  Likewise, according to the CHEST guidelines (You 
et al., 2012), a diagnosis of valvular AF, a low risk of bleeding, and a CHA2DS2VASc 
score ≥ 2 warrants long term anticoagulation with warfarin with a therapeutic INR of 2.0-
3.0 (Class I, Level of Evidence A).  With a CHADS2 score of 2 or higher, the 
combination of aspirin and clopidogrel is proposed if the patient is unable to take oral 
anticoagulants (Grade 1B; You et al., 2012).  Warfarin has displayed an annual reduction 
in stroke, myocardial infarction, and systemic embolism (3.9%) compared to dual 
antiplatelet therapy with aspirin and clopidogrel (5.6%).  The bleeding risk increases 
from 1.3% to 2.0% with monotherapy aspirin compared to dual antiplatelet therapy.  
Based upon these findings, antiplatelet therapy is not suggested to reduce stroke risk in 
patients with AF (Class III Harm, Level of Evidence A; Kirchhof et al., 2016).  
Dabigatran 150 mg twice daily is preferred to dose-adjusted warfarin for AF, including 
paroxysmal, with a CHADS2 score of 1 or 2 (Grade 2B); however, this drug is not 
indicated with a creatinine clearance (CrCl) less than 30 mL/min (You et al., 2012).  On 
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the contrary, the ESC recommends oral anticoagulation for AF patients with a 
CHA2DS2VASc score > 2 for men (Class I, Level of Evidence A) and > 3 for women 
(Class I, Level of Evidence A) to prevent blood clots (Kirchhof et al., 2016).   
Conclusions.  Oral anticoagulants have proven superior in preventing stroke with 
AF compared to antiplatelets such as aspirin (Manning et al., 2016); due to the 
heightened bleeding risk, aspirin is not considered safe as monotherapy (Shahid et al., 
2016).  Warfarin and NOACs have demonstrated similar stroke and bleeding risks in 
nonvalvular AF; however, evidence suggests treatment with a NOAC (direct thrombin 
inhibitor or factor Xa inhibitor) is superior (Manning et al., 2016).  More specifically, 
dabigatran, apixaban, edoxaban, and rivaroxaban have demonstrated non-inferiority to 
warfarin in preventing stroke with AF yet demonstrate superiority in a reduction of 
severe bleeding (a decrease in bleeding by 30-50%; Shahid et al., 2016).  A comparison 
of warfarin and NOACs is summarized within the Anticoagulation for Atrial Fibrillation 
Toolkit in Appendix A.  If a patient is unable to take an anticoagulant, dual antiplatelet 
therapy consisting of aspirin 75-100 mg daily in addition to clopidogrel 75 mg daily is 
recommended (Grade 2B; Manning et al., 2016).  Due to increased bleeding risk, a 
combination therapy of platelet inhibitors and oral anticoagulants is contraindicated post 
stroke (Class III Harm, Level of Evidence B; Kirchhof et al., 2016).  Based upon the 
above evidence-based recommendations, the stroke risk of every patient with AF should 
be assessed through the CHA2DS2-VASc score to determine if anticoagulation is the 





Bleeding Risk  
Overemphasizing bleeding risk is a predominant limiting factor in providers 
prescribing oral anticoagulation, especially to the elderly.  However, despite the risk of 
bleeding and stroke both increasing with advanced age, aspirin becomes less effective 
and oral anticoagulants become more effective in preventing ischemic stroke with 
increasing age with a comparable bleeding profile between the two drugs (Lane & Lip, 
2012).  Factors increasing the risk of bleeding while on anticoagulation include 
alcoholism (≥ 8 drinks weekly), poorly controlled hypertension (systolic blood pressure > 
160 mmHg), prior history of bleeding, labile INRs with warfarin, concurrent use of 
nonsteroidal anti-inflammatory drugs (NSAID)s or antiplatelet drugs, anemia, impaired 
renal function, impaired liver function, prior stroke, falls, dementia, age > 65 years old, 
genetics, malignancies, recent surgery, diabetes, recent myocardial infarction, and 
interruptions of anticoagulation prior to a procedure (Doherty et al., 2017, Jaffar & 
Bragg, 2003; Kirchhof et al., 2016).  Cautious signs and symptoms suggesting bleeding 
while on anticoagulation include bruising, fall to the head, severe headache of a long 
duration, frequent nosebleeds, coughing up blood, coffee ground emesis, heavy bleeding 
from the gums, swelling and pain in the abdomen, severe back pain, black or bloody 
stools, bloody urine, heavy menstrual periods, and prolonged bleeding from lacerations 
(Jaffar & Bragg, 2003).   
Currently, data have been inadequate to add recommendations to guidelines on 
assessing bleeding risk with anticoagulation through a validated tool, however, screening 
for bleeding risk should still be calculated through hypertension, abnormal renal and liver 
function, stroke, bleeding, labile international normalized ratio, elderly, drugs or alcohol 
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(HAS-BLED); hepatic or renal disease, ethanol abuse, malignancy, older age, reduced platelet 
count or function, re-bleeding, hypertension, anemia, genetic factors, excessive fall risk and 
stroke (HEMORR2HAGES), or another evidence-based tool and incorporated into the 
individualized treatment plan to help in the selection of anticoagulation (You et al., 
2012).  Data have suggested HAS-BLED more accurately predicts major bleeding risk 
compared to HEMORR2HAGES and is declared easier to use than other scales.  The 
AHA/ASA have endorsed the HAS-BLED score to assess for bleeding risk with 
anticoagulation for AF (Meschia et al., 2014).  A meta-analysis and systematic review of 
HAS-BLED, HEMORR2HAGES and anticoagulation and risk factors in atrial fibrillation 
(ATRIA) concluded HAS-BLED displays a better ability to predict severe bleeding risk 
in patients with atrial fibrillation, has increased sensitivity, and is more user friendly 
(Caldeira, Costa, Fernandes, Pinto, & Ferreira, 2014).   
According to the bleeding risk scores, the annual risk of bleeding while on 
anticoagulation increases with every positive risk factor with an overall bleeding risk of 
1.5%.  The scoring of these risk factors does not categorize the patient as low, 
intermediate, or high risk for bleeding while on anticoagulation (Hwang, 2016b).  The 
purpose of bleeding scores is not to deter providers from prescribing anticoagulants but 
rather to discover and adjust modifiable risk factors to reduce bleeding risk (Lane & Lip, 
2012).  The ESC recommends utilization of the HAS-BLED, ORBIT, or ABC bleeding 
risk scale to reduce risk factors (Class IIa, Level B) yet advises against withholding oral 
anticoagulation merely on the high risk of bleeding, as the patient’s individual bleeding 
risk profile and reduction of risk factors should be incorporated into the risk-benefit ratio 
(Kirchhof et al., 2016).  If severe bleeding occurs while on anticoagulation, medications 
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should be stopped until the etiology of the bleeding is discovered (Class I, Level of 
Evidence C; Kirchhof et al., 2016).  The hypertension, abnormal renal and liver function, 
stroke, bleeding, labile INR, elderly, drugs or alcohol (HAS-BLED) scoring is illustrated 
within the Anticoagulation for Atrial Fibrillation Toolkit in Appendix A. 
Summary 
Research has demonstrated CHA2DS2-VASc and HAS-BLED scores are a simple 
and efficient means to assess whether anticoagulation is appropriate for a patient without 
warranting further testing or lab work (Shahid et al., 2016).  To prevent systemic 
embolization and stroke, the CHA2DS2-VASc score is completed on patients to determine 
if they meet criteria for long-term anticoagulation as shown in Appendix A.  If the risk of 
bleeding is less than the risk of stroke, all patients with AF are recommended to start 
antithrombotic medications (Kumar, 2016b).  More specifically a CHA2DS2-VASc score 
≥ 2 suggests chronic anticoagulation and a score of 0 implies no anticoagulant therapy.  A 
score of 1 requires clinical judgement on whether to prescribe an anticoagulant, 
considering factors such as age > 75 years and sex.  According to CHADS2 scoring, the 
absolute risks of stroke annually in patients not treated with anticoagulation are 0.8% 
(score of 0), 2.2% (score of 1), 4.5% (score of 2), and 9.6% (score of 3-6; You et al., 
2012). 
Direct Oral Anticoagulants Versus Warfarin 
Comparison 
Oral direct thrombin inhibitors or factor Xa inhibitors are recommended over 
warfarin for NVAF (Grade 2B); however, research currently does not support selecting 
one NOAC over the other (Manning et al., 2016).  The baseline risk of extracranial 
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bleeding per year is 0.5% in patients treated with warfarin.  Randomized control trials 
have demonstrated vitamin K antagonists such as warfarin decrease the risk of death by 
one-fourth in patients with AF, in addition to the risk of nonfatal stroke by two-thirds, 
when compared to patients with no anticoagulation (You et al., 2012).  A meta-analysis 
concluded morality rates decreased by 10%, stroke rates decreased by 19% 
(predominantly hemorrhagic), and the risk of intracranial hemorrhage was reduced by 
half with NOACs in comparison to warfarin, yet the rate of gastrointestinal bleeding 
increased (You et al., 2012).  The reduced bleeding risk was more prominent in patients 
with labile INR values, yet the correlation of INR value and risk of intracranial 
hemorrhage was unable to be confirmed.  In general, warfarin is suitable for patients with 
INRs within the therapeutic range 65% of the time who prefer lab monitoring, prefer 
once day dosing, cost is an issue, chronic kidney disease, prosthetic heart valves, mitral 
stenosis, or concurrent use of protease inhibitors or phenytoin contraindicated with 
DOACs (Manning et al., 2016).   
Oral anticoagulants have not been tested for safety and efficacy in patients with 
kidney transplants.  Dabigatran and rivaroxaban should be avoided with an estimated 
glomerular filtration rate (eGFR) < 30 mL/min/1.732, apixaban with an eGFR < 25 
mL/min/1.732, and edoxaban with an eGFR > 95 mL/min (Manning et al., 2016).  In 
patients with mild or moderate chronic kidney disease (CKD), NOACs demonstrated less 
strokes, hemorrhages, and systemic embolisms compared to warfarin.  However, only 
warfarin has been safely utilized in patients with moderate or moderate-severe CKD.  
Warfarin has displayed safety and efficacy in reducing stroke in dialysis patients 
(Manning et al., 2016), while the pharmacokinetics and pharmacodynamics of dabigatran 
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were not affected in patients with worsening renal impairment and chronic hemodialysis 
(Dias et al., 2016). 
Recommendations 
  The current 2014 recommendations of the AHA/ACC/HRS do not differentiate 
between warfarin or DOACs for anticoagulation in AF.  Since January 2016, CHEST 
prefers oral anticoagulants rather than warfarin to treat atrial fibrillation and 
thromboembolism without a cancer etiology (Samuelson et al., 2017).  More specifically, 
with venous thromboembolism without cancer, dabigatran, rivaroxaban, apixaban, or 
exoxaban are recommended for long-term anticoagulation instead of warfarin (Grade 
2B).  In patients with venous thromboembolism and cancer, low-molecular weight 
heparin is preferred instead of warfarin (Grade 2B) and any of the DOACs (Grade 2C; 
Kearon et al., 2016).  Warfarin has been used as an anticoagulant for over 60 years, yet 
the drug contributes to 12.5% of hospitalizations for drug-drug interactions, 43% higher 
costs for hemorrhages, and 33% of hospitalizations for adverse drug events in the elderly 
(Janssen Pharmaceuticals, 2014c).  
Research Studies 
Currently, no head-to-head studies have been completed comparing the DOACs 
(Shahid et al., 2016).  Noseworthy et al. (2016) completed a retrospective analysis of 
adult users of dabigatran, rivaroxaban, or apixaban from 2010-2015, assessing the safety 
outcome of bleeding and the efficacy outcome of prevention of stroke and systemic 
embolism in patients with NVAF.  Results demonstrated no difference in the efficacy 
outcome of preventing stroke or systemic embolism amongst the three drugs.  
Rivaroxaban demonstrated an increased risk of major and intracranial bleeding compared 
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to dabigatran and apixaban displayed a reduced risk of bleeding compared to both 
dabigatran and rivaroxaban.  The study concluded the efficacy of these anticoagulants is 
comparable; yet the bleeding risk profiles differed with the highest risk of bleeding with 
rivaroxaban and the lowest risk with apixaban (Noseworthy et al., 2016).  These four 
DOACs have demonstrated reductions in major bleeding and intracranial hemorrhage 
compared to warfarin; however, dabigatran, rivaroxaban, and edoxaban (excluding 
apixaban) demonstrated an increased risk of gastrointestinal bleeding compared to 
warfarin.  Attributed to their significant reduction in stroke and systemic embolism 
reduction, the net clinical benefit of DOACs outweighed their bleeding risk.  Unless the 
patient has a mechanical heart valve, DOACs extend anticoagulation options other than 
warfarin to a larger proportion of the population at risk for stroke (Shahid et al., 2016).  
The AHA/ASA (2016) released an analogous study comparing the safety and efficacy of 
apixaban, rivaroxaban, and dabigatran to warfarin with NVAF.  This study concluded 
apixaban has decreased stroke and bleeding risks compared to warfarin, dabigatran has 
comparable stroke risk but lower bleeding risks compared to warfarin, and rivaroxaban 
has comparable stroke and bleeding risks to warfarin in patients with nonvalvular atrial 
fibrillation (Yao et al., 2016).  The study by Noseworthy et al. appears to be a head-to-
head of the three DOACs themselves; yet the study by the AHA/ASA is a comparison of 
the DOACs individually with warfarin.  In summary, all four DOACs compared to 
warfarin demonstrate comparable efficacy (stable effectiveness independent of the time 
in therapeutic range) and improved safety (decreased intercranial hemorrhages).  In fact, 
even with a therapeutic INR in the 2.0-3.0 range, two-thirds of intracranial bleeds still 
occur (Guimaraes et al., 2015).  A comparison of DOACs in general and warfarin is 
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illustrated within the Anticoagulation for Atrial Fibrillation Toolkit located in Appendix 
A.  
Trends 
The use of warfarin and the DOACs (apixaban, rivaroxaban, and dabigatran) was 
reviewed in the outpatient setting from 2009 to 2014 through the IMS Health National 
Disease and Therapeutic Index survey (cited in Barnes, Lucas, Alexander, & Goldberger, 
2015).  Results demonstrated more people are receiving outpatient visits for 
anticoagulation, predominantly for initiation of DOACs for new onset AF (increase from 
51.9% to 66.9%).  Overall visits for anticoagulation increased from 2.05 quarterly to 2.83 
quarterly.  The use of DOACs for AF increased from 0.88 million to 1.72 million during 
this five-year period, yet the prescription of warfarin and DOACs for AF was equivalent.  
As far as individual NOACs for AF, rivaroxaban was prescribed most frequently 
(47.9%), followed by apixaban (26.5%), and dabigatran (25.5%).  This study concluded 
NOACs were increasing in popularity for the AF population compared to warfarin 
(Barnes et al., 2015).   
Research is starting to compare the safety (thromboembolism) and efficacy 
(bleeding) of specific dosing for DOACs versus warfarin as current dose adjustments for 
DOACs are based primarily on renal function, age, body weight, and drug interactions 
without a consensus suggesting the suitable consistent dose for patients.  In a propensity 
weighted, nationwide cohort study of patients with NVAF, apixaban 2.5 mg twice daily 
demonstrated higher rates of ischemic stroke and systemic embolism compared to 
warfarin; conversely, rivaroxaban 15 mg once daily and dabigatran 110 mg twice daily 
displayed lower rates of thromboembolisms (Nielsen et al., 2017).  Compared to 
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warfarin, bleeding rates were significantly decreased for dabigatran but not rivaroxaban 
and apixaban (Nielsen et al., 2017).  
Cost Comparison 
As atrial fibrillation is associated with more severe strokes, anticoagulation to 
prevent strokes is cost effective.  In 2010, AF management cost $6.65 billion--44% was 
attributed to hospitalizations for an AF diagnosis, 29% for AF as a comorbid condition 
contributing to hospitalization, 23% for outpatient treatment, and 4% for medications; 
improving medication management would save an estimated $1.3 billion per year 
(Fendrick, 2010).  Other costs to consider when selecting an anticoagulation include the 
individual agent, lab monitoring, and treatment for hemorrhages.  International 
normalized ratio monitoring occurs every two to four weeks depending on the time in 
therapeutic range and cost over $600 annually in 2014 for lab monitoring.  In 
comparison, warfarin cost $40-60 for a 30-day supply in 2014 compared to $350 each for 
dabigatran, rivaroxaban, and apixaban (Fendrick, 2010).   
The cost to treat adverse effects must be considered with oral anticoagulation: 
hospitalization for a gastrointestinal bleeds costs approximately $24,000 while 
hospitalization for an intracranial hemorrhage costs approximately $41,000.  In general, 
DOACs display a reduced risk of intracranial hemorrhage compared to warfarin; yet 
dabigatran has the highest rate of gastrointestinal bleed.  Conversely, adherence to a 
treatment plan is important such as INR monitoring and heparin bridging with warfarin 
and ingesting a DOAC once or twice daily as prescribed.  As DOACs have a shorter half-
life, missing one dose could increase the risk of thromboembolism compared to missing 
four to five days of warfarin.  The cost of the reversal agent should also be considered: 
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Vitamin K, the reversal agent for warfarin, is the cheapest treatment for overdose and 
bleeding compared to prothrombin complex concentrate or fresh frozen plasma (warfarin, 
rivaroxaban, and apixaban) with the most expensive treatment as hemodialysis for 
dabigatran (Crouse & Quigley, 2014).  
A meta-analysis of NVAF patients concluded a risk reduction of 0.81 for stroke or 
systemic embolism, 0.48 for intracranial hemorrhage, and 0.90 for overall mortality for 
the DOACs compared to warfarin, suggesting cost savings for DOACs related to 
increased prevention of complications.  Resulting from these benefits, DOACs are the 
preferred anticoagulants by the European Society of Cardiology and the Canadian 
Cardiovascular Society (cited in Singh & Wijeysundera, 2015).  The DOACs are 
associated with increased costs but also higher quality adjusted life years (QALYs), 
demonstrating cost effectiveness compared to warfarin (specifically to the DOACs, 
dabigatran is most cost effective).  However, warfarin is less costly when patients have 
increased time in the therapeutic range (Singh & Wijeysundera, 2015).   
Medicare Part D covers 94-99% the cost for apixaban, rivaroxaban, and 
dabigatran as well as100% for warfarin but does not cover edoxaban (Medicare.gov, 
n.d.).  When comparing the average monthly price of the anticoagulants, warfarin costs 
$11, rivaroxaban $371, apixaban $395, dabigatran $377, and edoxaban $326 
(GoodRx.com, 2017).  Manufacturers for all the DOACs offer drug savings cards and/or 
a free monthly trial to help reduce the higher costs for the patient (Boehringer Ingelheim, 
2016; Bristol-Myers Squibb, 2016; Daiichi Sankyo, 2017; Janssen Pharmaceuticals, 
2016b).    
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Dabigatran, rivaroxaban, and especially apixaban display higher QALYs, 
demonstrating cost-effectiveness compared to warfarin; yet, this is influenced by the cost 
of the individual anticoagulant agents (Harrington, Armstrong, Nolan, & Malone, 2014).  
All four DOACS (apixaban, dabigatran, edoxaban, and rivaroxaban) demonstrated 
decreased medical costs annually for events related to NVAF and thromboembolism 
compared to warfarin (-$204 for dabigatran, -$140 for rivaroxaban, -$495 for apixaban, 
and -$340 for edoxaban), which are estimated to continue rising within the next few 
years; within these drugs, apixaban is the most cost effective (Amin, Bruno, Trocio, Lin, 
& Lingohr-Smith, 2015).  Patients with steady time in the therapeutic range display 
improved outcomes; thus, the quality of life for warfarin is influenced by adherence to 
INR monitoring and corresponding dose adjustments.  Therefore, warfarin is more cost 
effective than DOACs in atrial fibrillation patients demonstrating quality anticoagulation 
(Janzic & Kos, 2013).   
Screening and Diagnosis of Atrial Fibrillation 
Evaluation of a patient with atrial fibrillation requires stringent monitoring and 
follow up to prevent complications related to the disease itself as well as adverse effects 
from the medications, predominantly bleeding risk.  Diagnostics for this disease include 
an exhaustive history and physical examination, a 12-lead electrocardiogram, and a 
transthoracic echocardiogram. (Kumar, 2016b).  Key components of the patient’s medical 
history and examination include assessing for comorbid conditions, stroke risk, 
symptoms associated with AF, the pattern of AF, and risk of thromboembolism or left 
ventricular dysfunction (Class I, Level of Evidence C).  A 12-lead EKG is necessary to 
diagnose AF, determine the rate of the dysrhythmia, and assess for ischemia, conduction 
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defects, and other signs of structural heart disease (Class I, Level of Evidence B; 
Kirchhof et al., 2016).  Once AF is diagnosed, a transesophageal echocardiography (TEE) 
is recommended with all patients to drive the treatment plan and evaluate for structural 
valve disease, atrial size, right heart function, and left ventricular size and function (Class 
I, Level of Evidence C).  Furthermore, a TEE is useful to assess for thrombi in the left 
atrial appendage, suggesting earlier cardioversion or catheter ablation.  Ambulatory 
electrocardiogram (EKG) monitoring can be helpful to measure the effectiveness of rate 
control treatments, correlate symptoms with ectopy, and discover paroxysmal AF 
episodes (Kirchhof et al., 2016).  Screening for atrial fibrillation is recommended by 
checking a pulse or obtaining an electrocardiogram strip annually in patients 65 years of 
age or older as this is the best means to detect silent atrial fibrillation in patients (Class I, 
Level of Evidence B--Kirchhof et al., 2016; Class IIa, Level of Evidence B--Meschia et 
al., 2014).  In patients who have suffered from an ischemic stroke or a transient ischemic 
attack, a rapid EKG followed by continuous EKG monitoring for 72 hours is 
recommended to assess for atrial fibrillation (Class I, Level of Evidence B; Kirchhof et 
al., 2016).  Alcohol consumption, marijuana use, and cigarette smoking all increase the 
risk of bleeding; thus, avoidance of these substances is urged while on any 
anticoagulation (Society for Vascular Medicine, 2015).  In summary, primary prevention 
of stroke suggests screening for silent AF through a pulse check and electrocardiogram in 
addition to 72 hours of cardiac monitoring in patients who have developed an ischemic 





Shared Decision-Making Tool 
The Society of Vascular Medicine (2015) created an online shared decision-
making tool for patients and providers to aid in the selection of anticoagulants.  The first 
series of questions asked the patients to choose “yes” or “no” if any of the following 
conditions exist: heart failure with an ejection fraction less than 40%; age 65-74 years 
old; age 75 years old or greater; diabetes mellitus (treated with insulin or oral 
medications); hypertension; previous stroke, thromboembolism or TIA; female sex; or 
vascular disease (myocardial infarction, aortic plaque or peripheral vascular disease).  
Other questions in this set included renal dysfunction (renal transplant, dialysis, 
creatinine clearance greater than 2.25 mg/dL); liver dysfunction (cirrhosis or elevated 
liver function tests); previous hemorrhagic stroke; previous major bleeding episode; 
anemia; use of antiplatelets (including aspirin and nonsteroidal anti-inflammatories); 
mechanical value replacement; or heavy alcohol use (greater than 16 beers or 10 glasses 
of wine weekly).  The next set of questions addressed the patient’s preference for 
medications: choice of a medication developed in 1954 versus 2010 to prevent stroke, 
choice of a medication with or without frequent blood draws and follow up with 
healthcare providers, selection of a medication where the dose is dependent on blood 
draws or standardized for everyone, and availability to afford a medication co-pay 
costing greater than $10 per month.  Based upon these results, the anticoagulant warfarin 
or a DOAC (direct oral anticoagulant)--apixaban, rivaroxaban, dabigatran, or edoxaban-- 
is provided to the patient with supporting rationale (Society of Vascular Medicine, 2015).   
In addition, bleeding and stroke risks while on anticoagulation are calculated for 
the patient and explained in depth (Society of Vascular Medicine, 2015).  This tool 
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highlights other factors for the patient to take into consideration when selecting an 
anticoagulant such as interactions with foods or other medications, adverse drug effects, 
cost, access to labs for INR monitoring, and potential compliance issues including 
support systems and foreign languages.  For warfarin and the DOACs, the website directs 
the patient to a further question and answer section, answering topics of pregnancy, food 
and medication interactions, consumption of alcohol and smoking, checking INRs while 
on vacation, steps to take when a dose of the medication is missed, physical activity 
while on anticoagulants, and stopping the anticoagulant prior to surgery or other invasive 
procedures.  The algorithm does not clarify whether the patient qualifies for 
anticoagulation, no anticoagulation, or aspirin; the algorithm merely addresses the 
appropriate anticoagulation based upon individualized patient preference and medical 
history (Society for Vascular Medicine, 2015).  
Lab Monitoring 
Atrial Fibrillation 
Routine monitoring of atrial fibrillation should occur annually--sooner in 
symptomatic patients.  This monitoring includes INRs for warfarin, CrCl for 
antiarrhythmics and newer anticoagulants, documentation of any changes in the patient’s 
medical history, EKG, labs assessing renal and hepatic function, and possible Holter 
monitoring of cardiac rhythm (Kumar, 2016b).  Analysis of thyroid stimulating hormone 
and free T4 are also recommended for a new diagnosis in addition to a complete blood 
count, a serum creatinine, a urinalysis for proteinuria, tests for diabetes mellitus (Kumar, 
2016b), and serum electrolytes (Kirchhof et al., 2016).  Natriuretic peptide values are 
increased in AF; yet, evidence does not recommend these blood tests for screening 
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purposes.  However, troponin or natriuretic peptide can further assess bleeding and stroke 
risk (Class IIb, Level of Evidence B).  A complete blood count (CBC) should be obtained 
every six months with all oral anticoagulants to assess for bleeding.  Renal function for 
all the NOACs should be obtained at least annually as well as hepatic function for 
rivaroxaban and apixaban annually (January et al., 2014).   
Warfarin 
As warfarin is contraindicated during pregnancy, a urine human chorionic 
gonadotropin (hCG) is recommended prior to initiating warfarin and as needed to assess 
for pregnancy in women of child bearing age (University of Colorado Health North, 
2015).  The INR was created by the World Health Organization in 1982 to standardize 
the prothrombin time (PT) to consistently and safely measure the effectiveness of 
warfarin (Jaffar & Bragg, 2003).  The anticoagulant effects of warfarin occur two to 
seven days after starting the drug; thus, if rapid anticoagulation is needed, bridging with 
heparin should occur for at least four days.  The initial dose of warfarin is usually 5 mg 
with an INR of 2 after four or five days; yet, lower doses should be used in the elderly 
and those with a high risk of bleeding.  Heparin can be stopped after the INR is 
therapeutic for two days.  The serum INR level should be checked daily until a 
therapeutic range is achieved for two days, followed by blood work two to three times 
weekly for one to two weeks, up to once per month with stable levels (Jaffar & Bragg, 
2003; January et al., 2014; Wigle et al., 2013).  More specifically, the AHA/ACA/HRS 
(2014) recommended a minimum of weekly INR monitoring until a therapeutic INR was 
achieved, then monthly lab draws (Class I, Level of Evidence A; January et al., 2014).  
For atrial fibrillation, the targeted INR for warfarin is 2.0-3.0 (Manning, 2016).  With 
39 
 
dose adjustments, alcohol use, dietary or medication changes, labile INRs (January et al., 
2014), when transitioning between warfarin and another anticoagulant, or during 
hospitalization (Hull & Garcia, 2016b), more frequent lab monitoring might be necessary.  
If a dose of warfarin is missed, the effect on the INR appears two to five days later.  With 
labile INRs, factors such as patient compliance, medication changes, fluctuations in the 
intake of vitamin K, and acute illness (diarrhea, fever, or vomiting) should be assessed 
before altering the dose of warfarin (Jaffar & Bragg, 2003).   
On average, it takes four months for a patient to reach a therapeutic INR with 
25% failing to achieve therapeutic INRs, 30% displaying supratherapeutic or 
subtherapeutic INRs, and a 10-fold increase in continuing therapy once stable INRs are 
attained (Janssen Pharmaceuticals, 2014e).  Surprisingly, only 55% of the time are AF 
patients within their target therapeutic range while on warfarin (Janssen Pharmaceuticals, 
2014e).  Poor INR control results in an increased incidence of patients discontinuing 
warfarin with one in four patients stopping warfarin within a year of treatment initiation.  
With a lower CHADS2 score, patients are at a higher risk of stopping warfarin 
prematurely with 50% of patients failing to adhere to their warfarin regimen (Janssen 
Pharmaceuticals, 2014b).  Furthermore, unstable INRs (< 2 or > 4) are present in 44% of 
patients on warfarin (Janssen Pharmaceuticals, 2014c).  The risk of thromboembolism 
increases with an INR < 2 and the risk of bleeding increases with an INR > 4, especially 
> 5 (Hirsh, Fuster, Ansell, & Halperin, 2003).  If a patient has labile INRs, replacement 
with a direct thrombin inhibitor or factor Xa inhibitor is an acceptable alternative (Class 




Direct Oral Anticoagulants  
As DOACs are administered in fixed dose regimens, routine lab monitoring is not 
required.  However, situations warranting lab monitoring include an epidural, severe 
bleeding, emergency surgery, or a stroke patient who may require thrombolysis.  
Malabsorption, obesity, malnourishment, DOAC overdose, acute kidney injury, treatment 
failure, or drug interactions may also necessitate lab testing for further investigation.  
Specifically, a dilute thrombin time (dTT), thrombin time (TT) or ecarin-based assay 
(also known as ecarin clotting time or ECT) are available for dabigatran anticoagulation 
effects and anti-Xa assays with drug-specific calibrators for rivaroxaban, edoxaban, and 
apixaban (Hu et al., 2016; Samuelson & Cuker, 2016; Samuelson et al., 2017).  If these 
specialized tests are not accessible, dabigatran levels can be measured through dTT or 
aPTT (activated partial thromboplastin time) or INR for the factor Xa inhibitors 
(rivaroxaban, edoxaban, and apixaban).  The level of the DOAC within plasma is 
influenced also by renal function, hepatic function, drug interactions, and the amount of 
time elapsed since the last dose was administered (Samuelson & Cuker, 2016; Samuelson 
et al., 2017).   
Clinic Managed Versus Home Monitoring of  
International Normalized Ratios 
Introduction 
International normalized ratio monitoring is managed within an outpatient 
anticoagulation clinic, a provider within the community, or at home by the patient; 
research suggested INR levels are best managed at an anticoagulation clinic or by the 
patient (Hull & Garcia, 2016b).  As the researcher was unable to discover a standardized 
warfarin dosing guideline or nomogram and anticoagulation clinics usually follow their 
41 
 
own protocols for dosing anticoagulation based upon the target INR, an in-depth 
discussion of warfarin dosing was not addressed within this paper.  Of note, resources 
such as warfarindosing.com can help providers determine the therapeutic dose of 
warfarin based upon the two genes: cytochrome P450 2C9 (CYP2C9) and vitamin K 
epoxide reductase (VKORC1; Washington University, 2016).   
Clinic Managed International  
Normalized Ratios 
An example of a guideline for registered nurses and healthcare providers who 
manage patients on anticoagulation includes indications and warnings for warfarin, 
laboratory testing (for target INRs), patient education, initiation and maintenance of 
warfarin therapy (including causes of abnormal INR levels), reversal agents for warfarin, 
perioperative management and bridging, transitioning to DOACs, quality assessment, 
nurse education, and how to manage non-compliant patients.  In a hypothetical dosing 
nomogram for initiating warfarin therapy, a dosage of 5-10 mg warfarin is initiated on 
day one, adjusting the dose on days two to five for the target INR range of < 1.5 all the 
way up to > 3 depending on the patient specific indication for anticoagulation.  For 
example, with a maintenance INR of 2.0-3.0 and if the INR is therapeutic, the serum INR 
would be checked within 4 to 12 weeks depending on the stability of the INR levels 
(University of Colorado Health North, 2015).   
In the presence of subtherapeutic (low INR) and supratherapeutic INR (high 
INR), a search for the cause of the poorly controlled INR is sought and the weekly 
dosage levels of warfarin and frequency of INR monitoring are adjusted concurrently.  
General recommendations include checking on new warfarin patients within the first 
three to five days of initiating therapy and starting 5-10 mg for the first two days (3-5 mg 
42 
 
with impaired liver function, malnutrition, heart failure, thyroid storm, drug interactions, 
or elderly greater than 65 years old; University of Colorado Health North, 2015).  
Compared to the 10-mg loading dose of warfarin, the 5-mg loading dose exerts less 
anticoagulation effects and achieves a therapeutic INR quicker; it also has less risk of the 
hypercoagulable state that can occur during the first 36 hours of starting warfarin 
(Harrison et al., 1997; Wigle et al., 2013).  Thus, to balance this anticoagulant and 
antithrombotic balance, the 5-mg loading dose is recommended (Jaffar & Bragg, 2003).  
Starting on day three, the maintenance dose of warfarin could be started, usually 5-mg 
daily (University of Colorado Health North, 2015). 
This hypercoagulable state when starting warfarin is the result of the decrease of 
clotting factor VII and the concurrent decrease in proteins C and S, thus the importance 
of bridging with heparin or low molecular weight heparin until the INR is therapeutic for 
at least 24 hours (Jaffar & Bragg, 2003; Wigle et el., 2013).  The consensus varies on the 
percentage to adjust warfarin doses safely per week to achieve a therapeutic INR: 5% to 
20% according to research studies (Jaffar & Bragg, 2003; Wigle, et al., 2013), 15% to 
20% according to an anticoagulation clinic (University of Colorado Health North, 2015), 
and 10% to 15% according to the RE-LY warfarin trial (Hull & Garcia, 2016b).  With 
continued maintenance of warfarin, past and current INR trends are considered as well as 
adverse effects (especially bleeding) and drug interactions, targeting the warfarin therapy 
to the individual patient.  In patients who are willing and able, home INR monitoring is 
preferred over monitoring within an anticoagulation clinic (University of Colorado 




Home Monitoring of International  
Normalized Ratios  
Randomized control trials have concluded in comparison to clinic-managed INR 
monitoring, home monitoring of INRs can decrease the risk of thromboembolic events by 
42%.  Patients treated with dabigatran 150 mg twice daily demonstrated a 35% decrease 
in strokes compared to treatment with warfarin, suggesting home-monitoring of INRs is 
as effective as a NOAC in patients adherent to their treatment plan with warfarin (You et 
al., 2012).  Other benefits include reduced costs (mileage reimbursement, appointment 
cost, and lost wages), time savings by not requiring a clinic visit, improved convenience, 
and increased patient preference.  In fact, 76% of patients would rather pay more money 
for point-of-care testing (POCT) at home than to travel to a monthly visit at an 
anticoagulation clinic (Meyer et al., 2013).  Cons of home monitoring include increased 
costs of the devices and test strips needed for this monitoring (You et al., 2012).  If cost is 
not a concern, CHEST recommends home monitoring of INRs in patients who have been 
thoroughly educated on how to use the devices and are willing to engage in self-
monitoring of INR levels (Ansell, 2013; Barcellona, Fenu, & Marongiu, 2016; Class IIB-
-Pozzi, Mitchell, Henaine, Safi, & Henaine, 2016).  Interestingly, 80% of patients can 
properly obtain a POCT INR level after education (Ansell, 2013).  
Quality of Life 
Quality of life assessments through the Duke Anticoagulation Satisfaction Scale 
(DASS; Samsa et al., 2004) suggest improved satisfaction with general treatment, self-
efficacy, distress, daily hassles, and strained social network with POCT INR testing, 
displaying consistent results two years later (Pozzi et al., 2016).  The DASS is a reliable 
and validated 25-question scale assessing a patient’s satisfaction and dissatisfaction with 
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an anticoagulation routine.  Negative implications of anticoagulation can result in labile 
INRs and reduced compliance to a treatment plan; thus, a tool such as DASS can aid in 
improving patient outcomes (Samsa et al., 2004).  A cost-analysis of POCT and clinic 
managed INRs for patients with similar CHADS2 scores, age, and sex demonstrated a 
cost of $32,484 for weekly POCT and $33,460 for the anticoagulation clinic.  However, 
the cost per quality adjusted life gain was $5,566, suggesting cost effectiveness and 
patient preference for POCT (Phibbs et al., 2016).  
Conclusions 
Data suggest longer times in therapeutic INR range (TTR) reduce adverse patient 
outcomes.  A study concluded physician-managed INRs achieved TTR 30-50% of the 
time, anticoagulation clinics achieved TTR 50-70%, and weekly POCT INRs achieved 
TTR 73% of the time (DeSantis et al., 2014).  Patients cannot only monitor their INR 
levels (patient self-testing or PST) but can be trained to self-manage their warfarin dosing 
(patient self-management or PSM); patients with PST, with or without PSM, have 
demonstrated safety and efficacy in TTRs (Ansell, 2013).  Weekly testing is 
recommended to achieve more stable TTRs and reduce critical INR values.  Patient self-
testing can reduce provider workload and expand access to patients requiring INR testing 
for warfarin (DeSantis et al., 2014).  Advantages of POCT and patient self-management 
of INRs compared to traditional clinic monitoring include the ability to easily and quickly 
obtain a capillary sample of blood, increased TTR (4.86% compared to the control 
group), a decrease in thromboembolism in 50% of patients, and a reduction in significant 
bleeding by 49%.  To improve the reliability of the device, as the coefficient of variation 
between devices can differ from 1.4-1.8%, the accuracy of the device should be checked 
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at the clinic at least twice annually when testing strips are changed.  Inter-laboratory 
variability can differ from 10-30%; thus, using the same lab is recommended for accuracy 
of results (Pozzi et al., 2016).  Point-of-care testing cannot be completed in patients with 
a hematocrit greater than 50% or with anti-phospholipid syndrome (Barcellona et al., 
2016).   
Management of Atrial Fibrillation 
Treatment of atrial fibrillation includes reduction of risk factors, medications to 
control the rate or rhythm of the heart, anticoagulants to prevent blood clots, and thus the 
risk of stroke, and surgery (CDC, 2015). 
Reduction of Risk Factors 
Patients should be educated on reversible risk factors for AF including obesity, 
alcohol overuse, hypertension, coronary artery disease, diabetes, infection, and 
hyperthyroidism (Ganz & Spragg, 2016).  Medical management of a secondary problem 
contributing to the atrial fibrillation should be encouraged to help determine the etiology 
of the disease as the inability to treat reversible comorbidities could result in recurrent 
AF.  Risk factors could be modified through lifestyle changes including physical activity, 
weight loss, incorporating extra virgin olive oil and omega-3 polyunsaturated fatty acids 
(fish oil) into the diet, and reducing the consumption of alcohol (Kumar, 2016b).  
Physical activity is beneficial to the cardiovascular system; yet, it could increase the 
lifetime incidence of AF with > 1,500 hours of endurance activity increasing atrial 
hypertrophy and dilatation, further affecting volume load and autonomic tone in the heart.  
Therefore, moderate physical activity is recommended as well as ablation therapy to 
prevent AF episodes in athletes (Kirchhof et al., 2016).   
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Heart failure.  Atrial fibrillation and heart failure display similar 
pathophysiology through cardiac remodeling, neurohormonal mechanisms, and impaired 
left ventricular functioning, resulting in worse patient outcomes with these dual 
diagnoses; treatment with anticoagulation could reduce the risk of strokes in this 
population.  Research has demonstrated treatment with an angiotensin-converting-
enzyme inhibitor (ACE inhibitor) or angiotensin II receptor blocker (ARB) could reduce 
the incidence of AF in patients with concurrent heart failure and hypertension (Kirchhof 
et al., 2016) and is recommended for heart failure preserved ejection fraction (HFpEF) 
patients with permanent AF (Class I, Level of Evidence B).  Digoxin can control resting 
heart rate in AF patients with heart failure reduced ejection fraction (HFrEF; Class I, 
Level of Evidence C) or digoxin along with a beta blocker to control heart rate during 
exercise (Class IIa, Level of Evidence B).  Intravenous amiodarone is used as the last 
resort in patients with AF and heart failure who are unable to achieve a normal heart rate 
through other pharmacological methods (Class IIa, Level of Evidence C), as well as AV 
node ablation or rhythm control treatments (Class IIa, Level of Evidence B/C; Kirchhof 
et al., 2016).  
Other comorbid diagnoses.  Echocardiograms diagnose AF with valve disease in 
30% of patients.  Valvular AF classifies patients with mitral stenosis or mechanical heart 
valves.  With a diagnosis of severe mitral stenosis, referral for mitral valve surgery is 
recommended to decrease stroke risk.  Decreasing obesity by 10-15 kg can decrease AF 
symptoms and recurrences.  In diabetic patients, treatment with metformin can decrease 
the risk of AF and stroke as poorly controlled diabetes increases the risk of 
thromboembolism and bleeding while on NOACs.  As obstructive sleep apnea 
47 
 
contributes to AF, screening for this disease and treatment with continuous positive 
airway pressure ventilation is recommended.  In patients with chronic obstructive 
pulmonary disease, beta blockers and theophyllines used to treat bronchospasm can 
exacerbate AF and complicate rate control.  Ventricular rate control with hyperthyroidism 
or chronic obstructive pulmonary disease can be managed with beta blockers or 
nondihydropyridine calcium channel blockers (Class I, Level of Evidence C; Kirchhof et 
al., 2016).  After acute coronary syndrome in patients with AF, warfarin with aspirin is 
recommended to prevent future cardiovascular events compared to dual treatment with 
aspirin and clopidogrel (Grade 2C; You et al., 2012).   
Approximately 15 to 20% of patients with AF have chronic kidney disease (CKD)  
(creatinine clearance < 60 mL/min); thus, dosages of NOACs are calculated through the 
Cockcroft-Gault formula to determine their utility for renal patients (Kirchhof et al., 
2016).  Evidence recommends all patients on oral anticoagulants have their kidney 
function assessed prior to initiating direct thrombin or factor Xa inhibitors and receive a 
minimum of annual screenings of renal function (Class I, Level of Evidence B; January et 
al., 2014) to assess for CKD in addition to screening of all patients with AF through 
serum creatinine or creatinine clearance for appropriate anticoagulation dosing (Class I, 
Level of Evidence A; Kirchhof et al., 2016).  After acute coronary syndrome in patients 
with AF, warfarin with aspirin is recommended to prevent future cardiovascular events 
compared to dual treatment with aspirin and clopidogrel (Grade 2C; You et al., 2012).   
When postoperative AF occurs, first line treatment is a beta blocker (Grade I, 
Level of Evidence A) with second choice of a nondihydropyridine calcium channel 
blocker (Grade I, Level of Evidence B).  Postoperative AF can be prevented through 
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administration of amiodarone prior to the cardiac surgery (Class IIa, Level of Evidence 
A).  With postoperative AF, sinus rhythm can also be achieved through antiarrhythmics, 
ibutilide, or direct-current cardioversion, urging the use of anticoagulants for 
thromboembolism prophylaxis (Class IIa, Level of Evidence B; January et al., 2014).  
Treatment Options 
The treatment of AF consists of stroke prevention (anticoagulation) and symptom 
management (rate and rhythm control; Kirchhof et al., 2016; Kumar & Manning, 2016).  
A summary from the AHA/ASA (2016) simplifying the atrial fibrillation treatment plan 
is illustrated within the Anticoagulation for Atrial Fibrillation Toolkit in Appendix A. 
Anticoagulation.  The selection of anticoagulant agent should be derived from 
shared decision-making between the patient and provider assessed through a thorough 
evaluation of thromboembolism, stroke risks, patient preference (Class I, Level of 
Evidence C), and risk of bleeding (Class I, Level of Evidence B; January et al., 2014).  
Atrial fibrillation management is improved when the treatment plan and patient education 
are individualized (Class I, Level of Evidence C; Kirchhof et al., 2016).  Factors to 
consider when selecting an anticoagulant include risk factors, predominantly intracranial 
bleeding, INR lability, drug interactions, adverse effects, cost, and patient choice 
(Meschia et al., 2014).  Furthermore, patients should be educated on the importance of 
adhering to the treatment plan and not missing a dose of medication; as DOACs have a 
shorter half-life than warfarin, missing only one dose can greatly increase the risk of 
stroke.  Net clinical benefit suggests DOACs offer benefits of improved convenience, 
fewer lab monitoring and food and drug interactions, and comparable safety and efficacy 
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profiles in preventing stroke in AF patients; yet, the choice of anticoagulant should 
continue to be prescribed on a patient specific basis (Shahid et al., 2016).   
The only approved anticoagulant for moderate to severe mitral valve disease 
(valvular AF) or mechanical heart value replacement is warfarin (Class I, Level of 
Evidence B--January et al., 2014; Class I, Level of Evidence B--Kirchhof et al., 2016), 
with a target INR of 2.0-3.0 (Grade 1B; You et al., 2012).  Aspirin with clopidogrel is a 
suitable alternative for valve patients unable to take warfarin (Grade 1B; You et al., 
2012).  Due to the heightened risk of stroke, a history of mitral stenosis with either a prior 
embolus or a left atrial thrombus, even in the presence of sinus rhythm, warrants 
anticoagulation (Class I, Level of Evidence B). With a bioprosthetic aortic or mitral valve 
replacement, the two approaches to prevent stroke include aspirin or warfarin with a 
target INR of 2.0-3.0 for the first three months after the valve is replaced (Class IIa, 
Level of Evidence C; Meschia et al., 2014). 
Rate versus rhythm control.  Symptom management is dependent on patient 
preference and can include pharmacological treatment, cardioversion, or catheter 
ablation.  Controlling ventricular rate is suggested initially to decrease symptoms.  
Subsequent rhythm versus rate control is dependent on symptoms, left ventricular systolic 
dysfunction, and patient preference with both methods displaying similar morbidity rates, 
mortality rates, and quality of life assessments.  Rates of thromboembolism are 
comparable between rhythm and rate control therapies (You et al., 2012).   
Rate control utilizes medications decreasing atrioventricular (AV) node 
conduction including beta-blockers, digoxin, and non-dihydropyridine calcium channel 
blockers (diltiazem or verapamil) or a combination of the aforementioned options 
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(Kirchhof et al., 2016; Kumar, 2016b).  The medication combination to control heart rate 
is dependent on the left ventricular ejection fraction (LVEF): with an LVEF ≤40%, beta-
blockers and/or digoxin is suggested while with an LVEF ≥40%, beta-blockers, digoxin, 
and a calcium channel blocker are recommended (Class I, Level of Evidence B).  The 
goal of rate control therapies is a resting heart rate less than 110 beats per minute while 
avoiding bradycardia (Class IIa, Level of Evidence B; Kirchhof et al., 2016).  Rate 
control tends to simplify the treatment regimen, costs less, and eliminates the risks 
associated with antiarrhythmics and catheter ablation.  Thus, rate control is preferred in 
asymptomatic or mildly symptomatic patients 65 years of age and older (Kumar & 
Manning, 2016) in addition to pregnant women with AF (Class IIa, Level of Evidence C; 
Kirchhof et al., 2016).   
Rhythm control utilizes antiarrhythmic drugs, percutaneous catheter ablation, 
and/or surgery (Kumar & Manning, 2016) and is recommended in patients who are 
unable to remain asymptomatic with rate control medications (Class I, Level of Evidence 
B; Kirchhof et al., 2016).  Flecainide, propafenone, or beta blockers are preferred 
antiarrhythmics in patients without structural heart disease, bradycardia, or tachycardia; 
dronedarone or statolol is preferred for coronary heart disease; and the combination of 
amiodarone and dofetilide is preferred with heart failure (Kumar, 2016a).  The European 
Society of Cardiology (Kirchhof et al., 2016) also recommends flecainide or propafenone 
for rhythm control of patients without structural heart disease (Class I, Level of Evidence 
A), and prescribing amiodarone to prevent recurrent AF with heart failure (Class I, Level 
of Evidence B) or for cardioversion with ischemic or structural heart disease (Class I, 
Level of Evidence A).  Nondihydropyridone calcium channel blockers are 
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contraindicated with heart failure (Class IIb, Level of Evidence C; January et al., 2014).  
Rhythm control is used more frequently in younger patients (less than 65-years-old) to 
regain normal sinus rhythm, recurrent symptoms despite rate control, and persistent AF 
with irreversible remodeling of the heart (Kumar & Manning, 2016).  Other options to 
achieve normal sinus rhythm include atrioventricular (AV) node ablation and ventricular 
pacing (Kumar & Manning, 2016) in AF resistant to medication management; yet, the 
majority of these patients eventually require pacemaker implantation to control 
ventricular rate (Kirchhof et al., 2016).  Even if patients with AF are treated via a rhythm 
control method, their stroke risk and necessity for anticoagulation should be evaluated 
equivalently to other AF patients (Grade 2C; You et al., 2012). 
Left atrial appendage closure.  In patients with contraindications to long-term 
anticoagulation, since 2005 percutaneous left atrial appendage (LAA) procedures such as 
WATCHMAN© (Boston Scientific, 2016) are an alternative within the United States and 
Europe (Hijazi & Saw, 2016).  With NVAF, greater than 90% of blood clots from the left 
atrium originate in the left atrial appendage; thus, implantation of the WATCHMAN 
device traps clots in the LAA.  Under general anesthesia within the catheterization lab 
and with the guidance of fluoroscopy and transesophageal echocardiography (TEE) to 
ensure accurate LAA measurement and fit, WATCHMAN is inserted through the femoral 
vein, advanced transseptally into the left atrium, and finally implanted into the LAA.  The 
WATCHMAN requires an hour to implant and approximately a one-day hospital 
admission.  Post implant, patients are required to take aspirin and warfarin for a minimum 
of 45 days to ensure the LAA is encapsulated by heart tissue (confirmed by a TEE), 
followed by clopidogrel and a higher dose of aspirin for six months, and finally aspirin 
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for life.  The WATCHMAN is covered by Medicare and most major insurance companies 
and is a permanent device only requiring a one-time insertion.   
Compared to warfarin, LAA closure has demonstrated a 52% reduction in 
cardiovascular death, a 72% decrease in severe bleeding six months after the procedure, 
and a 78% decrease in hemorrhagic stroke (Boston Scientific, 2016).  However, LAA has 
an increased risk of pericardial effusion, excessive bleeding, and procedure-related 
complications compared to warfarin (You et al., 2012).  Evidence has demonstrated LAA 
closure is non-inferior to warfarin in preventing stroke in AF patients with reduced 
bleeding risk.  The AHA/ASA (2016) endorse left atrial appendage closure with AF; 
patients demonstrating a high risk of stroke are poor candidates for anticoagulation if the 
patient can temporarily take anticoagulation 45 days after the surgery (Class IIb, Level of 
Evidence B; Meschia et al., 2014).  The ESC (Kirchhof et al., 2016) also proposes 
anticoagulation after LAA to prevent strokes (Class I, Level of Evidence B).  
Furthermore, WATCHMAN is cost effective within seven years after implantation, costs 
less, is more effective than five years of treatment with DOACs, and is more effective 
than 10 years of treatment with warfarin (Desai et al., 2017).   
Cardioversion.  Patients may be candidates for cardioversion to restore sinus 
rhythm before initiation of antiarrhythmics (Naccarelli, Ganz, & Manning, 2016).  Two 
forms of cardioversion are available--pharmacological and direct current (electrical); 
pharmacological methods can restore sinus rhythm in 50% of patients with AF without 
sedation or nothing by mouth while electrical methods can more successfully achieve 
sinus rhythm within a shorter duration of time and are recommended with hemodynamic 
instability.  With electrical cardioversion, the patient is sedated with intravenous propofol 
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and/or midazolam followed by synchronized shocks delivered through a biphasic 
defibrillator to anterior and posterior electrodes.  Risks with electrical cardioversion 
include bradycardia and skin burns (Kirchhof et al., 2016).  Direct current cardioversion 
is suggested in patients with a rapid ventricular rate who are unable to be converted via 
pharmacological means (Class 1, Level of Evidence B).  Pharmacological cardioversion 
can consist of the following agents: flecainide, dofetilide, propafenone, ibutilide (Class I, 
Level of Evidence A) or amiodarone (Class IIa, Level of Evidence A; January et al., 
2014) with heart failure and ischemic heart disease.  Patients with paroxysmal AF can 
self-cardiovert at home (“pill in the pocket”) with one dose of flecainide or propafenone 
when symptoms arise (Kirchhof et al., 2016) concurrent with a beta blocker or 
nondihydropyridine calcium channel blocker (Class IIa, Level of Evidence B; January et 
al., 2014).  
In stable patients with atrial fibrillation duration greater than 48 hours, oral 
anticoagulation should be started three weeks prior to cardioversion to reduce the risk of 
stroke (Class I, Level of Evidence B--January et al., 2014; Class I, Level of Evidence B--
Kirchhof et al., 2016; Naccarelli et al., 2016) and continued four weeks after the 
cardioversion (Level of Evidence B--January et al., 2014; Class I, Level of Evidence B--
Kirchhof et al., 2016; Class 1B--You et al., 2012; Class I).  The CHEST (cited in You et 
al., 2012) suggests either warfarin with a target INR of 2.0-3.0, dabigatran, or low-
molecular weight heparin as suitable options prior to cardioversion with AF duration 
longer than 48 hours (Grade 1B).  An alternative to anticoagulation prior to cardioversion 
is a TEE to assess for the presence of cardiac thrombi; if a thrombus is not discovered in 
the left atrial appendage, cardioversion is completed immediately (Class I, Level of 
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Evidence B; Kirchhof et al., 2016).  To prevent stroke, the American Academy of Chest 
Physicians guidelines recommend brief anticoagulation before TEE guided cardioversion 
(Grade 1B; You et al., 2012).  The AHA/ACC/HRS (2014) recommends using warfarin 
as the anticoagulant for four weeks after the cardioversion (Class I, Level of Evidence B), 
or dabigatran, rivaroxaban, or apixaban (Class IIb, Level of Evidence C; January et al., 
2014).   
With AF duration less than 48 hours, anticoagulating the patient with low-
molecular weight heparin or unfractionated heparin should occur prior to the 
cardioversion (Grade IIb, Level of Evidence C--January et al., 2014; Grade 2C; You et 
al., 2012); yet, starting anticoagulation should not delay an urgent cardioversion (Grade 
2C; You et al., 2012).  In emergent cases, heparin is utilized as the anticoagulant 
(Naccarelli et al., 2016).  Of note, the first 72 hours and up to 10 days after cardioversion 
displays the highest risk of stroke and thromboembolism as it can take weeks for the 
atrial dysfunction to subside.  Within one year after cardioversion, one-half of the 
patients will have a recurrence of AF (You et al., 2012).  The necessity of anticoagulation 
after cardioversion is based upon the patient’s individualized risk profile for 
thromboembolism (Class I, Level of Evidence C; January et al., 2014).  
Ablation.  Radiofrequency ablation or cryotherapy balloon catheterization of the 
pulmonary veins, a primary cause of paroxysmal AF, can be utilized to achieve normal 
sinus rhythm and symptom control in patients who have failed antiarrhythmic therapies.  
Anticoagulation should be prescribed eight weeks prior to the ablation to reduce the risk 
of stroke.  Catheter ablation results in a one-year period absent of symptomatic atrial 
fibrillation in 80% of patients without structural heart disease; however, complications of 
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this procedure include cardiac tamponade, stroke, and vascular trauma.  With recurrent 
AF after an ablation, a second ablation or antiarrhythmic medication may be warranted 
(Passmar, 2016).  In heart failure patients with AF, catheter ablation can reduce recurrent 
AF and even improve LVEF (Kirchhof et al., 2016).  
Cox-Maze.  The Cox-Maze surgical procedure creates alternative electrical 
pathways from the sinoatrial node to the atrioventricular node, preventing AF conduction 
in patients with symptomatic persistent or long-standing persistent AF (Lee, 2017).  The 
Cox-Maze IV is completed to improve diastolic filling and atrial synchrony plus alleviate 
AF.  In this procedure, bipolar frequency and/or cryothermal energy are used to fabricate 
scar tissue on the right atrium (superior vena cava to inferior vena cava), left atrium 
(posterior wall), the four pulmonary veins forming a “box” attached to the mitral valve 
annulus, and removal of the left atrial appendage.  Often, the invasive sternal approach is 
completed during a coronary artery bypass graft (CABG) or valve surgery or a less 
invasive thoracotomy approach is available.  Risks include increased incidence of 
subsequent pacemaker implantation, pericardial tamponade, requirement of a sternotomy 
approach, and TIA (Kirchhof et al., 2016).  Anticoagulation is recommended for three 
months after the Cox-Maze procedure in patients who have had the left atrial appendage 
ligated or removed to decrease the risk of stroke (Lee, 2017).   
Atrial fibrillation management team approach.  The ESC (Kirchhof et al., 
2016) recommends the following approach to managing AF successfully:  
1. Patient involvement (patient education, patient empowerment, reduction of 
risk factors, lifestyle modifications, and shared decision making) 
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2. Multidisciplinary team (primary care providers, cardiologists, AF 
specialists, surgeons, and allied health providers working together 
collaboratively) 
3. Navigation system for providers and patients (tools and checklists to 
improve communication, clinical decision support, availability of 
information on AF, and the ability to monitor the compliance and 
effectiveness of the treatment plan)  
4. Complex management decisions (anticoagulation, rate control, lifestyle 
modifications, antiarrhythmics, and catheter and surgical options).   
The goals of this integrated approach to AF management include reduction of 
hospitalizations, enhanced patient adherence to the treatment plan by incorporating 
patient preference into the decision-making process, improved patient outcomes, and 
decreased mortality.  Atrial fibrillation can be well managed within the primary care 
setting; however, a referral to an AF specialist is recommended in the presence of the 
following factors: hemodynamic instability (severe symptoms), history of TIA or stroke 
necessitating anticoagulation, symptomatic bradycardia, poor rate control (fast heart rate), 
deteriorating left ventricular function, severe angina, assessment for rhythm control, or 
special conditions (thyrotoxicosis, sepsis, or postoperative AF; Kirchhof et al., 2016). 
Performance and quality measures.  In 2016, the ACC and AHA (Heidenrich et 
al., 2016) released performance and quality measures related to AF management in both 
the inpatient and outpatient settings to improve the management, safety, and care 
coordination of these patients.  Performance measures for the outpatient setting include 
documentation of a completed CHA2DS2-VASc score, prescribing anticoagulation when 
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appropriate, and completing monthly INRs for patients on warfarin.  Quality measures 
include prescribing a beta blocker with a left ventricular ejection fraction < 40% and not 
prescribing a direct thrombin inhibitor or factor Xa inhibitor with mechanical heart 
values, end-stage kidney disease, or dialysis.  Other quality measures include not 
prescribing oral anticoagulants and antiplatelets (unless the patient has coronary artery 
disease or vascular disease) to reduce bleeding risk, not prescribing a calcium channel 
blocker with reduced ejection failure heart failure, and the necessity of shared decision-
making between the patient and provider when prescribing anticoagulation (Heidenrich et 
al., 2016).  
Pregnancy.  In pregnant women with atrial fibrillation, digoxin or beta-blockers 
are safe for rate control during pregnancy and breast feeding.  For rhythm control, sotalol 
and flecainide are safe during pregnancy.  Electrical cardioversion is a harmless 
alternative during all stages of pregnancy, especially with hemodynamic instability.  
Vitamin K antagonists should be avoided during the first trimester and two to four weeks 
prior to delivery of the fetus due to bleeding risks and teratogenic effects.  A safe 
alternative for anticoagulation is low-molecular weight heparin as it does not cross the 
placenta.  In pregnant women with mechanical valves who decide not to continue with 
warfarin, within 6 to 12 weeks of gestation, they should be transitioned to dose-adjusted, 
subcutaneous, low-molecular weight heparin or unfractionated heparin.  During the third 
trimester, INRs should be checked every 10 to 14 days.  Data have been inconclusive in 
determining whether NOACs are excreted into breastmilk (Daiichi Sankyo, Inc., 2015; 
Drugs.com, 2015a, 2015c, 2016).  Warfarin is not present in breastmilk but should be 
avoided during lactation due to the increased risk of bleeding for the fetus (Drugs.com, 
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2015c).  The pregnancy categories of NOACs are as follows: Category B--apixaban 
(Drugs.com, 2016); Category C--rivaroxaban (Drugs.com, 2015b), dabigatran 
(Drugs.com, 2015a), edoxaban (Daiichi Sankyo, 2015), and warfarin with mechanical 
valves (Drugs.com, 2015c); and Category X--warfarin without mechanical valves 
(Drugs.com, 2015c).  However, due to lack of safety evidence, NOACs should be 
avoided during pregnancy and in women attempting to become pregnant (Class III Harm, 
Level C; Kirchhof et al., 2016).  
Other comorbid diagnosis.  With a diagnosis of hypertrophic cardiomyopathy, 
lifetime anticoagulation with AF is recommended to decrease the risk of stroke regardless 
of the CHA2DS2-VASC score (Class I, Level of Evidence B--January et al., 2014; Class 
I, Level of Evidence B--Kirchhof et al., 2016).  In the presence of an atrial septal defect, 
surgical closure prior to 40-years-old or a Cox-Maze procedure are suggested to decrease 
the risk of atrial fibrillation or atrial flutter.  Treatments for atrial flutter with 
anticoagulation (Class I, Level of Evidence C--January et al., 2014; Class I, Level of 
Evidence B--Kirchhof et al., 2016; You et al., 2012), electrical cardioversion, and 
antiarrhythmics are congruent with AF therapies as the stroke risk is comparable; 
however, rate control is often more difficult to achieve with atrial flutter (Kirchhof et al., 
2016).  With a CHA2DS2VASc score ≥ 2 in addition to hemodialysis or end-stage chronic 
kidney disease (creatinine clearance < 15 mL/min), warfarin is the preferred 
anticoagulant (Class IIa, Level of Evidence B).  With the diagnosis of moderate to severe 
chronic kidney disease and CHA2DS2VASc score ≥ 2, dose adjusted direct thrombin 
inhibitors or factor Xa inhibitors are viable options instead of warfarin for anticoagulation 
(Class IIb, Level of Evidence; January et al., 2014).   
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With comorbid AF and acute coronary syndrome and a CHA2DS2VASc score ≥ 2, 
anticoagulation is suggested (Class I, Level of Evidence C; January et al., 2014), more 
specifically dose-adjusted warfarin with a target INR of 2.0-3.0 instead of warfarin 
combined with aspirin (Grade 2C; You et al., 2012).  Furthermore, CHEST (cited in You 
et al., 2012) suggests triple therapy (oral anticoagulant, warfarin, and clopidogrel) for 
three to six months after a drug-eluting stent is placed (Grade 2C), followed by dual 
therapy for up to one year (Grade 2C) to prevent occlusion of the coronary artery and 
further ischemic events.  One year after placement of the stent, the same anticoagulant 
recommendations for dose-adjusted warfarin in patients with stable coronary artery 
disease (no incidence of acute coronary syndrome within the past year) and AF apply 
(Grade 2C).  In a patient with acute coronary syndrome and a CHADS2 score of 1 or 
greater who does not receive a coronary stent, dose-adjusted warfarin plus aspirin of 
clopidogrel is recommended for one year (Grade 2C; You et al., 2012).   
Reversal Agents for Anticoagulants 
Introduction 
If the CHA2DS2-VASc recommends a patient initiate or continue anticoagulation, 
the HAS-BLED score is useful for determining bleeding risk (Hwang, 2016b) as shown 
within the Anticoagulation for Atrial Fibrillation Toolkit in Appendix A.  A HAS-BLED 
score of 1 suggests a risk of 1.13 bleeds per 100 patient-years, a score of 4 implies 8.70 
bleeds, and scores > 5 display insufficient evidence to predict bleeding risk.  Major 
bleeding may result in hospitalization, the need for blood transfusions, surgery, or the 
complication of intracranial hemorrhage (Manning et al., 2016).  With minor bleeding 
such as epistaxis or ecchymosis, applying manual compression to control the source of 
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bleeding or stopping the anticoagulant with high bleeding risk are appropriate treatments.  
is an appropriate treatment.  With a major bleed, cessation of the offending anticoagulant 
is warranted as well as administration of intravenous fluids, packed red blood cells, and 
platelet transfusions as needed (Hu et al., 2016).  Methods to reduce bleeding risk include 
hypertension control using an agent other than dabigatran at patients with high risk of 
gastrointestinal bleeding, and reducing alcohol consumption (Kirchhof et al., 2016).   
Warfarin 
If the patient develops life-threatening bleeding while on warfarin, the reversal 
agent for warfarin is vitamin K1 (Hull & Garcia, 2016a).  According to the European 
Society of Cardiology, fresh frozen plasma and prothrombin complex demonstrate 
quicker reversal of bleeding than vitamin K1 administration (Kirchhof et al., 2016).  
Managing patients with high INRs on warfarin is very specific.  With a high INR, 
warfarin should be stopped as an INR will return to normal within four to five days.  The 
second choice is to administer the antidote vitamin K1 as needed.  The third choice, 
which would most quickly return the INR to normal, is administration of fresh plasma or 
prothrombin concentrate.  Below is a summary of the recommended reversal treatments 
based on INR levels:  
• With an INR high but < 5, the warfarin dose can be reduced or omitted until 
the INR nears the normal range.   
• With an INR between 5 and 9 without bleeding, the next one to two warfarin 
doses are held with the dose lowered when the INR approaches normal or 
vitamin K1 (1.5 to 2.5 mg) can be administered orally if the risk of bleeding 
is high.  If rapid reversal of warfarin is necessitated, such as for surgery, 
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vitamin K1 (2.0 to 5.0 mg) can be given orally with a decrease in the INR 
within the next 24 hours.  If the INR is not therapeutic within 24 hours, 
another dose of vitamin K1 (1.0 or 2.0 mg) can be administered.   
• With an INR >9 but without bleeding, vitamin K1 (3.0 to 5.0 mg) can be 
given orally with a drop in the INR within 24 to 48 hours.   
• With an INR > 20 or severe bleeding, vitamin K1 (10 mg) should be given 
intravenously followed by fresh plasma or prothrombin complex 
concentrate; extra vitamin K1 may be given every 12 hours as needed (Hirsh 
et al., 2003).   
High doses of vitamin K1 should be avoided if possible, as resistance to warfarin can 
occur for a duration of one week after reversal with vitamin K1.  Thus, if warfarin is 
administered after vitamin K1, heparin bridging may be necessary to achieve therapeutic 
INRs (Hirsh et al., 2003).  
Direct Oral Anticoagulants 
Reversal of a DOAC can occur through drug removal, bypassing to other 
coagulation pathways, or sequestration using precise reversal agents.  Activated charcoal 
(dabigatran and apixaban; Garcia & Crowther, 2017; Hull & Garcia, 2016b) and 
hemodialysis (dabigatran) are methods to remove NOACs from the body (Samuelson & 
Cuker, 2016), especially in the case of drug overdoses (Garcia & Crowther, 2017; Hu et 
al., 2016).  Nonspecific prothrombin complex concentrate, activated prothrombin 
complex concentrate (PCC), and recombinant factor VIIa are means to bypass 
coagulation pathways.  The intravenous drug-specific agents bind to the NOAC molecule 
to reverse the anticoagulant effects: Idarucizumab (humanized monoclonal antibody 
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fragment) sequesters dabigatran, and Andexanet alpha (factor Xa decoy) and Ciparantag 
(synthetic cationic molecule) are two factor Xa inhibitors currently undergoing clinical 
investigation.  If approved by the FDA as a universal reversal agent, Ciparantag could 
also reverse the anticoagulant effects of dabigatran and heparin (Hu et al., 2016; Ruff, 
Giugliano & Antman, 2016; Samuelson & Cuker, 2016).   
Until a specific factor Xa inhibitor reversal agent is developed, severe or life-
threatening bleeding with these agents (edoxaban, rivaroxaban, and apixaban) can be 
reversed with 4-factor PCC 50 IU/kg, which contains clotting factors, heparin, and 
coagulation inhibitors protein C and protein S (Garcia & Crowther, 2017; Hull & Garcia, 
2016a; Ruff, Giugliano, & Antman, 2016).  Neither vitamin K1 nor fresh-frozen plasma 
can reverse DOACs (Ruff et al., 2016).  If major bleeding occurs during or post 
procedure, antifibrinolytics such as tranexamic and Ɛ-aminocaproic acid are cost effective 
and safe options (Garcia & Crowther, 2017; Hull & Garcia 2016b; Hu et al., 2016).  Of 
significance, drug specific antidotes should only be utilized in either the presence of life 
threatening bleeding or for emergency surgery (Hu et al., 2016).  
Switching Between Warfarin and  
Direct Oral Anticoagulants 
Direct Oral Anticoagulants  
to Warfarin 
Factors to consider when switching from a DOAC to warfarin and vice versa 
include cost, interactions, and availability.  When transitioning between classes of 
anticoagulants (warfarin, factor Xa inhibitors, and direct thrombin inhibitors), an overlap 
period must occur to prevent an increased risk of stroke while new drug levels are 
becoming therapeutic.  A minimum of a two-day overlap is recommended when 
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switching from a DOAC to warfarin.  As a DOAC can alter the accuracy of INR levels 
for warfarin dosing, edoxaban and apixaban should be continued until the INR is ≥ 2.0.  
A recommended regimen when transitioning from any of the four approved DOACS 
(dabigatran, apixaban, edoxaban, and rivaroxaban) to warfarin suggests a reduced dose of 
the DOAC, INR testing for a goal of ≥ 2.0, and adjusted dose of warfarin for up 14 days 
(or until the INR is therapeutic) to decrease the risk of bleeding and stroke.  Parental 
agents are used concurrently with the DOAC as needed to achieve a therapeutic INR 
quicker (Manning et al., 2016).  A longer overlap is recommended between warfarin and 
dabigatran if the CrCl is prolonged (Drugs.com, 2015a).  
Warfarin to Direct Oral  
Anticoagulants 
When switching to apixaban (Drugs.com, 2016) or dabigatran (Drugs.com, 
2015a), warfarin can be discontinued followed by initiating the DOAC once the INR is < 
2.0.  For rivaroxaban, warfarin can be discontinued and then followed by starting the 
DOAC once the INR is < 3.0 (Drugs.com, 2015b).  Of note, when switching between 
DOACs, the current DOAC should be stopped with the new DOAC administered at the 
standard dose time; no period of overlap between drugs is necessary (Guimaraes et al., 
2015; Manning et al., 2016).  For edoxaban, warfarin can be discontinued, followed by 
starting the DOAC once the INR is 2.5 (Daiichi-Sankyo, 2015; Guimaraes et al., 2015).  
Cessation of Anticoagulants Prior to  
Invasive Procedures and Surgery 
Warfarin 
Warfarin is usually stopped four to five days before surgery for the INR to 
decrease to < 1.2.  With a low risk of blood clots, the warfarin dose can also be reduced 
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for this four to five-day period prior to surgery to achieve an INR of 1.3-1.5.  For up to 
two to three days postoperative, the patient is at risk for a thromboembolism.  As a result, 
prophylactic doses of heparin or low molecular weight heparin can be administered every 
12 hours for four to five days until the INR becomes therapeutic again (Hirsh et al., 
2003).   
Direct Oral Anticoagulants 
Cessation of DOACs prior to an invasive procedure to decrease bleeding risk is 
dependent on the anticoagulant.  Recommendations for cessation of the individual DOAC 
agents are as follows:  
• Rivaroxaban: Rivaroxaban is discontinued 24 hours pre-procedure and can 
be resumed 6 to 10 hours after hemostasis is achieved post-procedure 
(Drugs.com, 2015b).   
• Dabigatran: With a CrCl >50 mL/min, dabigatran should be held one to two 
days prior to the procedure.  With a CrCl < 50 mL/min, dabigatran should be 
held three to five days prior to the procedure (Drugs.com, 2015a).   
• Apixaban: Apixaban should be discontinued 48 hours pre-procedure in 
patients with a moderate to high risk of bleeding or 24 hours pre-procedure 
with a low risk of bleeding.  The anticoagulant should be resumed 12 to 24 
hours post-procedure after hemostasis is achieved (Drugs.com, 2016).   
• Edoxaban: Recommendations suggest edoxaban be discontinued 24 hours 
pre-procedure with a high risk of bleeding and then resumed as soon as 
hemostasis is achieved.  Indwelling intrathecal catheters and epidural 
catheters should not be removed less than 12 hours after the last dose of 
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edoxaban to prevent bleeding; the next dose should be given two hours after 
the catheter is removed (Daiichi Sankyo, 2015).   
In general, factor Xa inhibitors should be withheld a minimum of 24-48 hours 
before a procedure with an intermediate bleeding risk and 48-72 hours before a high 
bleeding risk procedure while direct thrombin inhibitors should be withheld a minimum 
of 72 hours before the procedure.  With renal impairment, the DOAC should be withheld 
even longer.  Permitting hemostasis is achieved, DOACs can be resumed within 24 hours 
after the procedure and up to 48 hours with a high risk of bleeding (Doherty et al., 2017; 
Hu et al., 2016).  
Recommendations 
The ACC (2012) released an expert consensus providing guidance on cessation of 
anticoagulants in NVAF prior to procedures (periprocedurally) as every year 
approximately 250,000 patients require this momentary disruption in therapy.  The ACC 
recommends assessing for stroke risk via the CHA2DS2-VASc (rather than the CHADS2) 
score and utilizing a bleeding risk score through HAS-BLED to identify risk factors for 
bleeding.  Key components for providers to assess prior to interruption of anticoagulation 
therapy include the need to interrupt (low, intermediate, or high risk of bleeding 
periprocedure), when to interrupt, the need to bridge with a parenteral anticoagulant post-
procedure, how to bridge, and when to restart oral anticoagulation.  Recommendations 
for cessation of anticoagulants periprocedurally are as follows: 
• Low bleeding risk procedures: Common procedures such as implantation of 
a pacemaker/defibrillator or a catheter ablation demonstrate lower rates of 
bleeding with uninterrupted oral anticoagulant during the procedure 
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compared to bridging post-procedure.  Specifically, a VKA should not be 
interrupted prior to a procedure with a low bleeding risk and no patient 
specific risk factors increasing bleeding risk (Doherty et al., 2017) such as 
minor dental procedures, cataract surgery, and minor dermatological 
procedures (University of Colorado Health North, 2015).   
• Intermediate and high bleeding risk procedures: A VKA should be 
interrupted with an intermediate bleeding risk procedure, high bleeding risk, 
or unknown bleeding risk.  Prior to cessation of anticoagulation, an INR 
should be checked five to seven days before the procedure.  Cessation of the 
INR before the procedure depends on the INR, which should be assessed 24 
hours periprocedurally: the VKA should be interrupted three to four days 
before a procedure with an INR of 1.5-1.9, five days prior to the procedure 
with an INR of 2.0-3.0, and greater than five days with an INR greater than 
3.0.  Higher dosages of warfarin may require shorter periods of interruption 
(Doherty et al., 2017).   
Bridging with Heparin 
As warfarin takes five to seven days to regain therapeutic effects once restarted, 
bridging with parenteral low molecular weight heparin (LMWH) or unfractionated 
heparin (UFH) is often required to prevent thromboembolism postprocedural, especially 
with an INR < 2.0 in NVAF.  Parenteral bridging initiation is recommended within 24 
hours post-procedure with an intermediate to high risk of stroke or thromboembolism in 
patients with NVAF and is contraindicated with high bleeding risk (delaying any 
anticoagulation 48-72 hours post-procedure).  Bridging does not come without its own 
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perils such as increased cardiovascular sequalae and bleeding risk; recent evidence 
suggests thromboembolic events are not decreased greatly with bridging (NVAF patients 
have a 0.4% risk of thromboembolism regardless if they received or did not receive 
bridging when starting warfarin; Doherty et al., 2017).   
Parenteral agents.  Length of hospital stay is shortened with parenteral LMWH 
but UFH should be used in patients with a CrCl < 30 mL/min; both drugs demonstrate 
comparable bleeding and thromboembolism risks.  The level of anticoagulant effect can 
be measured through an activated partial thromboplastin time (aPTT) for UFH and an 
LMWH-specific antifactory Xa assay.  Post-procedure, a VKA can be restarted within 24 
hours at the prior therapeutic dose if hemostasis is achieved; the parenteral drug is 
stopped once the INR is > 2.0.  Furthermore, LMWH should be stopped 24 hours pre-
procedure and UFH stopped four to six hours pre-procedure (Doherty, et al., 2017).   
Direct oral anticoagulants.  Despite the lack of specific reversal agents for 
DOACs, their short half-life requires less therapeutic interruption periprocedurally, 
bridging is not required, and the drug can be started as soon as hemostasis is achieved.  
For DOACs specifically, the bleeding risk, individual drug, and the creatinine clearance 
predicted through the Cockcroft-Gault equation determine when to halt and resume 
therapy for procedures.  All the DOACs have a black box warning contraindicating the 
use of these medications during neuraxial analgesia to prevent the occurrence of spinal or 
epidural hematomas.  Thus, direct thrombin inhibitors should be withheld four to five 
days and factor Xa inhibitors held three to five days before neuraxial analgesia; these 
drugs can be safely restarted 24 hours after the procedure.  Current research recommends 
against using DOACs for anticoagulation post mechanical valve surgery but can be used 
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27 hours after hemostasis is obtained post coronary artery bypass grafting (Doherty et al., 
2017). 
Conclusions.  In a patient with a low thromboembolism risk (<5% annually), a 
CHA2DS2-VASc score ≤4 with no history of a prior stroke, systemic embolism or 
transient ischemic attack, a VKA can be restarted post-procedure without bridging.   
With an intermediate risk of thromboembolism (5-10% annually) and a CHA2DS2 
VASc score of 5-6, recommendations are based upon bleeding risk: with a higher  
bleeding risk, bridging is contraindicated but with a low bleeding risk, parenteral  
bridging is recommended only with a history of a prior stroke, systemic embolism, or 
TIA.  With a high risk of thromboembolism (> 10% annually), a CHA2DS2-VASc score 
of 7-9, and a history of prior stroke, systemic embolism, or transient, bridging with a 
parenteral agent is recommended (Doherty et al., 2017). 
Drug and Food Interactions with Anticoagulants 
Warfarin 
With warfarin, cytochrome P450 inducers and inhibitors or CYP2C9, CYP1A2, 
CYP2C19, and CYP3A4 isoenzymes influence the pharmacology of this medication and 
thus its INR values.  Predominantly, drug interactions with warfarin result in severe 
bleeding and usually do not occur until three to five days after administration.  Factors 
influencing the effects of warfarin include age, broad spectrum antibiotics, intake of 
vitamin K, sex, body surface area, substances with a high protein concentration, and 
genetic polymorphisms CYP2C9 and VKORC1.  Foods to avoid with warfarin include 
grapefruit, green tea, chamomile, soybeans, mango, ginseng, St. John’s wort, ginkgo 
biloba, cranberry, and green leafy vegetables with a high concentration of vitamin K.  
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Concurrent use of NSAIDs, aspirin, and clopidogrel increase the risk of bleeding while 
on warfarin; use of estrogen increases the risk of clotting (DiMinno et al., 2017).  
Specific medications which can affect the INR are illustrated within the Anticoagulation 
for Atrial Fibrillation Toolkit located in Appendix A. 
Direct Oral Anticoagulants 
Factor Xa inhibitors are influenced by administration of inducers or inhibitors of 
CYP3A4 and P-gp.  Specific to dabigatran, P-gp inhibitors and inducers should also be 
avoided.  Drug interactions with DOACs appear less severe than with warfarin; however, 
limited evidence is available on food interactions with the DOACs (DiMinno et al., 
2017).  Furthermore, protease inhibitors to treat human immunodeficiency infection 
(HIV) and enzyme-inducing antiepileptics such as phenytoin and carbamazepine are 
contraindicated with DOACs (Manning et al., 2016).   
Anticoagulation in the Elderly Population 
Research Studies 
According to the AHA, “Atrial fibrillation (AF) is increasingly recognized as the 
single most important cause of disabling ischemic stroke in the elderly” (Perera et al., 
2016, p. 2197).  A survey of Medicare patients with atrial fibrillation demonstrated the 
average age is 80-years-old and over 55% are female; new data suggest women with AF 
over age 75 have a heightened risk of stroke compared to their male cohorts (Foody, 
2017).  When anticoagulating the elderly, a clinician should consider factors such as 
polypharmacy, impaired cognition, fall risk, comorbidities contributing to bleeding risk, 
CKD, nutritional status, and weight (Barbosa & Falcao, 2016).  Other factors to 
investigate include compliance to the treatment plan, health literacy, ability to obtain 
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medications and INR monitoring, adverse drug effects, cognition, family support, and the 
relationship between the patient and provider.  Hospitalization for AF may be related to 
drug-drug interactions with oral anticoagulants, contributed to the most frequent 
comorbidities of heart failure, renal failure, chronic obstructive pulmonary disease, and 
diabetes mellitus (Foody, 2017).   
Advanced age ≥ 65 years old is a risk factor for thromboembolism, yet is also a 
risk factor for increased bleeding risk.  Non-vitamin K oral anticoagulants (NOACs) 
selectively inhibit one coagulation pathway--either thrombin/factor IIa or factor Xa.  
Resulting from the mechanisms of action, the NOAC effects are more predictable, have a 
quicker onset of action, a reduced half-life, and a larger therapeutic window.  Therefore, 
NOACs do not require routine lab monitoring compared to warfarin and are more highly 
recommended in the elderly.  Non-vitamin K oral anticoagulants are not endorsed in 
elderly patients with chronic kidney disease (CrCl < 30 mL/min with dabigatran and CrCl 
< 15 mL/min with factor Xa inhibitors) nor with a body weight ≤ 60 kg (edoxaban and 
apixaban).  Other considerations in the elderly patient on warfarin include a deficient 
vitamin K diet and alcohol consumption, which increase bleeding risk, as well as genetic 
polymorphisms affecting metabolism of this drug.  The overall bleeding risk for NOACs 
is comparable to warfarin; however, the risk of GI bleeding is higher for NOACs. 
Intracranial hemorrhage is the cause of 90% of warfarin-related deaths, yet NOACs have 
demonstrated a reduced risk of this complication.  Astonishingly, for an AF patient on 
long-term anticoagulation, this patient could fall 300 times annually before the risk of 
bleeding offsets the risk of anticoagulation use (Barbosa & Falcao, 2016).  Another study 
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suggests patients would have to fall over 5.7 times per week before the risk-benefit ratio 
would favor no anticoagulation (Janssen Pharmaceuticals, 2014a).   
Despite the three-fold risk of strokes in patients older than 75-years-old, only 30% 
to 50% of applicable patients receive anticoagulation.  In studies examining stroke 
prevention in elderly NVAF patients, the NOACs rivaroxaban, apixaban, and dabigatran 
demonstrated improved efficacy and safety compared to warfarin.  Additionally, these 
same three NOACs have been approved to decrease cardiovascular risk prior to 
cardioversion in NVAF.  Related to safety and efficacy data, particularly the decreased 
risk of intracranial hemorrhage, this study concluded NOACs are superior to warfarin 
when anticoagulating the elderly including NVAF.  In summary, despite the increased 
risk of stroke in this population, the elderly population is undertreated with 
anticoagulation (Barbosa & Falcao, 2016).  
Negative Outcomes with  
Anticoagulation 
Elderly patients demonstrate an amplified risk of hospitalization related to drug 
reactions convoluted by factors such as polypharmacy, comorbid diseases, fragility, and 
physiological changes associated with increasing age as evidenced by a seven-fold 
increased risk compared to a younger population.  A study in the New England Journal of 
Medicine (Budnitz, Lovegrove, Shehab, & Richards, 2011) concluded two-thirds of 
hospitalizations for patients 65 years of age and older were related to accidental 
overdoses of four high-risk medications: warfarin (33.3%), oral antiplatelet medications 
(13.3%), insulins (13.9%), and oral hypoglycemic medications (10.7%).  Specific to 
warfarin, 46.2% of emergency department visits for warfarin related adverse effects 
resulted in hospitalization for patients.  In addition, 50% of these hospitalizations were in 
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patients older than 80 years of age.  National hospitalization rates for adverse drug effects 
related to warfarin included intracranial hemorrhage (5.6%), gastrointestinal hemorrhage 
(40.8%), epistaxis (6.1%), hemoptysis (2.0%), genitourinary hemorrhage (4.7%), 
abnormal laboratory value (increased INR or drug toxicity, 23.7%), or other hemorrhage 
(5.3%; Budnitz et al., 2011).  Furthermore, over 90% of elderly AF patients are at an 
increased risk of stroke and less than 50% of patients with AF in a long-term care facility 
receive adequate anticoagulation (Janssen Pharmaceuticals, 2014a).   
Beers Criteria 
The updated 2015 American Geriatrics Society (AGS) Beers Criteria, which 
highlights medications deemed high risk for the elderly population, emphasized specific 
recommendations for cautious use of aspirin, warfarin, and dabigatran in this population.  
Quality of evidence (high, moderate, and low) and strength of recommendations (strong, 
weak, and insufficient) were evaluated using the American College of Physician’s 
guideline grading system.  Aspirin to prevent cardiovascular events should be used 
cautiously in patients 80 years of age or older (low quality of evidence, strong strength of 
recommendation) due to insufficient data showing a risk-benefit ratio.  Beers Criteria 
recommends cautious use of dabigatran in patients 75 years of age or older with a CrCl < 
30 mL/min as dabigatran has demonstrated a greater risk of gastrointestinal bleeding in 
comparison to warfarin for anticoagulation purposes in this population (AGS, 2015).  
Limited evidence is available on the safety of this drug with low CrCl levels (moderate 
quality of evidence, strong strength of recommendation).  Due the increased risk of 
bleeding, the combination of warfarin and amiodarone should be avoided (moderate 
quality of evidence, strong strength of recommendation) in addition to the combination of 
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warfarin and NSAIDS (high quality of evidence, strong strength of recommendation).  
Furthermore, to minimize the risk of bleeding, Beers Criteria lists the following 
recommendations: dabigatran and edoxaban should be avoided with a CrCl <25 mL/hr 
and <30 mL/hr, respectively; the edoxaban dose should be reduced with a CrCl of 30-50 
mL/hr and avoided with a CrCl < 30 or > 95 mL/hr; and rivaroxaban dose should be 
reduced with a CrCl 30-50 mL/hr and avoided with a CrCl <30 mL/hr (moderate level of 
evidence, strong strength of recommendation; AGS, 2015).   
Recommendations 
Evidence has demonstrated the bleeding risk while on oral anticoagulants does 
not outweigh the benefits of stroke prevention including high risk populations such as the 
elderly, cognitive dysfunction, or patients at high risk of falls.  The bleeding risk is 
equivalent with warfarin, NOACs, or aspirin; however, only NOACs and warfarin have 
demonstrated a reduction in stroke risk.  Bleeding risk is the primary reason for 
discontinuing oral anticoagulation prematurely or failure to initially prescribe.  Oral 
anticoagulation should only be withheld in patients with severe falls related to epilepsy or 
dementia where the patient is no longer able to comply with the treatment regimen 
(Kirchhof et al., 2016).  Furthermore, elderly patients within the nursing home on 
anticoagulation display increased adverse outcomes: greater than 50% of patients have 
subtherapeutic or supratherapeutic INRs, 65% of patients stop warfarin therapy 
prematurely, concurrent use of warfarin with commonly used NSAIDs and antibiotics 
increases bleeding risk, and warfarin dosing is one of the most common medication errors 
within this setting (Janssen Pharmaceuticals, 2016a).   
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As aforementioned, the risk factor of increasing age alone augments the risk of 
ischemic stroke in the elderly population.  As people age, bleeding risk--predominantly 
intracranial, traumatic from falls, and gastrointestinal--complicates the use of 
anticoagulation.  Fear of bleeding risk in the elderly population inhibits its proper 
utilization as evident by a study that concluded only 64% of Medicare patients with high 
stroke risks were using warfarin (Desai et al., 2017).  The safety of anticoagulation 
studies is evaluated for the risk of severe bleeding; the risk of intracranial hemorrhage is 
stable from age 60 to 80 years, yet rises greatly after 80 years old regardless of 
anticoagulation status, suggesting increasing age alone may be sufficient to intensify 
bleeding risk.  A net clinical benefit (NCB) infers all elderly patients with AF 65 years of 
age or older and with at least a CHA2DS2-VASc score ≥ 1 would benefit from 
anticoagulation.  Furthermore, as the CHA2DS2-VASc or HAS-BLED scores increase, 
suggesting augmented risk of stroke and bleeding, respectively, the risk of stroke still 
outweighs the risk of severe bleeding, thus confirming why high-risk populations require 
anticoagulation.  Comparisons of the NOACs (apixaban, edoxaban, rivaroxaban, and 
dabigatran) to warfarin have demonstrated a reduced rate of intracranial hemorrhage and 
a decreased risk of ischemic stroke in the elderly population.  However, regardless of the 
anticoagulant, intracranial bleeds occur in less than 1% of the population annually (Desai 
et al., 2017).     
With increasing age, the ability to metabolize drugs slows; thus, the weekly dose 
of warfarin should decrease 0.4 mg/yr to prevent supratherapeutic levels and thus lower 
augmented bleeding risk.  The cost of NOACs may be more expensive to the individual 
patient; yet on a system level, costs decrease significantly.  Antiplatelets demonstrate 
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reduced efficacy in preventing strokes and should not be used in the elderly; however, 
left atrial appendage closure is a viable option for patients unable to take long-term oral 
anticoagulation.  Elderly patients with AF should strive for a heart rate control less than 
80 bpm, moving to a rhythm strategy (with anticoagulation) or catheter ablation with 
failure to control symptoms (Desai et al., 2017).  A novel study examined 23,356 patients 
with atrial fibrillation age 80- to 100-years-old who had suffered a recent ischemic stroke 
from 2006 to 2013 (Appelros, Farahmand, Terént, & Asberg, 2017).  Approximately 27% 
(6,361) patients were started on anticoagulation after the stroke, demonstrating less 
recurrent strokes in this population and only an increased incidence of bleeding in 
patients older than 90 years old.  The study concluded even this increased bleeding risk in 
the older population did not outweigh the benefits of anticoagulation to prevent recurrent 
ischemic strokes (Appelros et al., 2017).  
Literature Review 
The literature review was exhaustive and within the past five years including 
systematic reviews obtained from a PubMed and an UpToDate database search.  Other 
noteworthy data if older than five years were also included in this paper as oral 
anticoagulants have been utilized in practice since the 1950s.  The literature review 
focused on a comparison between the five oral anticoagulants predominantly used to 
prevent thromboembolism in patients with atrial fibrillation (warfarin, apixaban, 
dabigatran, rivaroxaban, and edoxaban) as displayed in Appendix B.  Additionally, a 
summary of noteworthy drug trials highlighting the safety and efficacy of oral 
anticoagulants, reversal agents, and other novel treatments for atrial fibrillation are 
displayed in Appendix C.  The efficacy outcome of stroke incidence and safety outcome 
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of bleeding events were the primary purposes of these anticoagulant drug trials to 
promote their clinical relevance and utilization in practice.  Finally, the most recent 
guidelines from the American Stroke Association, American Heart Association, 
American College of Chest Physicians, American College of Cardiology, and European 
Society of Cardiology (ESC) were the foundation and final consensus of 
recommendations for atrial fibrillation management addressed within this toolkit.  The 
summaries of these guidelines are attached in the appendices as follows: (a) 2016 ESC 
Guidelines for the Management of Atrial Fibrillation Developed in Collaboration with 
EACTS (see Appendix D); (b) 2014 AHA/ACC/HRS Guideline for the Management of 
Patients with Atrial Fibrillation: Executive Summary (see Appendix E); (c) 
Antithrombotic Therapy for Atrial Fibrillation: Antithrombotic Therapy and Prevention 
of Thrombosis (see Appendix F); and (d) 2014 AHA/ASA Guidelines for Prevention of 
Primary Stroke; see Appendix G). 
Problem Statement or Purpose 
Integrated Summary of Literature  
Research and practice have indicated patients, especially the elderly, do not 
receive adequate assessment or management of atrial fibrillation, resulting in higher 
ischemic stroke rates.  A small percentage of patients with silent AF are diagnosed with 
arrhythmia only after suffering from a stroke; in the primary care setting, an annual pulse 
check with subsequent EKG for an abnormal rhythm could greatly reduce the incidence 
of strokes in this high-risk population.  Patients at moderate to high risk for stroke are not 
receiving oral anticoagulants, predominantly due to the overexaggerated risk of bleeding 
with these medications or lack of provider knowledge on current treatment 
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recommendations for AF.  Furthermore, inconsistencies exist with assessing bleeding risk 
and stroke risk for every patient through reliable tools such as HAS-BLED and 
CHA2DS2-VASc scores, respectively, as well as translating these scores into practice.  
Consensus is universal on initiating anticoagulation with a CHA2DS2-VASc score ≥ 2; 
yet, guidelines and organizations vary on their recommendations for anticoagulation with 
a CHA2DS2-VASc score of 1, ultimately relying on patient and provider opinions that 
may result in an increased frequency of stroke in patients with a higher risk profile.  
Even though trends are slowly shifting, most patients are prescribed warfarin with 
atrial fibrillation when newer anticoagulants are available.  Anticoagulation is 
recommended indefinitely for patients with AF and a moderate to high risk of stroke; 
however, prescription of these medications becomes convoluted when factors such as 
cost, patient compliance, adverse effects, safety, access, reversal agents, and provider 
preference must be involved in the decision-making process.  Due to these 
inconsistencies and the lack of a comprehensive, universal guideline for assessment and 
management of atrial fibrillation, this topic was selected for a capstone project.  A toolkit 
consisting of a guideline with algorithms and guideline was formulated to direct primary 
care providers on an evidence-based path to diagnose and assess for atrial fibrillation in 
the elderly as well as prescribe and manage anticoagulation safely and individually for 
the patient with the overall objective of reducing the occurrence of ischemic stroke in this 
high-risk population.  The researcher utilized expert consensus, national and international 






In adult patients with atrial fibrillation older than 65 and at a moderate to high risk 
of stroke, how effective is an anticoagulation toolkit in guiding primary care providers on 
(a) diagnosing atrial fibrillation and (b) initiating and maintaining oral anticoagulation 
safely to reduce the incidence of ischemic stroke?  
Challenges 
The providers themselves are a major challenge as generational gaps and 
individual preferences and experiences influence their decisions to prescribe 
anticoagulants in general--let alone a newer agent.  Less safety and efficacy data are 
available on the DOACs compared to warfarin, further complicating the prescription of 
these novel drugs as providers often prescribe medications with which they are most 
familiar and comfortable.  A recent impetus in the anticoagulation movement is to 
prescribe the best anticoagulant for the individual patient.  By expanding the quantity of 
available oral anticoagulants from only one with warfarin to five with the DOACs, 
patients have more opportunities to find the most appropriate anticoagulant and thus 
reduce their risk of stroke.  Additionally, providers must be consistently up to date on 
anticoagulant research findings and management of atrial fibrillation to utilize evidence-
based practice, especially as the release of new research studies, antidotes for the new 
agents, and alternative treatments become available on the market.  Furthermore, many 
providers continue to use the CHADS2 scoring system to assess for stroke risk; however, 
this tool excludes patients with heightened risk factors that would be anticoagulated 
based on CHA2DS2-VASc criteria.  The evidence-based HAS-BLED tool is rarely 
utilized in practice as providers deduce bleeding risk based on past history rather than 
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assessing for and reducing risk factors for bleeding, which is the essence of this tool.  
Another key problem to diagnosis and management of atrial fibrillation is the patient.  
With atrial fibrillation, there are varying presentations, effects on quality of life, and 
patient preference for anticoagulation versus WATCHMAN (Boston Scientific, 2016) or 
preferring no treatment at all.  As far as anticoagulants themselves, cost, health literacy, 
lab monitoring, support systems, transportation, and resources all influence the ability of 
patients to take anticoagulants as prescribed.  Furthermore, both patients and providers in 
primary care often lack knowledge on the universal impact and significance of atrial 
fibrillation contributing to ischemic strokes.  Thus, improved education for all parties 
involved is essential to advance management of this chronic disease.   
Problems 
Multiple factors influence the decision of the type of anticoagulant prescribed by 
practitioners such as cost, insurance coverage, and reversal agent availability.  Other 
factors include patient preference; patient comorbidities such as renal function, hepatic 
function, and artificial valves; the purpose of the anticoagulation, efficacy, and the 
adverse effects profile of the drugs.  Patient compliance is significant as dietary changes, 
monitoring via lab work, access to care including lab monitoring facilities, reversal 
agents, and adhering to the prescription regimen as directed are all essential to the careful 
balance of preventing thromboembolisms while also reducing bleeding risk.  Initiation of 
treatment is challenging to primary care providers as well as managing this chronic 
disease with anticoagulation.  Four evidence-based guidelines exist for anticoagulation 
with atrial fibrillation and are considerably congruent in their recommendations.  
However, keeping up to date with updates is challenging for providers working in a 
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primary care setting who cannot focus continuing education on only one medical 
specialty.  Providers should be familiar with multiple agents available for anticoagulation 
and AF including alternative treatments such as WATCHMAN (Boston Scientific, 2016).  
Yet, providers are often limited on their training and experience with these options and 
treat the patient based on what they know rather than what could be best for the patient.  
Providers who prescribe anticoagulation must be familiar with food and drug interactions, 
temporary interruption of therapy for circumstances such as surgery, how to switch 
between DOACs and warfarin, initiation and maintenance lab monitoring (including 
home versus clinic INRs), recommendations for genetic testing, and how to treat severe 
bleeding. 
Assessing for atrial fibrillation through secondary prevention should be 
incorporated into the annual physical examination, especially with the elderly; yet, 
providers are not informed of the necessity of assessing and diagnosing an irregular 
rhythm to ultimately prevent strokes.  Furthermore, primary prevention of disease is more 
significant than treating the disease after the fact; thus, providers should be aware of risk 
factors for AF and teach their patients how to reduce these risk factors to improve their 
health.  Unfortunately, providers have limited time during appointments to educate 
patients on anticoagulation, yet alone atrial fibrillation, contributing to limited 
comprehension, noncompliance, and misinterpretations of the disease state or 
medications.  Relentless advances in medicine such as genetic testing, time constraints 
with high patient loads, and limited or unknown resources to educate patients on 
anticoagulant use further complicate this decision-making process; thus, directing 
providers and patients to reliable resources and shared decision-making tools is essential 
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to improve efficiency.  Atrial fibrillation can be diagnosed and managed safety within the 
primary care setting but providers should be trained on situations warranting a referral to 
a specialist.  
Situations 
A chart review was conducted within a private primary care clinic in northern 
Colorado, focusing on the diagnosis and management of patients with atrial fibrillation 
during 2017.  Through the confidential collection and assessment of patient 
demographics, risk factors, patient presentation, diagnosis, treatment plan, and negative 
outcomes all related to AF, the researcher could compare current evidence to practice, 
assessing for any gaps and offering solutions.   
Current evidence-based literature was utilized to formulate said toolkit with 
guideline and algorithms including expert opinion and national and international 
guidelines.  Upon completion of this toolkit, it was distributed to two primary care clinics 
as well as two cardiology clinics within northern Colorado; the goal was to achieve 70% 
consensus from 13 providers (physicians, nurse practitioners, and physician assistants).  
Even though this toolkit was designed and intended for the primary care setting, expert 
opinions were obtained from specialists in cardiology when formulating and revising the 
guideline with algorithms.  Before analyzing the toolkit in Round 1 of the Delphi method, 
providers within the primary care setting received via email a consent form (see 
Appendix H) describing the purpose and phases of the project.  Consent was implied if 
the providers submitted the online survey through Survey Monkey within the two-week 





This project provided an opportunity to illustrate a comparison of the 
anticoagulants in a table format including pharmacology, FDA (CDC, 2016b) prescribing 
information, economics, and safety and efficacy of the drugs based upon clinical trials.  A 
summary of noteworthy drug studies for the five oral anticoagulants was provided to 
address the safety and efficacy of these anticoagulants plus these drugs trials discussed 
alternative treatments for AF such as WATCHMAN (Boston Scientific, 2016) left atrial 
appendage implants.  Additionally, providers were distributed an evidence-based toolkit 
comprised of a guideline and algorithms to aid in the decision-making process of the 
atrial fibrillation diagnosis as well as safe and effective initiation and management of the 
appropriate anticoagulant for the individualized patient.  The purpose of this toolkit was 
not to persuade a provider to select one anticoagulant over another but allow an 
opportunity to expose and educate providers to the vast array of products available to 
select the best agent for each patient.  This toolkit provided evidence-based practice and 
reliable resources within one document to improve the overall treatment for atrial 
fibrillation.  Settings to obtain expert opinion and implement this project focused on 
family practice (primary care) clinics as this setting is often where AF is diagnosed and 
treated primarily.  However, providers have limited knowledge and experience compared 








Promoting Action on Research  
Implementation in Health  
Services Framework  
The Promoting Action on Research Implementation in Health Services (PARIHS) 
framework created in 1998 was relevant to this capstone as it integrates the three 
components of evidence, context, and facilitation into practice.  These three elements are 
ranked on a scale from low to high with improved implementation of evidence into 
practice when all factors are ranked high.  Evidence can be derived from experience 
(patient and clinician), research (qualitative and quantitative), and local data.  The context 
of the practice can vary but is influenced by history, psychosocial factors, economics, and 
politics, especially culture, leadership, and evaluation.  Facilitation improves and 
simplifies the process of implementing research into practice with strong facilitators 
encompassing the characteristics of purpose, role, skills, and attributes and strives for a 
holistic process (Rycroft-Malone, 2004).   
The PARIHS framework has been effectively used to improve implementation of 
retrospective and prospective healthcare research including 40 research papers from 
2011-2016 alone.  For instance, PARIHS was used in a retrospective study on improving 
implementation of methicillin resistant staphylococcus aureus (MRSA) guidelines into 
the U.S. Department of Veteran’s Affairs (VA), concluding high evidence, mixed 
content, and mixed facilitation (Rycroft-Malone, 2004).  Similarly, a prospective study 
on the implementation of the VA’s MyHealtheVet personal health record portal, which 
allows patients to access their medical health records, concluded low evidence, low 
context, and high facilitation (Hill et al., 2017).  The results from these PARIHS 
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frameworks were used to brainstorm strategies to improve the implementation of these 
healthcare programs into practice.  Strengths of this framework included investigating the 
complexity of implementing research into practice, focusing on the context of the 
research, ease of use, and clinical applicability (Harvey & Kitson, 2016).   
A revised PARIHS framework was developed in 2008 to address limitations 
including a lack of prospective studies, inadequate focus on the influence of individuals 
and the system itself in implementation, a lack of theoretical foundations, and failure to 
address the intended audience and external context of the practice (Harvey & Kitson, 
2016).  The revised (integrated) iPARIHS framework added the element of recipient and 
innovation to the original triad of evidence, context, and facilitating, emphasizing 
facilitation as the key factor to successful research implementation.  Innovation included 
balancing evidence, knowledge, and local practice when considering change.  Recipients 
of the change occur at the individual, local, organizational, and system levels.  Context is 
redefined as the inner context (local setting) and outer context (organization and system 
levels).  The facilitator role is expanded into the interplay of novice, experienced, and 
expert facilitators who utilize their various skills to improve the implementation process 
(Harvey & Kitson, 2016).  
The plan for this project was an anticoagulation toolkit guiding providers on 
improved diagnosis of atrial fibrillation as well as patient-centered anticoagulation 
initiation and maintenance.  The three elements of the PARIHS framework (evidence, 
context, and facilitation into practice) were evaluated for this capstone project and ranked 
on a scale from low to high.  For this project, it was necessary to review patient charts for 
local data, obtain a literature review on current evidence and best practice, and acquire 
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expert opinion (evidence).  Subsequently, this evidence and experience were incorporated 
into an anticoagulation toolkit for managing atrial fibrillation in the primary care setting 
(context) by integrating the components of culture, leadership, and evaluation in this 
process.  Applications of this project addressed the role of a facilitator in successfully 
implementing this written material into practice, ultimately seeking expert commentary 
on the efficacy and feasibility of it use (facilitation into practice).  Elements of the 
iPARIHS model were incorporated into the evaluation of this toolkit and focused on 
innovation, recipients, and the influence of different context levels and experience of the 
facilitators. 
Reach, Effectiveness/Efficacy, Adoption,  
Implementation, and Maintenance  
Model  
 
The reach, effectiveness/efficacy, adoption, implementation, and maintenance 
(RE-AIM) framework is composed of five steps to “enhance the quality, speed, and 
public health impact of efforts to translate research into practice” (RE-AIM, 2017: Reach 
(target population), effectiveness/efficacy (impact of the intervention), adoption 
(healthcare providers and setting willing to initiate the change), implementation 
(reliability, costs, time constraints, transformations, and delivery to adopt the change), 
and maintenance (ability to continue the change over time for at least six months).  The 
RE-AIM model has been successfully used to assess the impact of the WISEWOMAN 
program to improve cardiovascular disease screening and lifestyle changes in uninsured 
women (Farris, Will, Khavjou, & Finkelstein, 2007) and to hone strategies for chronic 
disease management (Glasgow, McKay, Piette, & Reynolds, 2001).  
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 The RE-AIM model was utilized for this capstone project to assist with the 
effective implementation and evaluation of this anticoagulation toolkit.  Reach addressed 
the target population of elderly patients with a new or chronic diagnosis of atrial 
fibrillation within the primary care setting.  Effectiveness was the impact of this 
anticoagulation toolkit to prevent stroke in patients with atrial fibrillation.  Adoption 
assessed the willingness and feasibility of primary care providers to incorporate this 
toolkit into practice.  Implementation addressed the factors contributing to the successful 
use of this toolkit in primary care such as provider and patient preference, costs, access, 
time constraints, and training.  Maintenance assesses the duration of implementing this 















Synthesized Summary of Project  
For this quality improvement capstone project, a retrospective chart review was 
completed on the diagnosis and treatment of atrial fibrillation patients in the primary care 
setting.  Through implementation of two rounds of the Delphi technique, expert opinions 
from providers in primary care and cardiology were utilized to create an anticoagulant 
toolkit emphasizing improved diagnosis of atrial fibrillation in the elderly within the 
primary care setting and followed by appropriate initiation and management of 
individualized anticoagulation to reduce the incidence of stroke.  Recommendations to 
improve this variance between research and practice included evaluating the necessity of 
anticoagulation through stroke risk (CHA2DS2-VASc) and bleeding risk (HAS-BLED) 
scales, screening all elderly patients in the primary care setting for atrial fibrillation 
through an annual pulse check with follow-up electrocardiogram as necessary, and 
highlighting key resources for providers (guidelines, quality and performance measures, 
and a shared decision-making tool) to improve implementation of evidence-based 
research into practice.  This toolkit also contained a tabular comparison of warfarin and 
direct oral anticoagulants (edoxaban, rivaroxaban, dabigatran, and apixaban), and patient- 




The objectives of this capstone project were to (a) examine current and local 
diagnosis and management of atrial fibrillation within the primary care setting, (b) create 
a toolkit (guideline with algorithms) directing practitioners on diagnosis of atrial 
fibrillation as well as initiation and maintenance of oral anticoagulation, (c) promote 
safety and efficacy in the management of anticoagulants, (d) endorse patient-centered 
anticoagulation based upon current evidence-based literature and expert opinion, and (e) 
evaluate the effectiveness of a toolkit influencing the diagnosis of atrial fibrillation and 
anticoagulation management within a primary care setting. 
Congruence of Organization’s Strategic  
Plan to Project 
Confidential chart reviews of atrial fibrillation patients were completed at Family 
Physicians of Greeley.  Tentative primary care organizations in northern Colorado to 
implement the toolkit included Family Physicians of Greeley-Central and University of 
Colorado Health Family Medicine--North Loveland.  Additionally, as cardiologists 
specialize in atrial fibrillation, their expertise and experience were incorporated into the 
construction and revisions of the anticoagulation algorithm and guideline.  Proposed 
cardiology sites included the Cardiovascular Institute of Northern Colorado and the 
University of Colorado Health Heart Center--Fort Collins.  Expert opinions from all sites 
were obtained from physicians, nurse practitioners, and physician assistants.  To more 
effectively reach a diverse population with this toolkit, expert consensus was obtained 
from providers who delivered care to patients in both rural and urban settings and were 
employed at commercial and privately-owned clinics.  Organizations aiding in the 
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execution of this capstone project display similarities in their missions, values, 
perspectives, and approaches to diagnosing and managing atrial fibrillation.  
Project Design 
Literature Review on Atrial Fibrillation  
and Anticoagulation   
For this quality improvement project, an extensive literature review included 
relevant background information on AF that focused on the diagnosis and management, 
especially with anticoagulants.  Literature was current (within the past five years) and 
relevant (inclusive of the key words of “atrial fibrillation”), obtained from PubMed and 
UpToDate databases, as well as guidelines on anticoagulation with atrial fibrillation.  
Additional necessary research compared oral anticoagulants (warfarin, apixaban, 
dabigatran, rivaroxaban, and edoxaban) for patient-specific factors as well as assessed 
safety and efficacy of each agent.  As this project focused on a population of elderly 
patients with AF, noteworthy literature was analyzed to discover how best to manage this 
disease to reduce negative sequelae of stroke as well as its impact on patients and society 
in general.  Ultimately, this research was the foundation for the anticoagulation toolkit 
designed for the primary care setting: guideline, algorithms, and provider resources to 
manage AF.  This research was also applied to identify practice gaps, effectively 
translating research to practice to improve patient outcomes.  
Patient Chart Reviews 
A goal of 100 retrospective patient chart reviews through Next Generation was 
confidentially reviewed at Family Physicians of Greeley-Central.  Patients were included 
if they had a diagnosis of atrial fibrillation and were seen in the clinic during 2017.  Data 
collected included demographics (age, sex, race/ethnicity, insurance status, and 
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rural/urban residence), risk factors, patient presentation, diagnosis (focusing on pulse 
checks and EKG results), comorbid diagnoses, imaging/laboratory data, treatment plan 
(focusing on oral anticoagulants), negative outcomes, patient tolerance/quality of life, 
follow-up, and interdisciplinary management for patients with atrial fibrillation.  
Additionally, the patient charts were assessed for the use and interpretation of bleeding 
risk and stroke risk scores (HAS-BLED and CHA2DS-VASc respectively).  The purpose 
of obtaining this data was to compare current evidence to practice. 
Delphi Technique 
The Delphi technique is utilized to obtain data from experts in a particular field 
during a short time period to establish a group consensus from a series of surveys.  The 
Delphi technique is described as “iterative and sequential” (Hsu & Sanford, 2007, p. 5).  
Since the 1950s, the Delphi technique has been used as a group communication tool to 
obtain controlled expert consensus for “goal setting, policy investigation, or predicting 
the occurrence of future events” (Hsu & Sanford, 2007, p. 1).  This technique can be used 
to offer choices, recognize assumptions, make predictions, set goals, increase knowledge, 
and summarize judgments within a group for the purposes of program structuring, needs 
evaluations, policy writing, and resource management.  The researcher reviews each 
survey from an expert and creates a group consensus that is returned to each expert along 
with a summary of the expert’s own viewpoint.  The purpose of repetitive surveys is to 
obtain feedback from the experts; re-evaluations of perspectives can ultimately formulate 
an improved consensus and communication among the group.  The Delphi technique 
maintains the confidentiality of subject identifiers, controls the feedback process (the 
summary of the prior surveys is given to experts to decrease “noise” of the individuals, 
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which inhibits problem solving and alters data), and multiple statistical analyses are 
completed, all decreasing influences of coercion and biases common in group settings.  
Usually a minimum of three rounds of survey distribution is sufficient for the Delphi 
technique but up to five can be implemented to achieve group consensus.   
In Round 1, a survey with open-ended questions or derived from a literature 
review is given to the experts.  In Round 2, a more structured survey is given to the 
experts that requests the subjects create a summary of the results from the first round.  
Also in Round 2, questions may require ranking or rationale to support their decisions.  In 
Round 3, the experts receive a summary of the results from Round 2 and the subjects are 
asked to reassess their responses including rationale and to request further explanations.  
In Round 4, an overall summary of the prior three rounds is given to all the subjects, 
allowing one final chance to reassess their responses (Hsu & Sanford, 2007).  
Subjects and time are essential factors to consider when determining if the Delphi 
technique is the appropriate tool.  Choosing subjects is important for the Delphi study as 
it influences the quality of the data obtained.  A minimum of 10-15 experts in a field is an 
adequate sample size with an average of 15-20 subjects per study.  The Delphi technique 
assumes all the experts have similar experiences and knowledge of the subject matter are 
stakeholders who will use these results either for clinical or research purposes, and these 
subjects are willing to work as a team to reach a consensus.  On average, 45 days are 
required to complete the Delphi study in its entirety with a recommended two-week 
period between administration and subject response for each individual survey.  To 
decrease time constraints, the use of e-mail or teleconferencing to distribute surveys was 
utilized so feedback could be obtained more quickly and enhanced subject 
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confidentiality.  Methods of data analysis included central tendency (mean, median, and 
mode) as well as level of dispersion (standard deviation and inter-quartile range) with 
median and mode preferred.  Consensus was attained when “80 percent of the subjects’ 
votes fall within two categories on a seven-point scale…at least 70 percent of Delphi 
subjects need to rate three or higher on a 4-point Likert-type scale and the median has to 
be a 3.25 or higher” (Hsu & Sanford, 2007, p. 4).  Limitations of the Delphi technique 
included potential molding of opinions to coincide with group opinion (through 
persuasion of researchers or after receiving misleading feedback) and presumed all 
experts in the field were equal in experience and knowledge in order to develop a general 
rather than a topic-specific consensus.  As multiple rounds are required for the Delphi 
technique, possible low response rates from subjects could negatively influence feedback 
and lengthy time commitments to collect and analyze data could limit the study’s 
successful implementation (Hsu & Sanford, 2007). 
The Delphi technique has been utilized to assess several atrial fibrillation studies 
such as a systematic review with a one-round Delphi technique ranking 54 outcomes and 
performance indicators internationally to better assess AF management (Berti, Van 
Vlasselaer, Moons, & Heidbuchel, 2015).  The Cardiovascular Health in Ambulatory 
Care Research team (Tu et al., 2017) assessed performance indicators (risk factor 
prevalence, screening, management, intermediate outcomes, and long-term outcomes) for 
primary prevention of cardiovascular disease using a two round Delphi technique.  This 
study concluded the five key risk factors for cardiovascular disease were smoking, 
obesity, hypertension, diabetes, dyslipidemia, and atrial fibrillation.  These identified 
performance indicators could be measured in the outpatient setting by researchers, 
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stakeholders, and clinicians to prevent cardiovascular disease (Tu et al., 2017).  
Furthermore, the AF-SCREEN International Collaboration (Freedman et al., 2017) 
composed of 60 experts utilized the Delphi technique to establish a consensus on AF 
screening.  The collaboration focused on the importance of anticoagulation to prevent 
stroke if AF was diagnosed via an EKG, the superiority of using handheld EKG devices 
for screening, increasing monitoring of patients with recent embolic stroke to better 
diagnose AF, and the importance of multidisciplinary management of AF regardless of 
the clinic or health system (Freedman et al., 2017).   
For this capstone, two rounds of the Delphi technique were utilized.  Round 1 
focused on a qualitative, open-end survey to assess the comfort level, experience, and 
baseline knowledge of the expert providers diagnosing atrial fibrillation as well as 
prescribing and managing anticoagulation for this high-risk population within the primary 
care setting.  Along with the first survey, the providers received a consent form 
highlighting the purpose and format of this project.  Additionally, providers were asked 
to list their credentials, specialty, and years of expertise for demographic and statistical 
purposes.  The survey for Round 1 is provided in Appendix I; the consent form to 
participate in the research that affirmed all identifying information would remain 
confidential was also sent. 
In Round 2 of the Delphi method, providers received a consensus of the group 
from Round 1 and completed a second mixed quantitative and qualitative survey 
addressing ease of use, applicability, relevance, and the impact of this toolkit on practice.  
Providers were asked to evaluate the benefits and challenges of this toolkit and offer 
feedback for revisions.  To clarify, providers received the first draft of the anticoagulation 
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toolkit composed of an algorithm and guideline during Round 2.  The anticoagulation 
toolkit was drafted after Round 1 and then revised further after Round 2 to incorporate 
expert consensus into the toolkit, thus increasing relevancy and clinical applicability to 
the primary care setting.  The survey for Round 2 is provided in Appendix J.  
The goal sample size was 10 to 15 family practice and cardiology practitioners 
consisting of physicians, nurse practitioners, and physician assistants.  Providers had two 
weeks to complete each survey through Survey Monkey, which was accessible through 
the link sent to each provider individually through e-mail.  Upon completion of the two 
rounds of the Delphi method, data and demographics were analyzed through standard 
qualitative measures.  Consensus was achieved if the panel agreed on the components in 
Round 2 at least 70% of the time.  If a consensus of 70% was not accomplished after two 
rounds, subsequent rounds were indicated, time permitting.   
Evidence-Based Projection Plan 
 The evidence-based projection plan consisted of the following six phases: 
• Phase 1: Thorough literature review on anticoagulation and atrial fibrillation.  
Current literature focused on the diagnosis and management of atrial 
fibrillation obtained from PubMed and UpToDate databases as well as 
international and national guidelines.  Novel drug trials and 
pharmacokinetics/pharmacodynamics of the five most prescribed oral 
anticoagulants (warfarin, dabigatran, apixaban, edoxaban, and rivaroxaban) 
were summarized additionally. 
• Phase 2: Medical records review at Family Physicians of Greeley-Central, 
assessing demographics, risk factors, patient presentation, diagnosis, 
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comorbid diagnoses, imaging/laboratory data, treatment plan, negative 
outcomes, and interdisciplinary management for patients with atrial 
fibrillation.  Records of patients on anticoagulation were reviewed for 
assessment of stroke risk and bleeding risk through CHA2DS2-VASc and 
HAS-BLED scores, respectively, as well as patient preference. 
• Phase 3: Development of an anticoagulation toolkit guideline and algorithms 
based upon best evidence and expert opinion (literature review, clinical 
practice guidelines, review of current practice, and consensus from primary 
care providers and cardiologists).  The design of this project was the Delphi 
technique with a minimum of two rounds and a goal of 70% consensus.  The 
toolkit was devised after completion of Round 2 of the Delphi method. 
• Phase 4: Distribution and revision of the anticoagulation toolkit in the primary 
care and cardiology settings.  The goal was to reveal this toolkit to two or 
three different primary care clinics and one to two cardiology clinics within 
northern Colorado with a 100% participation rate of 10-15 providers. 
Providers completed the first survey during Round 1 and the second survey 
with toolkit evaluations during Round 2.  
• Phase 5: Using qualitative statistical analysis, the data and demographics from 
patient charts and the Delphi surveys were evaluated to derive conclusions 
comparing evidence to practice.  
• Phase 6: Future project involved a pilot study to assess any impact on patient 




Timeline of Project Phases 
 The researcher utilized the following timeline for the project phases: 
• Phase 1 (literature review)--Completion by June 2017.  
• Statement of Mutual Agreement signed—July 6, 2017 (see Appendix K) 
• University of Northern Colorado (UNC) Institutional Review Board approval 
--Obtained August 11, 2017 (see Appendix L). 
• Phase 2 (medical records review)--Completion by September 2017. 
• Phase 3 (development of anticoagulation toolkit)--Completion by September 
2017. 
• Phase 4 (distribution and revision of toolkit)--Completion by October 2017.  
• Phase 5 (data analysis)--Completion by October 2017.    
• Phase 6 (pilot study)--Future research project  
Subjects 
Subjects for the patient chart review included any adult greater than 18 years of 
age who required anticoagulation for the indication of atrial fibrillation for ischemic 
stroke prophylaxis.  Despite the focus of this project on elderly patients older than 65 
years, a thorough assessment of the diagnosis of AF and anticoagulation management in 
all adults was essential for the data analysis portion of this project to address current 
practice.  Subjects were obtained from the Next Generation electronic health records at 
Family Physicians of Greeley-Central, focusing on patients who were seen in the clinic 
during 2017 related to a diagnosis of atrial fibrillation.  The sample size was based on 
availability of patients meeting inclusion criteria; yet, the researcher aspired for a goal of 
at least 75 patient chart reviews.  The providers analyzing the toolkit were primary care 
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and cardiology providers within northern Colorado including either physicians, nurse 
practitioners, or physician assistants who prescribed anticoagulation.  Specific patient 
characteristics such as pregnancy status, heart valve replacement, increased risk of 
gastrointestinal distress, decreased creatinine clearance, and poor patient compliance 
were addressed in the toolkit to help providers manage future anticoagulant prescriptions 
more safely and effectively.   
Implementation Methods/Tools 
An anticoagulation toolkit comprised of a guideline with algorithms was created 
based upon recent literature and expert opinions.  Two surveys were formulated to 
evaluate the toolkit through the Delphi method.  The first survey compared current 
practice to literature.  The second survey focused on the safety, efficacy, 
comprehensiveness, and ease of administration of the toolkit.  The second survey also 
focused on how implementation of this toolkit influenced the initiation and management 
of anticoagulation for AF in the primary care setting.  
Resources 
Personnel 
Expert opinions were obtained from providers specializing in family practice and 
cardiology in addition to the recommendations from national and international guidelines 
on anticoagulation management.   
Technology 
Literature was acquired from the UNC library databases, PubMed, and 
UpToDate.  Microsoft Office was utilized to generate the toolkit.  Patient charts were 
reviewed through Next Generation.  Electronic surveys were created and completed on 
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Survey Monkey along with the consent form, survey link, and additional relevant 
information delivered to providers via confidential e-mail. 
Budget 
At this point, no financial constraints were foreseen with planning, formulation, 
revision, implementation, and evaluation of this project.  
Risks and Benefits  
A potential risk was a provider following the toolkit but not considering the 
patient’s comorbidities, concurrent medications, and individualized indications and 
contraindications, resulting in an incorrect prescription or management of 
anticoagulation.  Other risks included the provider not following the toolkit correctly, the 
provider not incorporating the patient’s preferences into the decision of which 
anticoagulation to prescribe (including self-monitoring of INRs with warfarin), or the 
provider not staying up to date with current evidence and best practice recommendations 
on anticoagulants.  The primary benefit was evidence-based, patient-centered, 
individualized prescription and management of anticoagulants.  A strength of this 
anticoagulation toolkit was its composition: a current and user-friendly guideline with 
algorithms created and revised based upon expert consensus from both cardiology and 
primary care experts within the field.  Another benefit was a summary of the most current 
guidelines from the leading medical associations (American Stroke Association, 
American Heart Association, American College of Chest Physicians, American College 
of Cardiology, Heart Rhythm Society, and European Society of Cardiology) driving best 
practice.  Additionally, key results, both positive and negative, from pharmaceutical drug 
trials were summarized to help guide practice as well as a conclusive summary of the five 
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most currently used oral anticoagulants in practice (warfarin, apixaban, edoxaban, 
rivaroxaban, and dabigatran).  Furthermore, this toolkit did not attempt to sway 
practitioners toward one anticoagulant versus another but instead provided unbiased, 
evidence-based data to promote the best anticoagulant initiation, management, and 
monitoring for the individualized patient rather than provider preference.  
Financial Plan 
  A financial plan was not applicable as no financial costs were presumed for this 
project other than time and labor of the researcher and subjects.  No cost was incurred 
from the data collection and analysis completed by the researcher, and the surveys and 





















 The following objectives were evaluated in this capstone project: 
 
1. Examine current and local diagnosis and management of atrial fibrillation 
within the primary care setting. 
• Plan: An analysis of 75 patient medical records during 2017 at a local, 
privately owned primary care clinic (Family Physicians of Greeley-
Central) that would highlight current management and diagnosis of 
atrial fibrillation while also identifying gaps in practice.  Patient charts 
were assessed for the diagnosis of atrial fibrillation, symptoms, risk 
factors, diagnostics, laboratory and imaging data, comorbid diagnoses, 
management (focusing on anticoagulation), negative outcomes, and 
multidisciplinary providers managing the patient.  Charts were also 
reviewed for any assessment of stroke and bleeding risk through 
CHA2DS2-VASC and HAS-BLED tools.  Patient demographics 
obtained included age, sex, race/ethnicity, rural or urban residence, 
and insurance coverage.   
• Methods of analysis: Data were analyzed statistically through 
measures of central tendency to determine the norms and exceptions 
for diagnosis and management of atrial fibrillation in a primary care 
101 
 
setting.  These data were then compared to current evidence-based 
guidelines to assess for gaps in practice and offer solutions for 
improvement. 
2.  Create a toolkit (guideline with algorithms) directing practitioners on  
diagnosis of atrial fibrillation as well as initiation and management of oral 
anticoagulation. 
• Evidence-based measures/instruments: The toolkit was created based 
upon a literature review and expert opinions.  Additionally, the most 
recent guidelines from the American College of Cardiology, American 
Stroke Association, American Heart Association, American College of 
Chest Physicians, Heart Rhythm Society, and European Society of 
Cardiology were implemented into this toolkit (see Appendices D, E, 
and G).  Expert opinions were obtained from northern Colorado 
providers in primary care and cardiology.  The toolkit provided a 
simplified, evidence-based direction in diagnosing atrial fibrillation in 
the primary care setting as well as prescribing and managing 
anticoagulation in patients with atrial fibrillation to prevent stroke.  
• Methods of analysis: The Delphi method was utilized to formulate and 
improve the anticoagulation toolkit through expert consensus.  Two 
surveys consisting of 8 to 10 questions each, one from Round 1 and 
one from Round 2, were analyzed statistically (through measures of 
central tendency) to determine providers’ comfort level and expertise 
with providing anticoagulants and diagnosing atrial fibrillation as well 
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as how incorporation of this toolkit could influence practice.  The 
survey for Round 1 was administered prior to providers viewing the 
anticoagulation toolkit for the first time.  The survey for Round 2 was 
administered after reviewing the toolkit and obtaining consensus from 
the group in Round 1 of the Delphi method.  Round 1 and Round 2 
Delphi survey questions can be found in Appendices I and J, 
respectively.  
• Components of anticoagulation toolkit: Contents of this toolkit 
included a guideline with algorithms in addition to resources for 
providers on atrial fibrillation management.   
o Guideline: The guideline provided a step-wise recommendation 
to: 
1)  Reduce risk factors for atrial fibrillation (AF).  
2)  Diagnose AF early through an annual pulse check in all 
symptomatic or asymptomatic patients ≥65 years old. If an 
irregular pulse is detected, confirm the rhythm through an 
EKG.  
3)  If a patient has AF, assess for bleeding and stroke risk 
through the HAS-BLED and CHA2DS2-VASc scores 
respectively to determine if that patient is a candidate for 
oral anticoagulation.  
4)  Prescribe the patient specific anticoagulant with a 
CHA2DS2-VASc score ≥2 and a low risk of bleeding.  
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Consider anticoagulating with a CHA2DS2-VASc score of 
1, dependent on patient preference and clinical judgment. 
o Algorithms:  
1)  Reduce risk factors for atrial fibrillation (AF) 
2)  How to calculate and interpret the CHA2DS2VASc and 
HAS-BLED scores was provided for easy reference. 
3)  A comparison of warfarin and direct oral anticoagulants 
 was summarized in a table.   
4)  An algorithm illustrating the indications and 
contraindications for specific oral anticoagulants (warfarin, 
dabigatran, apixaban, rivaroxaban, and edoxaban).  More 
specifically, this algorithm addressed rationale for selecting 
an anticoagulant: mechanical or prosthetic valves, kidney 
function, liver function, pregnancy, frequency of dosing, 
reversal agents, lab monitoring, drug or food interactions, 
age, gastrointestinal distress, cost, compliance, and weight 
adjustments.  The purpose of these algorithms was not only 
to encourage improved diagnosis and management of AF 
but to promote assessment for patient-specific factors 
driving prescription of a specific anticoagulant.     
o Atrial Fibrillation Resources for Providers: To simplify the 
convoluted regimen of anticoagulation and managing AF in 
general, this toolkit provided resources on appropriate reversal 
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agents, assessment for symptom severity with AF, genetic 
testing, lab monitoring (including home versus clinic INRs), and 
discontinuation of anticoagulation prior to surgery or invasive 
procedures including bridging therapy with warfarin.  Food and 
drug interactions, INR and warfarin dosing, transitioning 
between warfarin and DOACs safely, and when to refer to a 
specialist were also included.  Essential anticoagulation websites 
for anticoagulation (genetic testing, shared decision-making 
tools, performance and quality measures), WATCHMAN, and 
national/international guidelines for anticoagulation) were briefly 
summarized within in the toolkit with their corresponding 
references.  Additional resources for providers were added or 
eliminated based upon the results of the Delphi survey Round 1.  
The toolkit offered one reliable resource for providers to review 
when managing anticoagulants to improve safety and efficacy of 
these drugs as well as provided resources to better educate 
patients.  
3.  Promote safety and efficacy in the management of anticoagulants.   
• Evidence-based measures/instruments. As aforementioned in objective 
2, literature review and expert opinions were the foundation of this 
guideline with algorithms.  The purpose of this toolkit was to promote 
safety and efficacy when prescribing anticoagulants.  Thus, available 
literature on all five anticoagulants (warfarin, dabigatran, apixaban, 
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rivaroxaban, and edoxaban) was scrutinized thoroughly and presented in 
a chart format.  A shortened version of this chart was included in the 
anticoagulation toolkit with websites provided to healthcare providers on 
where to find more information on drug trials and individual oral 
anticoagulant agents.  
• Methods of analysis: These data were analyzed statistically through 
measures of central tendency to obtain expert feedback of what factors 
influenced safe and efficacious prescription of anticoagulants, striving 
for a 70% consensus. 
4.  Endorse patient-centered anticoagulation based upon current evidence-based 
literature and expert opinion.   
• Evidence-based measures/instruments.  As aforementioned in 
objective 2, literature review and expert opinions were the foundation 
of this toolkit.  Summaries from key anticoagulation guidelines and 
landmark drug trials were also analyzed.  Background information, 
pharmacokinetics, and pharmacodynamics on the five individualized 
drugs (warfarin, apixaban, rivaroxaban, edoxaban, and dabigatran) 
were obtained from the FDA (CDC, 2016b) prescribing information 
and summarized in a chart.  Individual patient factors to consider when 
prescribing anticoagulants were compared in a chart format.  A 
comparison of novel drug trials was included to assess the safety and 
efficacy of the five commonly prescribed oral anticoagulants; these 
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results were summarized in the capstone paper and the website link 
was included in the anticoagulation toolkit. 
• Methods of Analysis.  These data were analyzed statistically through 
measures of central tendency to obtain expert feedback of what factors 
influenced patient-centered management of anticoagulants, striving for 
a 70% consensus. 
5. Evaluate the effectiveness of a toolkit influencing the diagnosis of atrial 
fibrillation and anticoagulation management within a primary care setting.  
• Plan: The effectiveness of this toolkit was evaluated through a Round 
2 Delphi survey completed by two primary care clinics and two 
cardiology clinics within northern Colorado.  Four providers examined 
and critiqued this guideline for its usefulness and applicability in 
practice.  The surveys were completed through Survey Monkey with 
the consent forms and other corresponding communication 
individually delivered to providers via confidential e-mail. 
• Methods of analysis: To evaluate the effectiveness of the 
anticoagulation toolkit, the PARIHS and RE-AIM frameworks were 
utilized.  Through the PARIHS framework, strategies were devised to 
tailor the algorithm and guideline to the target population and 
appropriate context while utilizing the best evidence innovatively.  
Furthermore, this framework aided in applying the unique skills and 
experience levels of the providers to improve facilitation of the 
intervention.  The RE-AIM framework examined how to reach the 
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intended population, evaluate the impact of this toolkit in the primary 
care setting, brainstorm techniques to enhance adoption by providers, 
address barriers to implementation, and strengthen utilization of this 













RESULTS AND OUTCOMES 
 
 
Results from Literature Review  
 
 As this was a quality improvement project, the core of this capstone paper was an 
extensive literature review on atrial fibrillation and anticoagulation, which was 
successfully achieved.  Through PubMed and UpToDate databases, the researcher located 
current research studies (including systematic reviews and nationwide cohort studies) 
within the past five years on atrial fibrillation diagnosis and management, displaying an 
impressive collection of background information on the topic.  As oral anticoagulation 
(warfarin) has been prescribed since the 1950s, older but relevant research and evidence 
were included in the literature review.  Approximately 145 individual references were 
reviewed including the most current recommendations from four international and 
national guidelines on anticoagulation for atrial fibrillation.  Over 25 components of atrial 
fibrillation were researched in this literature review, e.g., novel evidence on anticoagulant 
reversal agents, alternative treatments for AF, epidemiology, risk factors and 
pathophysiology for AF, genetic testing with warfarin, lab monitoring, and the impact of 
AF on patient quality of life and the economics of the United States.  As the focus of this 
project was reducing the incidence of stroke in elderly patients with AF, the researcher 
found numerous studies discussing how best to manage AF in this high-risk population as 
well as addressing the limited knowledge providers and society have on the contribution 
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of AF to strokes in general.  The objective was to obtain literature comparing the five 
current oral anticoagulants (warfarin, apixaban, dabigatran, edoxaban, and rivaroxaban); 
this was thoroughly completed based upon FDA (CDC, 2016b) prescribing information 
and was ultimately summarized within a chart.  This same evidence was utilized to create 
the algorithm comparing warfarin to DOACs as well as the algorithm highlighting 
patient-specific factors to consider when prescribing an oral anticoagulant.  The objective 
to research noteworthy drug trials for the oral anticoagulants was accomplished as the 
researcher discovered and summarized 30 trials for these drugs including studies from 
1989 to 2015 as well as discussed studies on WATCHMAN©, reversal agents, and dual 
antiplatelet therapy, effectively accentuating the safety and efficacy data on these drugs.  
The four-step guideline to diagnose and manage AF was based solely on current evidence 
and recommendations from guidelines including the importance of utilizing CHA2DS2-
VASc and HAS-BLED scores to assess for stroke and bleeding risk with anticoagulants 
and AF.  The depth of this literature review allowed the researcher to create a resource 
section for providers within the anticoagulation toolkit, addressed suggestions and 
requests to improve management of AF, enhanced shared-decision making with the 
patient, and promoted multidisciplinary care.  Furthermore, this research was successfully 
utilized to compare current evidence and practice (through the patient chart reviews), 
identify gaps, and propose solutions through the anticoagulation toolkit.  Due to the 
complexity of atrial fibrillation, this literature review was more timely and lengthy than 
originally anticipated but was highly inclusive of all necessary components to better 




Results from Patient Chart Reviews 
 Over 100 patient charts were retrospectively reviewed in the Next Generation 
electronic health records at Family Physicians of Greeley-Central.  Over 396 patients 
who met the criteria of “atrial fibrillation” and “seen in the clinic during 2017” were 
identified within Next Generation.  Out of this population, 100 patients were randomized 
alphabetically and each patient was identified with only a unique number and initials.  
Patient charts were evaluated to obtain the following demographics: age, sex, ethnicity, 
rural or urban residence, and insurance status.  Other data collected included stroke or 
bleeding scores, patient presentation (symptomatic or asymptomatic), clinical 
manifestations, risk factors (AF, bleeding, and stroke), current anticoagulation agent, 
negative outcomes, and gaps between evidence and practice.  Statistical data analysis for 
the patient chart reviews was calculated through measures of central tendency: mean, 
median, and mode.   
Age 
The most common ages for patients with atrial fibrillation were ages 60 to 69 
years (22%), ages 70 to 79 years (33%), and ages 80-89 years (24%), coinciding with the 
increased incidence of patients with atrial fibrillation over 65 years of age (You et al., 
2012).  A summary of the age demographics of patient chart reviews is provided in Table 





Age Demographics of Patient Chart Reviews 
Age (years) Number of Patients  
30-39 2 
40-49   1 




90+   9 


































With regard to sex, out of 100 patients, 44 were female and 56 were male, 
corresponding to the increased rate of AF in men compared to women (Kirchhof et al., 
2016).  However, with increasing age, AF is more prevalent in women (Kirchhoff et al., 
2016).  This statistic correlated to the chart reviews; of 33 patients older than 80 years of 
age, 22 were female (15 patients age 80-89 years and seven patients age 90+), and 11 
were male (nine patients age 80-89 years and two patients age 90+), suggesting how with 
increased age comes an increased risk of disease.   
Race/Ethnicity 
Race/ethnicity was not mentioned in the literature as a risk factor for AF other 
than an increased incidence with European heritage (Centers for Disease Control and 
Prevention, 2015).  This fact correlated with chart reviews where 94 of 100 patients were 
Caucasian, 49 were Hispanic, one was Asian, and one was of mixed-race.   
Health Insurance 
Selection of an anticoagulation is often related to health insurance coverage and 
the ability to pay for a prescription.  Research indicated all major insurance companies 
and Medicare cover warfarin, rivaroxaban, dabigatran, and apixaban, yet Medicare does 
not cover edoxaban (GoodRx, 2017).  The chart reviews displayed over 51 patients had 
Medicare and 20 patients had MCR Humana; only five patients had either no insurance or 
unknown insurance coverage.  As 95% of patients had insurance coverage, the issue of 
cost could be reduced through copays or drugs saving cards, offering more oral 
anticoagulation options to fit individualized patients’ preferences, medical conditions, 
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and budget.  Insurance coverage of the patient chart reviews is provided in Table 3 and 
Figure 5.  
 
Table 3 
Health Insurance Coverage Reflected in Patient Chart Reviews 
Health Insurance  Number of Patients 
Medicare 51 
Cigna   3 
Anthem Blue Cross Blue Shield   8 
Banner   4 
Colorado Choice (Medicaid)   1 
Kaiser Permanente   2 
MCR Humana 20 
United Healthcare   6 
Unknown/None/   5 





Figure 5.  Health insurance coverage reflected in patient chart reviews. 
 
 
Rural or Urban Residence 
The researcher wanted to insure this project was inclusive of both rural and urban 
residences as access to care was a large issue influencing patients’ ability to receive 
appropriate medical care.  The chart review demonstrated 70 patients resided rurally 
while 30 patients lived in urban residences; thus, the researcher was successful in 
targeting a diverse population.   
Stroke and Bleeding Scores 
Research demonstrated CHA2DS2-VASc scores (stroke risk) and HAS-BLED 
scores (bleeding risk) are simple and efficient tools to assess whether anticoagulation is 
appropriate for a patient with atrial fibrillation without warranting further testing or blood 
work (Shahid et al., 2016).  The CHAD2DS2-VASc is recommended over CHADS2 to 




























classify the degree of a patient’s stroke risk (Lane & Lip, 2012).  Despite these 
recommendations, only 29 patients had a documented CHADS2 score (13 patients or 9%) 
or CHA2DS2-VASc score (19 patients or 20%) mentioned in their medical charts while 
only 11providers utilized the more effective stroke risk tool of CHA2DS2-VASc.  
Furthermore, no patients had records of their HAS-BLED scores in their medical charts.  
These data greatly highlighted how providers in both primary care and cardiology were 
not utilizing evidence-based tools to define a patient’s stroke risk and lessen their 
bleeding risk, which ultimately could worsen patient outcomes (increased stroke risk) by 
not prescribing anticoagulation appropriately.  The utilization of screening tools by 
providers within the patient chart reviews is summarized in Table 4 and Figure 6.  
 
Table 4 
Utilization of Screening Tools by Providers Within Patient Chart Reviews 
Stroke and Bleeding Scores Number of Patients 
CHADS2 13 (9%) 
CHA2DS2-VASc 19 (20%) 
HAS-BLED 0 (0)%) 
Unknown 68 (71%) 





Figure 6.  Screening tools utilized by providers within patient chart reviews. 
 
 
Patient Presentation: Symptomatic  
of Asymptomatic  
Approximately 30% of patients with AF present asymptomatically; yet, this 
population demonstrates a higher CHA2DS2-VASc score and increased stroke risk.  
Furthermore, 20% of patients are diagnosed with AF after suffering their first stroke 
(Shahid et al., 2016).  Patient chart reviews indicated 44 patients were asymptomatic and 
56 were symptomatic, which was higher than the literature suggested.  However, this 
increase in asymptomatic patients could be related to the difficulty in determining 
through chart reviews whether the patient was symptomatic when diagnosed since a large 
percentage of patients was asymptomatic after being properly treated with rate and 














According to the CDC (2015), clinical manifestations of AF include heart 
palpitations/irregular heart rate, dizziness, fatigue, shortness of breath, presyncope, and 
chest pain.  The researcher assessed for all the aforementioned clinical manifestations in 
patient chart reviews.  Of 56 patients who were symptomatic with AF, the following 
symptoms were evident: 43 had fatigue, 21 had shortness of breath/dyspnea, 16 had chest 
pain, 14 had dizziness/lightheadedness, 13 had fatigue, and 7 had syncope/pre-syncope.  
Patients individually varied on the number of symptoms they experienced.   
Risk Factors: Atrial Fibrillation,  
Bleeding, and Stroke 
During the chart reviews, risk factors for AF, bleeding, and stroke were all 
evaluated.  More specifically, risk factors for AF included obesity, heart failure, diabetes 
mellitus, chronic kidney disease, hypothyroidism, alcohol abuse, obstructive sleep apnea, 
and left ventricular hypertrophy (CDC, 2015; Ganz & Spragg, 2016).  Risk factors for 
stroke risk were obtained from the CHA2DS2-VASc criteria and included heart failure, 
hypertension, age >65 years old, diabetes mellitus, prior stroke or TIA, vascular disease, 
and female sex (Hwang, 2016a).  Risk factors for bleeding risk were gathered from the 
HAS-BLED criteria and included hypertension, abnormal renal disease, abnormal liver 
disease, history of stroke, labile INR, age greater than 65 years old, concurrent drugs 
increasing bleeding risk, and heavy alcohol use (Hwang, 2016b).  Based upon these 
results, the 10 most common risk factors for these 100 patients were age greater than 65 
years old (78 patients), hypertension (71 patients), obesity (72 patients), female sex (44 
patients), cigarette smoker (36 patients), diabetes mellitus (33 patients), chronic kidney 
disease (33 patients), thromboembolism/hypercoagulable (31 patients), heart failure (29 
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patients) and valve disorder (29 patients).  The significance of obtaining data was to 
assess for risk factors increasing a patient’s risk for AF as treatment of these modifiable 
risk factors could prevent the onset or progression of disease.  In a patient with AF, 
assessing for and reducing risk factors contributing to stroke risk and bleeding risk could 
improve a patient’s treatment plan by ensuring the patient is receiving the correct 
anticoagulant while minimizing negative sequeale of bleeding.  Of note, 100% of patients 
in these chart reviews were treated for modifiable risk factors for AF such as 
hypothyroidism, hypertension, diabetes, sleep apnea, chronic kidney disease, and heart 
failure, with appropriate lab monitoring to confirm the diseases were being controlled.  
Also, providers were effective in educating patients on healthy lifestyle modifications 
such as reducing alcohol consumption, weight loss, healthy diets, and smoking cessation, 
which ultimately reduce the risk of AF as well as other chronic diseases.  As early AF has 
a genetic component (Shehab et al., 2010), patient charts were reviewed for a family 
history of AF; only one patient mentioned a known family history of AF.   
Current Anticoagulation Agent 
According to 100 charts reviewed, 43 patients were on Warfarin©, 27 were on a 
DOAC, 19 were on aspirin, 5 were on a combination therapy of aspirin and Plavix©, and 
6 patients were on no anticoagulation to treat atrial fibrillation.  The two most common 
DOACs prescribed were Xarelto© (11%) and Eliquis© (13%).  Literature recommended 
aspirin for AF only with a CHA2DS2-VASc score of 1 (January et al., 2014; Meschia et 
al., 2014); yet oral anticoagulants have proven superior to aspirin (Manning et al., 2016) 
and due to the heightened bleeding risk, aspirin is not recommended as monotherapy 
(Shahid et al., 2016).  Thus, in this chart review, 24 patients with AF had not been treated 
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according to current recommendations (monotherapty aspirin use or refusing any 
anticoagulant treatment) and only 27 were prescribed DOACs when research clearly 
demonstrated their safety and efficacy compared to warfarin.  Dual antiplatelet therapy 
with aspirin and Plavix© is recommended only if patients are unable to take oral 
anticoagulants (Manning, Singer, & Lip, 2016; You, et al., 2012), thus justification can 
be made for the five patients on Plavix and aspirin as an alternative anticoagulant 
regimen.  Rationales in the chart reviews for selecting an anticoagulant were limited but 
included stroke risk, age, bleeding risk, dosing, patient preference, provider preference, 
patient refusal, reversal agents, cost, food and/or drug interactions, insurance coverage, 
renal function, compliance, and convenience.  Better comprehension and awareness of 
factors for prescribing a specific agent are essential to ensuring patients are receiving the 
best individualized anticoagulant agent.  The utilization of specific oral anticoagulation 





Utilization of Specific Oral Anticoagulation Agents with Atrial Fibrillation 
Current Anticoagulation Agent for AF Number of Patients  
Warfarin 43 
Xarelto 11 
Pradaxa    3 
Eliquis 13 
Savaysa   0 
Aspirin 19 
Aspirin + Plavix   5 
None   6 





















CURRENT ANTICOAGULATION AGENT FOR AF
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Negative Outcomes Related to Atrial  
Fibrillation or Anticoagulation  
The purpose of this capstone project was to decrease negative outcomes related to 
poorly treated AF--predominantly reducing stroke risk.  Strokes or TIAs occurred in nine 
patients either before or after the diagnosis of AF, suggesting AF could have been a 
contributing cause to this medical emergency.  Approximately 750,000 hospitalizations in 
the United States are related to AF (CDC, 2015) with 46.2% of emergency department 
visits related to warfarin adverse effects (Budnitz et al., 2011).  The researcher wanted to 
evaluate how frequently patients were being hospitalized for AF (60 out of 100 patients), 
with some patients requiring multiple hospitalizations and others requiring none, 
primarily related to a new diagnosis of AF (symptomatic or atrial fibrillation rapid 
ventricular rate) or supratherapeutic INRs.  Only 27 patients went to the emergency 
department related to AF, either for bleeding, supratherapeutic INRs, requiring a head 
contrast tomography (CT) scan after a fall to assess for an intracranial bleed while on 
anticoagulation or symptomatic AF.   
Interesting, the annual bleeding risk while on anticoagulation is only 1.5% 
(Hwang, 2016b); this was relevant as 18 patients in the chart reviews had 
supratherapeutic (high) INRs, 13 had subtherapeutic (low) INRS, 7 suffered from 
epistaxis, 8 had GI bleeds, 1 had hematuria, 1 had hemoptysis, and 2 patients required 
reversal agents for bleeding.   
The biggest concern with oral anticoagulants is intracranial hemorrhage; 
regardless of the anticoagulant, intracranial bleeds occur in less than 1% of the population 
annually (Desai et al., 2017).  In these chart reviews, none of the 100 patients suffered 
from an intracranial hemorrhage while on oral anticoagulation, enhancing the safety 
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profile of these drugs to treat AF.  Of note, the risk of intracranial hemorrhage was 
reduced by half with NOACs in comparison to warfarin, yet the rate of gastrointestinal 
bleeding increased, (Manning et al., 2016).  This evidence corresponded to the patient 
chart reviews as eight patients in this population developed gastrointestinal bleeds while 
on anticoagulants.  An assessment of HAS-BLED scores within the chart reviews would 
have been helpful to determine if a reduction of risk factors for bleeding could have 
diminished the incidence of bleeding in patients while on anticoagulation.   
Approximately 17 patients displayed poor compliance to a treatment plan 
including taking anticoagulants as recommended or follow-up with providers and INR 
monitoring.  Approximately 25 patients did not report any adverse outcomes related to 
anticoagulation for AF, inferring these drugs could be safely prescribed when taken as 
directed.  However, these drugs do not come without risk and thus require close 
monitoring by providers to assess for and treat any complications that might arise.  
Providers must ensure they are thoroughly educating patients on the importance of taking 
anticoagulants as directed to reduce negative sequelae on both ends of the spectrum--
bleeding and stroke.  Compliance is a factor that should be considered when prescribing 
anticoagulation including the half-life of drugs, once or twice daily dosing, and INR 
monitoring to improve patient outcomes.  Negative outcomes related to AF and/or 





Negative Outcomes Related to Atrial Fibrillation and/or Anticoagulation 
Negative Outcomes Related to AF and/or 
Anticoagulation 
Number of Patients  
Stroke/TIA (before or after AF diagnosis)   9 
Hospitalization  60 
Supratherapeutic INR 18 
Subtherapeutic INR 13 
Epistaxis   7 
GI Bleed   8 
Bleed Requiring Reversal   2 
Fall 12 
Emergency Department 27 
Hematuria  1 
Hemoptysis   1 
Poor Follow-Up or Compliance 17 
Intracranial Hemorrhage   0 
None 25 
N = 100 
 
 
Gaps Between Evidence and Practice 
 The researcher discovered other gaps between evidence and practice for patients 
with AF when reviewing local patient chart reviews.  No annual EKGs were obtained for 
patients greater than age 65 years old despite recommendations suggesting this aging 
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population is at the highest risk for developing AF (Kirchhof et al., 2016; Meschia et al., 
2014; Shahid et al., 2016).  Furthermore, providers did not consistently obtain an EKG 
with an irregular pulse on examination to diagnose AF (Kirchhof et al., 2016).  An EKG 
was obtained more often in a patient who was symptomatic while in the clinic.  
Interestingly, five patients were diagnosed with AF pre-operation or pre-procedurally 
(mostly asymptomatic) and eight patients were diagnosed with AF post-operatively, 
which is also a risk factor for AF onset (Kumar, 2016b).  Despite inconsistencies of EKG 
analysis, providers correctly ordered subsequent testing for AF such as thyroid 
stimulating hormone, echocardiography, and ambulatory EKG monitoring (Kirchhof et 
al., 2016).  The researcher attempted to derive from chart reviews whether patients were 
diagnosed with paroxysmal, persistent, or permanent atrial fibrillation.  However, those 
terms were not commonly used and were difficult to decipher within the charts as 
multiple terms were often used to classify the type of AF for the same patient dependent 
on the provider.  
 Commonalities between research and practice were also evident in the patient 
chart reviews.  With atrial fibrillation, providers consistently used a goal INR of 2.0 to 
3.0 for warfarin as recommended by guidelines (You, et al., 2012).  For providers 
managing INRs within the clinic, anticoagulation tools were built into the electronic 
health records (EHRs) to document the history and trends of the INRs and corresponding 
warfarin levels as well as to determine the appropriate dose and frequency of warfarin.  
This tool was helpful in maintaining more therapeutic INRs.  Yet, chart reviews 
demonstrated the INRs of 24 patients were managed by an anticoagulation clinic, INRs of 
13 patients were managed by the primary care provider, and INRs of two patients were 
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managed at home.  As noted prior, a minimum of 18 patients had documented 
supratherapeutic INRs and 13 had subtherapeutic INRs, suggesting the management of 
warfarin was less than ideal to prevent negative outcomes.  The risk of thromboembolism 
increases with an INR < 2, and the risk of bleeding increases with an INR > 4, especially 
> 5 (Hirsh et al., 2003); labile INR replacement of warfarin with a DOAC is 
recommended (January et al., 2014).  Research recommended INRs are best managed by 
the patient or a clinic compared to provider management (Hull & Garcia, 2016b); thus, 
increased utilization of anticoagulation clinics or home monitoring of INRs could reduce 
labile INRs and associated negative outcomes of bleeding and stroke.   
 Providers used multiple recommended treatment options for AF in addition to 
anticoagulation: rate control in 88 patients, rhythm control in 22 patients, MAZE 
procedure in two patients, pacemaker implantation in 16 patients, WATCHMAN 
insertion in three patients, ablation in 24 patients, and cardioversion in 32 patients.  As 
aforementioned, providers were congruent with treating risk factors and chronic 
conditions associated with AF appropriately.  However, medication reconciliation was 
not consistent between providers and specialists, posing a safety issue for the patients 
such as double dosing of anticoagulants.  Also, the EHRs mislabeled patients with a 
thromboembolism who required chronic anticoagulation as atrial fibrillation, marking an 
incorrect diagnosis in patients’ charts.   
 According to the ESC (Kirchhof et al., 2016), patient involvement, a 
multidisciplinary team, complex management decisions, and a navigation system are all 
essential for successful management of AF.  Multidisciplinary care was evident in the 
chart reviews for patients with AF: 74 of the 100 patients were referred to cardiology, 11 
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patients saw electrophysiology in addition, five patients were seen at the heart failure 
clinic, and five patients received additional services through case management.  
Providers, both primary care and specialists, were excellent educators when discussing 
how medications such as antibiotics could affect INRs, explaining the differences 
between oral anticoagulants including risks and benefits, patient preference into the 
treatment plan, encouraging compliance to a treatment plan to reduce bleeding and stroke 
risk, the importance of consistent INR monitoring, and symptoms signifying AF.   
Results from Delphi Surveys 
Phase 1: Delphi Study Round 1  
Results  
 The Delphi Study Round 1 Survey was created via Survey Monkey with a 
specific weblink e-mailed to each provider individually including the consent form as an 
attachment (see Appendix H).  Participation was implied if the provider completed the 
survey via Survey Monkey.  The Round 1 survey containing 10 qualitative and 
quantitative questions was sent to 17 providers and the researcher received responses 
from 13 providers.  Five of these providers were forwarded the informed consent and 
Survey Monkey link through e-mail via another provider.  The Round 1 survey took 
providers 2 to 20 minutes to complete with an average time of seven minutes.  The 
researcher was notified through e-mail when new survey results were received via Survey 
Monkey and subsequently the data were easily accessible to statistically analyze.  A 
statistical data analysis for the Round 1 survey was calculated through measures of 
central tendency: mean, median, and mode.   
Regarding demographics, four providers were MDs, one was a DO, five were 
NPs, and three were PAs.  Four of the providers specialized in family practice, five in 
127 
 
cardiology, two in electrophysiology, and one in cardiovascular surgery.  The experience 
level of providers ranged from less than one year to 20 years with an average of four to 
seven years in practice.  The comfort level of the providers in managing atrial fibrillation 
varied; one provider ranked the comfort level as “0”--very uncomfortable, two providers 
ranked the comfort level as “3,” three providers ranked the comfort level with a score of 
“4,” and seven providers ranked the comfort level as “5”--very comfortable.  Therefore, 
the mix of survey responses was diverse and covered a wide range of specialties, 
didactics, training, and experience levels.  Out of 10 questions, >70% consensus was 
achieved on the following questions:  
• Palpitation (11 providers) and syncope/presyncope (8 providers) were noted 
as presenting symptoms of AF, warranting a further work-up. 
• 100% of providers did not routinely screen for AF through a pulse check in 
patients >65 years old. 
• An EKG was used by 12 providers to diagnose AF. 
• Oral anticoagulants were prescribed by 10 providers to treat AF.   
• Furthermore, the CHA2DS2-VASc score was a commonly used screen tool 
for initiating anticoagulation according to nine providers (a score of >2 
warranted anticoagulation with two providers, a score of 1 warranted 
anticoagulation with two providers, and an unspecified score was elucidated 
by six providers).   
• A CHA2DS2-VASc score was used to assess stroke risk by 11 providers, a 
CHADS2 score was used by five providers to assess stroke risk, and the 
HAS-BLED score was used by 7 providers to assess bleeding risk; multiple 
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providers mentioned they utilized both the CHADS2 and CHA2DS2-VASc 
tools.   
The most common guideline utilized by providers to treat AF was the American 
College of Cardiology (2012), yet a 70% consensus was not reached with this question.  
Additionally, a 70% consensus was not achieved with questions asking what would be 
most helpful in a guideline, least helpful in a guideline, and improve the management of 
AF.  Thus, the researcher attempted to include all these requests and suggestions into the 
revised Anticoagulation for Atrial Fibrillation Toolkit in addition to the responses 
achieving 70% expert consensus.  The researcher originally attempted to create one 
algorithm for this guideline but due to the complex nature of managing AF, four 
algorithms were designed to simplify and clarify the treatment regimen.  Providers were 
given a summary of the 70% consensus from Round 1 when they were given the link to 
take the Round 2 survey through Survey Monkey.  Data analysis from Phase 1: Delphi 
Study Round 1 is summarized in Tables 7 through 16 including clarification of which 





Summary of Responses for Survey Question 1: Please Fill in the Following 
Demographics 
 








Family  4 
Cardiology 5 
Electrophysiology  2 
Cardiovascular Surgery  1 
 











Summary of Responses for Survey Question 2: What Patient Presentation (Symptoms and 
Risk Factors) Warrants a Work-Up for Atrial Fibrillation? 
Symptom or Risk Factor Number of Providers (13 total) 
Fatigue   3 
Palpitations 11 (>70% consensus) 
Chest Pain    4 
Syncope/Presyncope   8 (>70% consensus) 
Poor Sleep   1 
Weakness   1 
Shortness of Breath/Dyspnea on Exertion   5 
Dizziness/Lightheadedness   4 
Level of Consciousness   1 
EKG Results   1 
Stroke/TIA   3 
History of AF   1 
Congestive Heart Failure   1 
Coronary Artery Disease   1 






Summary of Responses for Survey Question 3: Do You Screen for Atrial Fibrillation in 
All Your Elderly Patients Older Than 65 Years Old? 
Screening for Atrial Fibrillation Number of Providers 
Yes   0 






Summary of Responses for Survey Question 4: Explain Your Work-Up for Diagnosing 
Atrial Fibrillation 
Diagnostic Tool Number of Providers  
12-Lead EKG 12 (>70% consensus) 
Thyroid Stimulating Hormone   3 
Complete Blood Count   1 
Echocardiogram   1 
Event/Holter Monitor   8 
Telemetry    3 






Summary of Responses for Survey Question 5: How Do You Typically Treat Patients with 
Atrial Fibrillation? 
Treatment Number of Providers (13 total) 
Oral Anticoagulant (Warfarin or DOAC) 10 (>70% consensus) 
Rate Control Medication 6 
Echocardiogram  1 
Treat Risk Factors 1 
Cardioversion 2 
Consider Rate vs. Rhythm Control 3 
Rhythm Control 4 
Refer to Cardiology  3 
Treatment Dependent on Symptoms and Age 1 






Summary of Responses for Survey Question 6: Which Factors Influence Your Decision to 
Initiate Anticoagulation in a Patient With Atrial Fibrillation Including Selection of a 
Particular Agent? 
Factors Influencing Anticoagulation Number of Providers (13 total) 
CHA2DS2-VASc Score 9 (>70% consensus) 
Score >1 2 
Score ≥2 2 
Unspecified  5 
Cost of Medication/Insurance Coverage 4 
Patient Compliance 1 
Cognitive Ability 1 
Valve Disease 2 
Age 4 
Patient Preference 4 
Risk for Stroke 3 
American College of Cardiology Guidelines 1 
Bleeding Risk 2 
Contraindications or Oral Anticoagulants 1 
CHADS2 Score 1 
Provider Preference 2 
AF with a Duration >5 Minutes 1 
Co-morbidities 1 
Ease of Use 1 





Summary of Responses for Survey Question 7: What Is Your Comfort Level with 
Prescribing and Managing Anticoagulation for Atrial Fibrillation? 
Comfort Level Score Number of Providers (13 total) 










Summary of Responses for Survey Question 8: Do You Use Any Screening Tools to 
Assess for Stroke and Bleeding Risk with Anticoagulation and Atrial Fibrillation? 
 
Screening Tool Number of Providers (13 total) 
CHADS2   5 
CHA2DS2-VASc 11 (>70% consensus) 
HAS-BLED   7 





Summary of Responses for Survey Question 9: Atrial Fibrillation Guidelines and 
Algorithms 
 
What guidelines, algorithms, or resources 
do you reference for anticoagulating and 
treating atrial fibrillation?  
Number of Providers (13 total) 
Chest Guidelines 1 




American College of Cardiology (ACC) 5 
CHA2DS2-VASc 2 




What would you find most helpful in an 
AF algorithm or guideline?  
Number of Providers (13 total) 
Simple/Straightforward 4 
Unambiguous/Easy to follow 2 
Evidence-Based 2 
What is Considered Valvular Disease 1 
List of Medication Options (including rate 
and rhythm control) 
2 
Risk of Stroke Calculated 1 
Not Applicable  
 
2 
What would you find least helpful in an 
AF algorithm or guideline? 
Number of Providers (13 total) 
Too Complex or Lengthy 2 
List of Medication Options 2 
Ambiguity 1 
Subjectivity (ex. definitions) 1 
Focusing on the Negatives of NOACs 1 
No Clear Recommendations 1 





Summary of Responses for Survey Question 10: Which of the Following Would Improve 
Your Management of Anticoagulation for Patients with Atrial Fibrillation: Community 
Resources, Specialists, Shared Decision-Making Tools, Websites, Phone Apps, More 
Anticoagulation Clinics, Etc.? 
Tools to Improve Management of AF Number of Providers (13 total) 
Specialists 2 
Phone Apps 5 
More Anticoagulation Clinics 3 
Simplified Algorithms 3 
Patient Education Resources 2 
Shared Decision-Making Tools 2 
CHA2DS2-VASc Calculation in Algorithm 1 
Know When to Refer to Specialists 1 
Ease to Find Current Guidelines 1 
Cost of DOACs 1 
 
 
Phase 2: Delphi Study Round 2  
Results  
 The Delphi Round 2 survey link through Survey Monkey was e-mailed to the 13 
providers who completed Round 1 of the survey along with a summary of the results 
from Round 1, which received greater than 70% expert consensus.  As the survey results 
were anonymous, the researcher attempted to rationalize which providers responded to 
the Round 1 survey based upon knowledge of the individual providers (specialty, title, or 
years in practice).  The attrition rate for this survey was low as only four providers 
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completed Round 2.  With no demographics listed, the researcher was unable to 
determine which providers responded to Round 1 and thus could not send a reminder e-
mail to obtain more results nor readdress individual perspectives of the providers 
discovered in Round 1.   
A statistical data analysis for Round 2 was calculated through measures of central 
tendency: mean and mode.  Of these four providers, greater than 70% agreed the 
anticoagulation toolkit was  
• Straightforward and user-friendly 
• Improved safety and efficacy of anticoagulation 
• Influenced future practice 
• Applicable to practice 
• Inclusive of evidence-based practice.   
Consensus was achieved on a benefit of this toolkit as being user-friendly and 
straightforward; yet, this response was already analyzed and accounted for in Question 1 
of the survey.  Consensus otherwise was not achieved on quantitative questions 
addressing benefits, challenges, and other feedback for the anticoagulation toolkit.  
However, providers noted the toolkit was too lengthy and contained too much 
information, which was accounted for by the researcher and will be addressed in future 
revisions of this toolkit.  Overall feedback from the providers implied the providers 
perceived this toolkit as beneficial.  Table 17 provides Delphi Survey Round 2 results for 




Delphi Survey Round 2 Results Where Consensus Was Not Achieved  
Question Open-Ended Answer Number of 
Providers 
6. What are the benefits of this 
toolkit? 
Evidence-based 1 
 Straightforward/Easy to 
Follow 
3 
 Compiles Many Resources 
into One Place 
1 
 Up-To-Date 1 
 
7. What are the challenges of this 
toolkit? 
Lengthy 1 
 Too Much Information 2 
 N/A 1 
   
8. Any other feedback, questions, 
or concerns? 
  
 Thorough Toolkit 1 
 Look Forward to Using It 1 
 Passion for Topic 2 
 Minor Changes 1 
 
 
Objective One Outcomes 
Objective 1 was to examine current and local diagnosis and management of atrial 
fibrillation within the primary care setting; this objective was fulfilled in its entirety.  A 
total of 100 EHRs in Next Generation were confidentially reviewed retrospectively and 
analyzed within a privately owned primary care clinic in Greeley.  Patients were included 
in the study if they met the criteria of a diagnosis of AF and were seen in the clinic for 
this diagnosis during 2017.  The researcher planned to retrospectively review only 75 
charts, yet exceeded this goal by obtaining data from 100 electronic patient charts.  All 
required information was obtained from the 100 patient charts with AF including 
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demographics, diagnosis, management, risk factors, negative outcomes, and utilization of 
screening tools.  Through statistical analysis of these data, the researcher was 
successfully able to highlight current management and diagnosis of atrial fibrillation 
while also identifying gaps in practice according to current evidence-based guidelines.  
Objective Two Outcomes 
 The second objective was to create a toolkit (guideline with algorithms) directing 
practitioners on diagnosis of atrial fibrillation as well as initiation and management of 
oral anticoagulation; this objective was successfully executed.  The evidence-based 
Anticoagulation for Atrial Fibrillation Toolkit followed its original design based upon 
literature review, current guidelines on anticoagulation, and expert opinion from two 
rounds of Delphi surveys.  Round 1 assessed providers’ comfort level and expertise with 
prescribing anticoagulants and diagnosing and managing AF while Round 2 evaluated the 
anticoagulation toolkit and how its incorporation could influence practice.  Results from 
Round 1 were utilized to revise the anticoagulation toolkit the researcher had drafted 
based upon literature; data analysis concluded 70% consensus was achieved on at least 
five questions.  Even without 70% consensus, the researcher incorporated provider 
expertise, suggestions, and requests into the anticoagulation toolkit.  In Round 2, data 
analysis of greater than 70% consensus suggested the anticoagulation toolkit was 
evidence-based, safe, efficacious, user-friendly, and could positively impact practice.   
 The toolkit was revised after Round 1 and divided into two sections to enhance its 
usability and relevance to practice.  The first section, composed of the guideline with 
algorithms, remained unchanged as these toolkit components were step-wise, 
straightforward, concise, and evidence-based.  The guideline with algorithms achieved 
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the goal of not only encouraging improved diagnosis and management of AF but 
promoting assessment for patient specific factors driving prescription of a specific 
anticoagulant.   
The second section of the toolkit contained multiple resources for providers and 
was formulated based upon requests from providers as well as evidence suggesting how 
best to manage atrial fibrillation.  This toolkit achieved the purpose of providing one 
reliable resource for providers to review when managing anticoagulants as well as 
offering resources to better educate patients, enhance patient-provider relationships, and 
promote multidisciplinary care.  
Objective Three Outcomes 
The third objective was to promote safety and efficacy in the management of 
anticoagulants; this objective was completed simultaneously with the second objective as 
the literature review and expert opinions were the foundation for this Anticoagulation for 
Atrial Fibrillation Toolkit.  A core element of this toolkit was promoting safety and 
efficacy when prescribing anticoagulants; thus, available literature on all five 
anticoagulants and their corresponding noteworthy drug trials, (warfarin, dabigatran, 
apixaban, rivaroxaban, and edoxaban) were scrutinized thoroughly and presented in a 
chart format in this capstone project.  Two shortened versions of this chart--one 
comparing anticoagulants in general and one comparing individual patient factors 
influencing selection of a specific oral anticoagulant—as well as two algorithms were 
included in the anticoagulation toolkit.  Providers were given multiple resources in the 
toolkit on where to find more reliable information on drug trials and individual oral 
anticoagulant agents.  As calculated through statistical analysis, greater than 70% 
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consensus from the Delphi Round 2 survey implied providers agreed the Anticoagulation 
for Atrial Fibrillation Toolkit could improve safety and efficacy of anticoagulant therapy.   
Objective Four Outcomes 
 The fourth objective was to endorse patient-centered anticoagulation based upon 
current evidence-based literature and expert opinion; this objective was achieved 
alongside the first and second objectives as the literature review and expert opinions were 
the foundation of this toolkit.  Summaries from key anticoagulation guidelines and 
landmark drug trials comprised the majority of literature reviewed on this topic.  As 
mentioned in the third objective within this capstone, background information, 
pharmacokinetics, and pharmacodynamics on the five individualized drugs (warfarin, 
apixaban, rivaroxaban, edoxaban, and dabigatran) were obtained from the FDA 
prescribing information (CDC, 2015) along with a comparison of novel drug trials to 
assess the safety and efficacy of the oral anticoagulants.  The webpage link for novel drug 
summaries was included in the anticoagulation toolkit to provide a reliable and easy to 
navigate link for providers to review conclusions from drug trials on anticoagulants.  
Within the Anticoagulation for Atrial Fibrillation Toolkit, two algorithms focused on 
selecting the anticoagulant for the patient: (a) individual patient factors to consider when 
prescribing anticoagulants and (b) a general summary comparing warfarin to DOACs.  
As calculated through statistical analysis, greater than 70% consensus from the Delphi 
Round 2 surveys implied providers considered this toolkit as inclusive of evidence-based 
practice to promote individualized anticoagulation.  Objectives 3 and 4 were synonymous 
as prescribing patient-specific anticoagulation is dependent on the safety and efficacy of 
the anticoagulant agent. 
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Objective Five Outcomes 
 The fifth objective was to evaluate the effectiveness of a toolkit influencing the 
diagnosis of atrial fibrillation and anticoagulation management within a primary care 
setting.  This objective was effectively accomplished as the Anticoagulation for Atrial 
Fibrillation Toolkit was evaluated through the Round 2 Delphi survey by four providers 
who through greater than 70% consensus agreed this guideline was straightforward, user-
friendly, influential, and applicable to practice.  The Delphi surveys were 100% 
completed through Survey Monkey, allowing the provider to easily review the data and 
analyze the results.  Furthermore, the PARIHS and RE-AIM frameworks were 
successfully utilized to evaluate the anticoagulation toolkit.  In accordance with the 
PARIHS framework, this evidence-based and innovative toolkit was tailored to the target 
audience (providers treating patients with AF) and context (primary care setting).  
Providers who completed the Delphi surveys varied in their comfort level with AF 
management, experience, and specialty; thus, the results of these surveys were utilized to 
create a toolkit inclusive of diverse knowledge and input, which ultimately would 
improve its facilitation into practice.  The RE-AIM framework successfully examined 
how this toolkit could reach its intended population (primary care providers managing AF 
patients), evaluate the impact of this toolkit in the primary care setting, brainstorm 
techniques to enhance adoption by addressing barriers to implementation, and strengthen 
utilization of this toolkit over time (through Delphi surveys).  Implementation of this 
toolkit into practice and evaluating its influence on reducing stroke in AF is a future 




Key Facilitators, Key Barriers, and Unintended  
Consequences to Project Objectives  
 
Key Facilitators 
This researcher was very passionate with the topic of this project, enhancing its 
success and contributing to its comprehensiveness and effective execution.  Dedication, 
ambition, and curiosity fueled the extensive evidence-based literature review including a 
comprehensive summary of oral anticoagulants and noteworthy drug trials.  For the chart 
reviews, the researcher was very familiar with the EHR (Next Generation) and thus could 
easily navigate through patient records to obtain the desired information.  Also, the clinic 
manager selected only the patients seen in the clinic for 2017 with a diagnosis of AF, thus 
simplifying relevant patients to review.  The researcher had a goal of 75 patient charts to 
review and exceeded this goal by reviewing 100 charts of diverse patients with AF.  
Survey Monkey streamlined the process of the Delphi surveys immensely as the 
researcher easily created surveys, designed a unique web-link, and e-mailed this web-link 
to providers individually and confidentially.  The researcher was even alerted via e-mail 
when surveys were returned and could access and statistically analyze these results 
effortlessly and quickly.  Measures of central tendency--mean, median, and mode--were 
utilized to analyze the data for the Delphi surveys and patient chart reviews.  The 
guideline and algorithm components of this toolkit were evidence-based, user friendly, 
applicable and influential to practice, and could improve the safety and efficacy of 
anticoagulation as demonstrated by >70% consensus in Round 2 of the Delphi survey.  
Furthermore, the first round of the Delphi survey and consent form were forwarded and 
completed by five interested providers, not only increasing the number of subjects for the 
Delphi surveys but also expanding the specialties to include electrophysiology and 
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cardiovascular surgery.  The researcher utilized evidence from research as well as expert 
requests and suggestions when modifying this Anticoagulation for Atrial Fibrillation 
Toolkit by adding a large section on provider resources to improve the practice of 
diagnosing and managing AF, especially with the targeted population of older adults.  
This capstone project was technologically savvy by utilizing electronic databases for 
literature review, EHRs to compare evidence to practice, Survey Monkey to complete 
surveys, e-mail communication, and Microsoft Office to formulate the capstone paper 
and anticoagulation toolkit.  
Key Barriers  
The researcher was unaware of the complexity of AF management when initiating 
this project as anticoagulation is only a fragment of the entire treatment plan.  The 
researcher expanded the literature review on AF to be inclusive of all relevant avenues of 
risk factors, diagnosis, treatment, and negative outcomes of the disease; however, this 
also become problematic when trying to make the anticoagulation guideline succinct 
while also relevant to the desired audience.  The researcher concluded EHRs are not user 
friendly and important data were often hidden, misconstrued, or difficult to find, 
especially when records from outside sources were intermingled.  Consequently, the chart 
reviews become more complex and took longer than anticipated to obtain all the required 
data.   
Regarding the Delphi surveys, the researcher was unable to determine which 
providers returned the surveys due to anonymity.  A good return rate was noted for the 
first round of the survey (13 out of 17 providers), yet there was a poor return rate for the 
second round (4 of 13 providers).  An original two-week return rate was proposed for the 
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Delphi surveys; yet due to time constraints, providers were requested to return the 
surveys within one week.  The lack of time to complete the surveys could have 
contributed to the poor return rate.  In Round 1, providers were reminded via e-mail to 
complete the survey if they did not return it within the requested time, increasing the 
response rate by three providers.  However, time constraints and anonymity of the 
providers (as demographics were not collected in Round 2) limited the ability to wait for 
further results from the Round 2 survey.  In the Round 1 survey, a limited 70% consensus 
was obtained so the researcher attempted to include suggestions and requests from 
providers to improve AF management despite this lack of consensus.  In Round 2, a 70% 
consensus was achieved for all five of the qualitative questions; however, the poor 
attrition rate was attributed to the length of the toolkit and extent of content as these 
challenges were noted by providers in the survey.  Due to the intricacy of the evidence 
available to diagnose and manage AF, the researcher had difficulties trying to divide the 
toolkit into a guideline with algorithm section followed by a provider resources section.  
The table of contents helped with this delineation but despite requesting providers at a 
minimum review the guideline and algorithms for this project, it is presumed this clarity 
was not apparent and providers did not choose to review a 30-page toolkit.  Reformatting 
the toolkit to be more concise or possibly dividing it into two separate papers--one a 
guideline with algorithms and the other with provider resources--are plausible future 
expansions of this project to improve its relevancy and implementation into practice.  
Unintended Consequences to  
Project Objectives 
 Unfortunately, the clinic where the chart reviews were completed displayed a 
poor attrition rate for the Delphi survey portion of this test.  The clinic was welcoming, 
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helpful, and supportive of this research project but the lack of follow-up and participation 
with the project was discouraging.  One provider wanted to know the results of the chart 
reviews to help utilize these conclusions to improve practice; the researcher will follow-
up with the results of this entire study with any providers who voice interest in learning 
more about this AF toolkit, its implementation into practice, and how to improve the 
overall diagnosis and management of AF in the primary care setting.  Even though this 
project was directed toward primary care providers, only four of the 13 providers who 
volunteered to participate in this study specialized in primary care, leaving nine providers 
who specialized in cardiology or some specialty.  One primary care provider even noted a 
poor comfort level with AF, refusing to treat these patients and referring them to 
cardiology.  Knowing one’s comfort level, scope of practice, and expertise are necessary 
to practice medicine well; however, primary care is the first place most acute and chronic 
diseases are presented, diagnosed, and treated so AF cannot be the exception.  These 
findings clearly represented how little emphasis providers, especially in the primary care 
realm, gave to AF despite the high risk of stroke and its effect on quality of life.  The lack 
of response from primary care providers suggested improved education and awareness 
are both needed to improve the diagnosis and management of AF.  The Anticoagulation 
for Atrial Fibrillation Toolkit is a straightforward, evidence-based, and comprehensive 
resource to guide providers on the recommended path to properly treat AF to reduce its 
negative sequelae; with implementation, it offers the possibility of improved management 
of AF.  No issues with breeches of confidentiality with either patient- or provider-specific 
data occurred with this project.  No harm to participants was evident and no unexpected 

















The purpose of this capstone project was to address the following problem 
statement: In adult patients with atrial fibrillation older than 65 years old and a moderate 
to high risk of stroke, how effective is an anticoagulation toolkit in guiding primary care 
providers on (a) diagnosing atrial fibrillation and (b) initiating and maintaining oral 
anticoagulation safely, to reduce the incidence of ischemic stroke?  An extensive and 
current literature review was completed on atrial fibrillation, focusing on the diagnosis 
and management of atrial fibrillation.  As the capstone highlighted the importance of 
anticoagulating elderly patients with atrial fibrillation to prevent the incidence of stroke, a 
comprehensive comparison of warfarin and the four DOACs as well as a summary of 
noteworthy drug trials were included to address safety and efficacy of these drugs.  The 
literature review not only provided extensive background information on atrial fibrillation 
and anticoagulation but also highlighted key references to first compare evidence to 
practice (analyze patient chart reviews) and then utilized these identified gaps to translate 
evidence into practice (create the anticoagulation toolkit).   
Chart reviews were retrospectively reviewed on 100 patients in a primary care 
setting, assessing the diagnosis and treatment of AF.  In comparing evidence to practice, 
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inconsistencies were evident--predominantly a lack of utilization of CHA2DS2-VASc and 
HAS-BLED scores to assess for stroke and bleeding risk, poor continued monitoring of 
AF in the primary care setting, a disconnect between the treatment plan and providers, 
and the absence of consistently diagnosing an irregular pulse as AF through an EKG.   
Through utilization of two rounds of the Delphi method, expert opinions, and 
recommendations of national and international guidelines, an evidence-based 
anticoagulation toolkit was created and modified to guide primary care providers on 
improving diagnosis of atrial fibrillation and enhanced initiation and maintenance of oral 
anticoagulation to reduce the incidence of stroke in elderly patients with atrial fibrillation.  
This toolkit consisted of a four-step, simplified guideline supported by four algorithms: 
(a) CHA2DS-VASc score, (b) HAS-BLED score, (c) comparison of anticoagulants, and 
(d) patient-specific factors influencing selection of anticoagulant.  Additionally, this 
toolkit offered in one document a summary of additional information and resources for 
providers to improve the overall management of atrial fibrillation.  Round 1 of the Delphi 
method suggested no providers assess for AF annually through a pulse check in patients 
older than 65 years old despite the increased risk of AF in the elderly and the high 
incidence of asymptomatic patients.  In Round 2 of the Delphi survey, all providers felt 
the AF toolkit was evidence-based, applicable, influential to practice, user-friendly, and 
promoted safety and efficacy; however, the toolkit was too extensive and lengthy. 
In summary, this capstone project answered the problem statement.  The literature 
review, patient chart reviews, and two rounds of the Delphi method addressed how to 
effectively and safely diagnose atrial fibrillation in the elderly population as well as 
initiate and manage anticoagulation.  However, a future research project focusing on 
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implementation of this toolkit in practice could better evaluate the maintenance phase of 
anticoagulation and how this toolkit could reduce the incidence of stroke in this high-risk 
population.  
Recommendations for Guideline Implementation Within  
the Framework of the Organizations’ Strategic Plan 
  
Phase 6 of this project entails a future pilot study to assess the impact on patient 
outcomes related to implementation of this anticoagulation toolkit into the primary care 
setting.  Thus far, this capstone project has only completed two rounds of the Delphi 
method and requires further consensus on how to make the toolkit more concise and 
relevant to providers within the primary care setting.  Obtaining input from specialists is 
essential to determine what resources, guidelines, and practices are utilized by experts in 
the field.  However, the toolkit must be tailored to the audience and ultimately reflect 
what the primary care providers, in this instance, require and want to improve their 
practice while still ensuring their practice is current and based upon expert and evidence 
consensus.  Expanding knowledge on atrial fibrillation diagnosis and management is a 
priority action to ensure providers are up to date and providing the best practices for their 
patients, thus supporting this extensive toolkit with a guideline and algorithms.  Providers 
do not have time to seek reliable and most current resources for every diagnosis they 
encounter, especially in primary care; thus, by educating providers on how this toolkit 
summarizes multiple reliable resources in one document, the diagnosis and treatment of 
AF can be step-wise, simplified, and manageable to improve patient outcomes.  
Additionally, encouraging providers to follow this evidence-based guideline and remain 
up to date with guidelines is essential.  For instance, the consensus from the first round of 
the Delphi survey suggested 100% of 13 providers did not screen annually for AF in 
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every elderly patient older than 65 through a pulse check, even though this is 
recommended by the AHA/ASA and ESC as a means of primary prevention (Kirchhof et 
al., 2016; Meschia et al., 2014).  
Through the first round of the Delphi survey, providers were asked what 
resources would be beneficial to improve their management of atrial fibrillation.  
Although 70% consensus was not achieved for any of these requests, the researcher still 
incorporated all these ideas into the toolkit, especially phone apps, referrals to specialists, 
and shared decision-making tools.  Further revisions of this toolkit through consensus of 
more Delphi rounds is necessary to meet the following requirements for an effective 
toolkit: the importance of including patients in the plan of care, making evidence easy to 
access and utilize, and incorporating multidisciplinary care into the treatment plan.  To 
improve the implementation of this toolkit, organizations should provide care to a diverse 
population of patients with AF; display similarities in their missions, values, perspectives, 
and approaches to diagnosing and managing atrial fibrillation; and remain open-minded 
to change.   
Recommendations for Evaluation of  
Anticoagulation Toolkit 
Delphi Surveys 
The Anticoagulation for Atrial Fibrillation Toolkit (guideline with algorithms) 
was evaluated based upon its ability to uphold the elements of the PARIHS framework 
and RE-AIM model.  The second round of the Delphi survey evaluated the benefits and 
challenges of this toolkit and achieved 70% consensus for its ability to be straightforward 
and user-friendly, evidence-based, applicable to practice, influential to practice, and 
promote safety and efficacy of anticoagulation therapy.  However, the responses were 
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limited in this second round compared to the first, contained mostly close-ended 
questions, and only touched the surface of how to improve this toolkit.  Further rounds of 
the Delphi survey through Survey Monkey would be helpful to better assess and meet the 
requirements and requests of providers who manage AF, ensuring this toolkit is more 
applicable and relevant to practice.  Reducing the length of this toolkit could be less 
intimidating to providers to review, which could reduce the low attrition rate of the 
surveys.  
Promoting Action on Research  
Implementation in Health  
Services Framework 
 
The three elements of the PARIHS framework (evidence, context, and facilitation 
into practice) were ranked on a scale from low to high (Rycroft-Malone, 2004).  One-
hundred patient charts in Greeley were reviewed to assess for data, a comprehensive 
literature review on current evidence and best practice was completed, and expert 
opinions from 13 providers were acquired through two rounds of the Delphi surveys 
(High Evidence).  Evidence from the literature review and expert consensus from the 
Delphi surveys were incorporated into an anticoagulation toolkit for diagnosing and 
treating atrial fibrillation in the primary care setting (High Context).  The expert 
consensus was diverse including primary care, cardiology, cardiothoracic surgery, and 
electrophysiology providers; the more experienced clinicians and those who specialized 
in the cardiovascular system acted as leaders when voicing their opinions on the Delphi 
surveys.  The chart reviews were culturally diverse as well as they were composed of 100 
patients in both rural and urban settings, ranging from ages 30 to 100, both male and 
female, and comprised of many races/ethnicities.  The facilitator for this project was the 
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researcher who compiled a large array of research on the topic of AF into one resource 
(the anticoagulation toolkit) for providers to utilize to improve practice.  Observations 
from the chart reviews were analyzed to compare evidence to practice.  Utilization of the 
Delphi surveys was a means to seek expert comments on the efficacy and feasibility of 
the toolkit’s use (Low Facilitation into Practice).  Facilitation was ranked low as only two 
rounds of the Delphi surveys were completed and this toolkit has not yet reached 
adequate consensus to be implemented into practice.  Elements of the iPARIHS model 
(Harvey & Kitson, 2016) were incorporated into the evaluation of this toolkit: this toolkit 
was comprised of a simple guideline and four complementary algorithms followed by a 
section summarizing additional information and resources for providers (innovation). 
Also in accordance with the iPARIHS model, the focus for this toolkit was primary care 
providers; the presumption was knowledge on AF was more limited for a generalist 
rather than a specialist (recipients, context levels, and experience of the facilitators), thus 
requiring a more comprehensive resource section to better manage AF. 
Reach, Effectiveness/Efficacy,  
Adoption, Implementation,  
and Maintenance Model  
 
The RE-AIM model was utilized for this capstone project to assist with the 
effective implementation and evaluation of this anticoagulation toolkit (RE-AIM, 2017).  
Reach addressed the target population of elderly patients with a new or chronic diagnosis 
of atrial fibrillation within the primary care setting including patients with diverse 
demographics, co-morbidities, and treatment plans.  Effectiveness was the impact of this 
anticoagulation toolkit to prevent stroke in patients with atrial fibrillation.  As this toolkit 
has not yet been implemented into practice, this element of the RE-AIM model was not 
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met.  Adoption assessed the willingness and feasibility of primary care providers to 
incorporate this toolkit into practice.  This toolkit has not been implemented into practice 
but in Round 2 of the Delphi Survey, greater than 70% consensus agreed this toolkit was 
applicable to practice and could influence future practice of AF.  Implementation 
addressed the factors contributing to the successful use of this toolkit in primary care, 
which was evident in the algorithm comparing oral anticoagulants in general as well as 
the algorithm assessing patient specific factors to consider when selecting an oral 
anticoagulant.  Maintenance assesses the duration of the implementation of this toolkit in 
practice; however, as this toolkit is only in its preliminary stages, this component of RE-
AIM was not currently applicable to this capstone project. 
Ongoing Activities or Evaluations Outside the Scope 
of the Doctor of Nursing Practice Project 
 
 This Doctor of Nursing Practice (DNP) project shed light on the limited 
knowledge healthcare providers and the general public have on the contribution of atrial 
fibrillation to strokes.  For instance, the AHA/ASA (2016) created a public service poster 
on atrial fibrillation: even though 15% to 20% of all strokes are related to AF, only 50% 
of patients with AF think they are at risk for a stroke.  Research and observation of 
practice have demonstrated healthcare providers underestimate the increased risk of 
stroke with AF (especially with paroxysmal AF), overestimate the bleeding risk with 
anticoagulants, and do not consistently utilize screening tools such as CHA2DS2-VASc or 
HAS-BLED to assess for stroke and bleeding risk with AF despite evidence-based 
practice suggesting otherwise.   
To stay current with technological advances, medication safety, and treatment 
updates, subscribing to e-mail updates from reliable organizations for medication safety 
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(FDA MedWatch, Prescribing Letter, UpToDate) and newsletters from medical 
organizations (American Academy of Family Physicians, American College of 
Cardiology) is recommended for providers to increase evidence-based practice.  To 
simplify the practice of medicine and have updated practice available at their fingertips, 
providers can access toolkits and phone apps from reliable organizations such as the 
American College of Cardiology, Medscape, and Epocrates.  Promoting self-efficacy in 
patients, expanding public education efforts, and utilizing shared decision-making tools 
are proposals to enhance patient-provider relationships and influence patients to take 
control of their health to improve outcomes.  Working as a multidisciplinary team, 
including the collaboration with case managers, specialists, and anticoagulation clinics, 
could ensure practice for AF is evidence-based, patient-centered, cost-effective, and 
incorporates all available resources.  Atrial fibrillation is a complicated disease to 
manage, thus improving education and awareness is essential in this ever-changing and 
technologically advancing world of healthcare.  
Personal Goals and Contributions to  
Advanced Practice Nursing 
 Nurses enter health care to help people; advanced practice nurses seek this role to 
make a difference not only in their patients’ lives but to expand the roles, opportunities, 
autonomy, leadership, and abilities of their profession.  Advanced practice nurses are not 
merely a mid-level provider but are the foundation of a unique branch of medicine, 
utilizing the nursing model, theoretical frameworks, and scientific advances to treat the 
entire patient holistically.  A doctoral-prepared nurse practitioner can effectively conduct 
research, evaluate data impeccably, and successfully translate research into project; thus, 
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when passion, ambition, and fighting for a cause are intermeshed in the picture, the result 
is a meticulous capstone project.   
The purpose of this capstone project was quality improvement.  Prevention of 
disease is the basis for reducing health care costs, decreasing disease sequelae, and 
ultimately averting the onset of disease.  Atrial fibrillation is a significant example of 
how if executed effectively, primary prevention (reduction of risk factors) and secondary 
prevention (screening for AF through an annual pulse check in the elderly) could 
minimize the incidence of stroke.  Incorporating observations of practice through patient 
chart reviews, extensively reviewing literature, and gathering expert consensus from 
Delphi surveys, this Anticoagulation for Atrial Fibrillation Toolkit offers primary care 
providers a simple and comprehensive resource to improve the diagnosis and 
management of AF.  Ultimately, the goal of this anticoagulation toolkit is sufficient 
expert consensus through Delphi surveys and enough revisions to become ready for 
implementation and subsequent evaluation in the primary care setting.  If implementation 
of this toolkit in practice reduces the onset of even one stroke in a patient with atrial 
fibrillation, it has served its purpose to improve patient outcomes and has greatly 
contributed to the advanced practice of nursing.   
Five Criteria for Executing a Successful Doctor of  
Nursing Practice Final Project 
 In 2004, The American Association of Colleges of Nursing (AACN; 2006) 
declared the Doctor of Nursing Practice (DNP) as the final degree for advanced practice 
nurses (nurse practitioners, nurse midwives, nurse anesthetists, and clinical nurse 
specialists).  According to the AACN, “DNP programs’ goal are to produce nurses that 
are uniquely prepared to bridge the gap between the discovery of new knowledge and the 
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scholarship of translation, application, and integration of this new knowledge in practice 
(Waldrop, Caruso, Fuchs, & Hypes, 2014, p. 300).  The AACN created the following 
eight essentials of doctoral education in advanced nursing practice:  
• Scientific underpinnings in science 
• Organizational and systems leadership for quality improvement and systems  
thinking 
• Clinical scholarship and analytical methods for evidence-based practice 
• Information systems/technology and patient care technology for the  
improvement and transformation of health care 
• Health care policy for advocacy in health care 
• Interprofessional collaboration for improving patient and population 
health outcomes 
• Clinical prevention and population health for improving the nation’s health 
• Advanced nursing practice (p. 1).  
The acronym of EC as PIE suggests five criteria that ensure DNP programs 
uphold these eight outcomes of the AACN: Enhances, Culmination, Partnerships, 
Implements, Evaluation.  Upon meeting these five criteria, the project is deemed 
appropriate at the practice doctoral level (Waldrop et al., 2014).  The EC as PIE criteria 





Figure 8.  EC as PIE: Five criteria for executing a successful Doctor of Nursing Practice 




The first EC as PIE criterion for the DNP project “enhance(s) health outcomes, 
practice outcomes, or health care policy” (Waldrop et al., 2014, p. 301).  This quality 
improvement capstone project addressed health outcomes of reduced strokes and practice 
outcomes of consistent, evidence-based diagnosis and management of AF.  Health care 
policy was not addressed in this capstone but providers were encouraged to utilize 
national and international guidelines on anticoagulation with AF to enhance practice.  
The second EC as PIE criterion reflects a “culmination of practice inquiry…the 
DNP student must identify and become an expert on a specific problem....to enact 
change” (Waldrop et al., 2014, p. 302).  Through comprehensive literature reviews on 
atrial fibrillation including summarizing noteworthy drug trials and comparing oral 









fibrillation, and anticoagulation for this capstone project.  Through the step-wise 
guideline with corresponding algorithms, the researcher urged the change of improved 
diagnosis and management of atrial fibrillation in the elderly, focusing on anticoagulation 
to reduce the incidence of strokes.  
The third EC as PIE criterion “require(s) engagement in partnerships” (Waldrop 
et al., 2014, p. 302).  The patient chart reviews for this capstone project were 
retrospectively reviewed confidentially from the EHRs of a local and privately owned 
primary care clinic.  Additionally, primary care and cardiology providers were invited to 
participate in the two Delphi surveys with the researcher collaborating to receive expert 
consensus for the toolkit while also building partnerships with these clinicians.  Providers 
were encouraged to contact the researcher if they wanted additional information on the 
final results of this capstone project or to discuss the anticoagulation toolkit further, 
thereby enhancing interdisciplinary/interprofessional care.  
The fourth EC as PIE criterion entails the DNP student “implement/apply/ 
translate evidence into practice” (Waldrop et al., 2014, p. 302).  The researcher attained a 
solid comprehension of the research itself, its implications, and how best to translate this 
evidence into practice through an anticoagulation guideline with algorithms.  This toolkit 
was initially derived from conclusions from the literature review and chart reviews but 
was modified based upon expert consensus and requests.  In an extension of this project 
with further rounds of the Delphi method, the goal would be to implement this guideline 
into primary care practice.  In compliance with this fourth criterion, the DNP student was 
able to take into account the needs of individual patients, providers, and society in 
general related to AF diagnosis and management.  
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The fifth EC as PIE criterion expects the DNP student “require evaluation of 
health care, practice or policy outcomes. The DNP may include outcome measures such 
as direct patient health care measures, costs, quality improvement, and accessibility of 
care” (Waldrop et al., 2014, p. 302).  As this capstone project has not been implemented 
into practice, evaluation of this quality improvement Anticoagulation for Atrial 
Fibrillation Toolkit for was based upon the consensus of experts from the second round 
of the Delphi survey.  However, greater than 70% consensus suggested this toolkit could 
improve the safety and efficacy of anticoagulation, influence future practice, be 
applicable to practice, and be inclusive of evidence-based practice.  In summary, this 
capstone project successfully met all five EC as PIE criteria, approving it as a project at 
the doctoral practice level.   
Summary 
Atrial fibrillation is the most common cardiac arrhythmia in the United States 
(CDC, 2015), increasing the stroke risk by five times and contributing to 25% of strokes 
in the elderly population (Desai et al., 2017).  Research has demonstrated the bleeding 
risk of oral anticoagulants does not outweigh the benefits of stroke prevention in the 
elderly population (Kirchhoff et al., 2016); yet only 30 to 50% of applicable elderly 
patients receive anticoagulation (Barbosa & Falcao, 2016) and intracranial bleeds are less 
than 1% of the population on anticoagulants (Desai et al., 2017).  Overexaggerated 
bleeding risk in the elderly, the lack of head-to-head studies comparing anticoagulants, 
cost, patient compliance, safety, lab monitoring, and reversal agents all convolute the 
process of prescribing anticoagulation for atrial fibrillation, especially in a primary care 
setting where providers are not specialists with this disease.  Furthermore, variations exist 
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with assessing bleeding risk and stroke risk for every patient through reliable tools such 
as HAS-BLED and CHA2DS2-VASc scores, respectively, and translating these scores 
into practice.   
Due to inconsistencies and misconceptions observed in the diagnosis and 
management of atrial fibrillation, an extensive literature review, retrospective chart 
reviews on 100 patients, and expert consensus from two rounds of the Delphi survey 
method were utilized to create the Anticoagulation for Atrial Fibrillation Toolkit.  A 
thorough review of research and statistical analysis of data clearly identified gaps 
between research and practice, suggesting areas to improve practice, enhanced provider 
education, increased multidisciplinary care and shared decision making between the 
patient and provider, and development of a comprehensive, all-in-one resource for 
providers to better diagnose and manage AF.  Despite the toolkit being lengthy, expert 
consensus from Round 2 of the Delphi survey implied the guideline and algorithms were 
user friendly, evidence-based, and could safely and effectively enhance the care of 
patients with atrial fibrillation.  This toolkit offered evidenced-based recommendations to 
diagnose and treat AF; in addition, it was a means to implement primary and secondary 
prevention efforts to reduce the incidence of stroke. 
For this capstone project, the PARIHS framework and RE-AIM model were 
effectively utilized to assess the ability to translate this research into practice.  This 
capstone project met all five criteria of the EC as PIE model (Waldrop et al., 2014), 
inferring this was a successful Doctor of Nursing Practice capstone project.  A future 
extension of this project would evaluate patient outcomes with AF, predominantly a 
reduction in stroke incidence, after implementation of this toolkit in the primary care 
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setting.  In conclusion, through improved acknowledgement of the devastating sequelae 
of AF in addition to consistent diagnosis and thorough treatment for all elderly patients, 
one of the most predominant and preventable causes of stroke could be minimized.  This 
Anticoagulation Toolkit for Atrial Fibrillation is an innovative concept which if executed 
effectively could improve education and awareness of AF diagnosis and management, 
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Patient Specific Factors Influencing Selection of an Oral Anticoagulant 
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*All OAC are covered by commercial insurance and the DOACs 
*Coumadin©: avoid CYP2C9, CYP1A2, and CYP3A4 inducers/inhibitors; 
*Pradaxa©: no CYP450 interactions; cannot crush pills; high fat meals delay 
*Xarelto© and Eliquis©: avoid CYP3A4/5 inducers/inhibitors10, 12 
*Savaysa©: avoid CYP3A4 inhibitors/inducers, Rifampin, Digoxin, 
*With all OAC, avoid other drugs increasing bleeding risk (antiplatelets, 
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bileaflet mitral 
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of bleeding 
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to increase 
absorption. 
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*Drugs increasing 
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mg tablet can be 
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*Avoid use with 






Aspirin, and SSRI 
due to increased 









by CYP isoenzymes 
*Avoid drugs 





































Cmax of digoxin 








































2.5-10 mg SubQ, 
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administered. 
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Xarelto© 24 hours 





hours after surgery 
once hemostasis is 
achieved 
(Drugs.com, 2015b) 
*For CrCl >50 
mL/min: withhold 
Pradaxa© 1-2 days 
prior to procedure. 
*For CrCl<50 
mL/min: withhold 
Pradaxa© 3-5 days 
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with a moderate 
or high risk of 
bleeding. 
*Discontinue 
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of patients payed 
<$50 
*Medicare Part D: 
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patients with 
commercial 
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mg tablets), max of 
$3,400 annual 
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*99% coverage in 
Colorado by 
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(Good Rx, 2017) 
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KEY DRUG TRIALS FOR ANTICOAGULANTS, REVERSAL  
AGENTS, AND ALTERNATIVE TREATMENTS  













Stroke and Other 
Thromboembolic 
Events in Atrial 
Fibrillation) 
 





comparing apixaban to 
warfarin in subjects with 
atrial fibrillation to 
prevent stroke. 
 
Apixaban was administered 
5 mg BID. Warfarin was 
administered to reach a 
target INR or 2.0-3.0. These 
anticoagulants were 
administered for a median 
duration of 1.8 years. This 
study was completed from 
2006-2010 at 1,034 sites in 
39 countries. 
 
The efficacy outcome was 
ischemic stroke, 
hemorrhagic stroke, or 
systemic embolus 
occurrence. Safety 
outcomes were bleeding 
risk and death from any 
cause. 
A total of 18,201 subjects with 
atrial fibrillation or atrial flutter and 
at least one other stroke risk factor 
were randomized to the warfarin or 
apixaban group. The median age of 
subjects was 70 years old with 
35.3% women and an average 
CHADS2  score of 2.1. 
 
Inclusion criteria: at least two 
episodes of atrial fibrillation or 
atrial flutter on EKG, at least 2 
weeks apart within one year prior to 
initiation of this study. At least one 
risk factor for stroke: age >75 years 
old, prior stroke, transient ischemic 
attack (TIA), or systemic embolism, 
symptomatic heart failure within the 
past 3 months or a left ventricular 
ejection fraction (LVEF) <40%, 
diabetes, or hypertension. 
 
Exclusion criteria included 
moderate or severe mitral stenosis, 
prosthetic heart valve, atrial 
fibrillation due to a reversible cause, 
stroke within the past 7 days, the 
need of aspirin and Plavix© or 
aspirin dose >165 md daily, or 
severe renal insufficiency (CrCl <25 
mL/Min). 
The efficacy outcome of apixaban 
occurred annually in 1.27% of 
subjects in the apixaban group [HR 
(CI: 95%): 0.79 (0.66, 0.95); P<0.001 
for 
noninferiority; P=0.01 for 
superiority]. Ischemic or unknown 
type of stroke occurred annually in 
0.97% of subjects in the apixaban 
stroke, compared to 1.05% of 
subjects in the warfarin group [HR 




*Major bleeding occurred annually 
in 2.13% of subjects in the apixaban 
group compared to 3.09% in the 
warfarin group [HR (CI: 95%): 0.69 
(0.60, 0.80); P<0.001]. 
*Death from any cause occurred in 
3.52% of subjects in the apixaban 
group compared to 3.94% in the 
warfarin group [HR (CI: 95%): 
0.89 
(0.80, 0.99); P=0.047]. 
*Hemorrhagic stroke occurred 
annually in 0.24% of subjects in the 
apixaban group compared to 0.47% 
of subjects in the warfarin group [HR 
(CI: 95%) 0.51 (0.35, 0.75); 
P<0.001]. 
 
Conclusion: Apixaban was superior 
to warfarin in preventing systemic 
emboli or strokes in patients with 
atrial fibrillation, in addition to 
demonstrating decreased bleeding 
risk 




Acid to Prevent 








investigating subjects with 
atrial fibrillation, an 
increased risk of stroke, and 
an inability to take vitamin 
K antagonist 
anticoagulation. Subjects 
received apixaban 5 mg BID 
or aspirin 81- 342 mg daily, 
assessing for superiority. 
 
Apixaban or aspirin were 
administered for a follow- 
up of 1.1 years. This study 
was completed at 522 sites 
within 36 countries from 
2007 to 2009. 
Out of 5,599 subjects, 40% used a 
vitamin K antagonist as a prior 
anticoagulant. Subjects were 
randomly assigned to either the 
apixaban or aspirin group. 
Approximately 37% of the subjects 
were from North America or 
Europe with a mean age of 70 years 
old and approximately 58- 59% 
men per group. The mean CHADS2  
score was 2.0-2.1. 
 
Inclusion criteria: Subjects were at 
least 50 years old with at least a 6-
month diagnosis history of atrial 
fibrillation. 
Subjects required at least one of 
the following risk factors for 
stroke: age 74 or older, history of 
stroke or TIA, treated arterial 
The study was terminated early due 
to clear superiority of apixaban to 
aspirin in preventing strokes. 
 
The efficacy outcome was evident 
annually in 51 (1.6%) of subjects in 
the apixaban group, compared to 113 
(3.7%) of subject in the aspiring 




*Death rates occurred annually in 
3.5% of subjects in the apixaban 
group, compared to 4.4% in the 
aspirin group [HR (CI: 95%): 0.79, 
(0.62, 
1.02)]. 
*Major bleeding presented annually 
in 44 (1.4%) of subjects in the 




 The efficacy outcome was 
stroke or systemic embolus 
occurrence. The safety 
outcome was the rate of 
severe bleeding and death. 
hypertension, treated diabetes 
mellitus, heart failure (New York 
Heart Association class 2 or 
higher), left ventricular ejection 
fraction of 35% or less, 
documented peripheral artery 
disease, or not currently on vitamin 
K antagonist therapy. 
 
Exclusion criteria: valvular heart 
disease requiring surgery, serious 
bleeding within the past 6 months 
or a high risk of bleeding, a 
condition other than atrial 
fibrillation necessitating 
anticoagulation, platelet count 
<100,000/mm3, hemoglobin <10 
g/dL, hemorrhagic tendencies, 
blood dyscrasias, current alcohol or 
drug abuse, current psychosocial 
issues, life expectancy <1 year, 
severe renal insufficiency (CrCl 
<25 mL/min) liver transaminases 
>2x the upper limit,  a bilirubin 
>1.5x the upper 
limit, or allergy to aspirin. 
subjects in the warfarin group 
[HR (CI: 95%): 1.13 (0.74, 
1.75)]. 
Intracranial bleeding occurred in 13 
subjects in the apixaban group and 
13 in the aspirin group. 
*Reduced risk for hospitalization 
annually related to a cardiovascular 
cause was evident in both apixaban 
(12%) and aspirin (15.9%); 
P<0.001. 
 
Conclusion: In atrial fibrillation 
patients who are unable to take 
vitamin K antagonists as an 
anticoagulant to decrease the risk of 
stroke or systemic embolism, 
apixaban is a suitable alternative to 
aspirin without enhancing the risk of 
severe bleeding including 
intracranial hemorrhage. 







(Ezekowitz et al., 
2007) 
Randomized, double- blind, 
open-label, multicenter 
study comparing dabigatran 
(with or without aspirin) to 
warfarin in preventing 
thromboembolism in 
patients with nonvalvular 
atrial fibrillation. The goal 
of this study was to 
determine in patients with 
atrial fibrillation the safe 
dose of dabigatran. 
 
The study was designed for 
a duration of 12 weeks and 
was completed at 53 sites 
within Denmark, 
Netherlands, Sweden, and 
the United States. 
 
Labs were measured at 
baseline, 1, 2, 4, 8, and 12 
week intervals throughout 
the study, evaluating 
dabigatran plasma 
concentrations, activated 
partial thromboplastin time, 
D-dimer, liver function, 




The efficacy outcome 
measured the incidence of 
stroke or 
A total of 502 subjects were 
randomly assigned to one of four 
major groups 1) dabigatran 50 mg 
(105 subjects) 2) dabigatran 150 
mg (166 patients), 3) dabigatran 
300 mg (161 subjects), or 4) dose 
adjusted warfarin (70 subjects). 
Dabigatran was administered with 
or without aspirin. Subjects were 
assigned to one of a total of 10 
groups. 
The dabigatran dose was either 50, 
150 or 300 mg daily, the aspirin 
dose was either 81 or 325 mg daily, 
and the warfarin was dose adjusted 
to reach a therapeutic INR of 2.0-
3.0; these medications were 
administered for 12 weeks. 411 or 
81.9% of subjects were men with a 
mean age of 70.9 years with 
coronary artery disease and 68 
years without coronary artery 
disease. 
 
Inclusion criteria: documented 
diagnosis of atrial fibrillation 
coronary artery disease (with the 
initial half of participants) with a 
minimum of at least one of the 
following high-risk factors: 
hypertension, diabetes, 
symptomatic heart failure or a left 
ventricular ejection fraction 
<40%, prior stroke or transient 
ischemic attack, or age >75 years 
old. 
Efficacy outcomes: 
Thromboembolism occurred only in 
the 50-mg dabigatran group in 2 out of 
107 subjects (2%). 
 
Safety outcomes: 
*Severe bleeding occurred only in 
the dabigatran 300 mg plus aspirin 
group in 4 out of 64 subjects. In 
comparison, 0 out of 105 subjects 
had severe bleeding the dabigatran 
only group (p 
<0.02). 
*Total bleeding events in the 
dabigatran group were as following: 
300 mg (39 out of 169 subjects, 
23%, 
p = 0.0002), 150 mg (30 out of 169 
subjects, 18%; p = 0.01), and 50 mg (7 
out of 107 subjects, 7%). 
 
Labs: 
*D-dimer levels were suppressed 
in the 300 mg and 150 mg 
dabigatran doses as well as 
warfarin. 
*In 0.9% of patients on dabigatran, 
aminotransferase levels were 
greater than 3 times the normal 
level, with 2 subjects developing 
gallstones (aminotransferase levels 
>5 times normal). 
*Activated partial thromboplastin 
times were higher than baseline in 
the dabigatran group (1.2 with 50 
mg, 1.5 
with 150 mg, and 1.8 with 300 mg). 
*DTB2 concentrations were 
higher than baseline with the 
dabigatran group (31% with 50 
mg, 17% with 
150 mg, and 23% with 300 mg). 
 
Conclusion: Severe bleeding 




 thromboembolism. The 
safety outcome measured 
the rate of bleeding events. 
 
Exclusion criteria: mitral stenosis, 
prosthetic heart valves, scheduled 
cardioversion, myocardial infarction 
within the past month, recent stroke 
or transient ischemic attack, 
contraindication to anticoagulation, 
coronary artery stent placement 
within the past 6 months, major 
bleed within the past 6 months, 
glomerular filtration rate ≤30 
mL/min, pregnancy, abnormal liver 
function, or use of any other 
investigational drugs within the 
past 30 days. 
dabigatran 300 mg with aspirin and 
thromboembolism only occurred with 
dabigatran 50 mg. Severe liver 
toxicity did not arise with dabigatran. 














adjusted warfarin in 
prevention of stroke in 
patients with nonvalvular 
atrial fibrillation (NVAF). 
 
This study was completed 
at 951 sites within 44 
countries from 2005-2007. 
Median follow-up was 2 
years in 99.9% of patients. 
 
The efficacy outcome 
measured stroke or 
systemic embolism 
occurrence. Safety 
outcomes measured the 
incidence of severe 
bleeding and death. 
A total of 18,113 subjects with atrial 
fibrillation were randomly assigned 
to a dabigatran group (110 or 150 mg 
BID) or an adjusted- dose of 
warfarin. Subjects were from 44 
countries with a mean age of 71 
years, 63.6% men, mean CHADS2 
score of 2.1, and 50% of patients had 
a history of long-term term with 
vitamin K antagonists. 
 
Inclusion criteria: documented 
atrial fibrillation through an EKG 
within the past 6 months and at 
least one of the following 
characteristics: prior stroke or TIA, 
LVEF <40%, heart failure (New 
York Heart Association class II or 
higher) within the past 6 months, 
age >75 years old, or age 65-74 
years old with diabetes, 
hypertension, or coronary artery 
disease. 
 
Exclusion criteria: severe valvular 
disease, stroke within 14 days 
before the study, severe stroke 
within the past 6 months, high 
bleeding risk, creatinine clearance 
<30 mL/min, liver disease, and 
pregnancy. 
Discontinuation rates of 
anticoagulation: 1 year 
later: dabigatran 110 mg 
(14.4%), 
dabigatran 150 mg (15.5%), and 
warfarin (10.2%) 
2 years later: dabigatran 110 mg 
(20.7%), dabigatran 150 mg (21.2%), 
and warfarin (16.6%) 
In the warfarin group, the INR was 
therapeutic 64% of the time. 
 
Efficacy outcome: 1.69% annually in 
the warfarin group compared to 
1.53% annually in the 110-mg 
dabigatran [relative risk (CI: 95%): 
0.91 (0.74, 1.11); P<0.001 for 
noninferiority] and 1.11% annually in 
the 150-mg dabigatran group 
[relative risk (CI: 95%): 0.66 (0.53, 
0.82); P<0.001 for 
superiority]. *Hemorrhagic stroke 
occurred in 0.38% of subjects 
annually on warfarin, 0.12% of 
subjects on dabigatran 110 mg, and 





*Major bleeding occurred annually 
in 3.36% of patients on warfarin, 
2.71% of patients on 110 mg 
dabigatran, and 3.11% on 150 mg 
dabigatran. 
*Mortality rate annually was 4.13% 
in patients on warfarin, 375% in 
patients on 110 mg dabigatran, and 




*Dabigatran 110 mg demonstrated 
similar rates of stroke and embolism 
in patients with atrial fibrillation 
compared to warfarin, yet displayed 
less major bleeding. Dabigatran 150 
mg demonstrated lower rates of toke 
and embolism compared to 
warfarin, 
but displayed more major bleeding. 
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   *Increased risk of gastrointestinal 
bleeds and gastrointestinal effects 
(gastritis and dyspepsia) in patients 
taking 150 mg Dabigatran compared 
to Warfarin. 
*The risk of major bleeding was similar 
between Dabigatran and Warfarin, 
except for a higher risk of bleeding 
evident in patients >75 years old taking 
Dabigatran 
*The rate of all-cause mortality was 
lower in patients on Dabigatran than 
Warfarin. 
 
*After publishing of this article, safety 
and efficacy outcomes were expanded 
to include 81 new events in 80 patients: 
4 myocardial infarctions, 1 
stroke, 1 systemic embolic events, 69 
major hemorrhages, and 5 transient 
ischemic attacks. Conclusions to the 
original study remained the same 
(Connolly, et.al., 2010). 
*1500 cases were re-evaluated for 
stroke, systemic embolism, major 
bleeding or life-threatening bleeding as 
1,387 deaths occurred during the RE-
LY trial. Data was altered but  even 
with these alterations, no changes were 
made to the conclusions in the 
original study (Connolly, et.al., 2014). 















longitudinal cohort study 
evaluating the two-year 
follow-up of atrial 
fibrillation patients taking 
dabigatran 110 mg or 
dabigatran 150 mg and 
their effects on the 
prevention of stroke or 
systemic embolism. 
 
This study extended the 
RE-LY trial for an extra 
2.25 years. 
 
The efficacy outcome 
measured stroke or 
systemic embolism 
occurrence. The safety 
outcome measured 
bleeding rates and death. 
A total of 5,581 subjects were 
randomly assigned to a dabigatran 
group during the RE-LY trial were 
included in this trial if they had 
continued dabigatran for 
anticoagulation. These patients 
received the same dose of 
dabigatran (110 mg or 150 mg) they 
received during RE-LY for a mean 
follow-up of 2.25 years. 
 
Compared to RE-LY, more 
subjects in RELY-ABLE were 
male and had paroxysmal atrial 
fibrillation compared to 
permanent atrial fibrillation. 
Similarly, to RE-LY, patients in 
RELY-ABE had diabetes mellitus 
and coronary artery disease. 
 
Inclusion criteria: participants in 
the original RE-LY trial who were 
not assigned warfarin. In RELY- 
ABLE, subjects were 48% of the 
original subjects in the RE-LY trial. 
 
Exclusion criteria included: 
necessity for anticoagulation for 
other reasons, a gastrointestinal 
ulcer within the past 30 days, 
Efficacy Outcomes: 
*Stroke and systemic embolism 
occurred in 1.46% of patients on 
dabigatran 150 mg BID and in 1.60% 
of patients on dabigatran 110 mg BID 
[HR (CI: 95%) 0.91 (0.69, 1.20]. 
*Annual hemorrhagic stroke rates 
were 0.13% for dabigatran 150 mg 




*Bleeding rates were 3.74% on 
dabigatran 150 mg compared to 2.99% 
on dabigatran 110 mg [HR (CI: 95%): 
1.26 (1.04-1.53)]. 
*Death rates were 3.02% on dabigatran 
150 mg compared to 3.10% on 
dabigatran 110 mg [HR (CI: 95%): 0.97 
(0.80, 1.19)]. 
 
Conclusion: Longer-term use of 
dabigatran 150 mg BID demonstrated 
an increased risk or major bleeding 
compared to dabigatran 100 mg BID. 
Rates of stroke and death were similar 
between the two doses of dabigatran. 
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  anemia (hemoglobin <100 g/L), 
thrombocytopenia (platelet count 
<100x109L), liver transaminases 
>2 times normal, CrCl <30 
mL/min, pregnancy, high risk of 
bleeding, scheduled ablation for 
AF, and unstable cardiovascular 
disease. 
 














(Eikelboom et al., 
2013). 
Prospective, randomized, 
phase 2, open-label trial 
investigating warfarin 
versus dabigatran in 
patients undergoing aortic 
or mitral valve replacement 
within the past 7 days or a 
history of a valve 
replacement within the past 
three months. 
 
This study was completed 
at 39 sites within 10 
countries from 2011-2012. 
 
Initial dabigatran dose was 
based upon kidney function, 
with adjustments based 
upon reaching a trough 
plasma level of 50 ng/mL. 
INR dose was based upon 
attaining an INR of 2-3 
(low thromboembolic risk) 
or 2.5.-3.5 (immediate or 
high thromboembolic risk). 
Patients were administered 
the anticoagulant for 12 
weeks. 
 
The efficacy outcome was 
the trough plasma level of 
dabigatran. The safety 
outcome measured was 
major bleeding. 
Out of a total of 252 subjects, 168 
were randomly assigned to the 
dabigatran group while 84 were 
assigned to the warfarin group in a 
2:1 ratio. Approximately 64-67% of 
the subjects were male and the 
mean age was 56 years old. 
Approximately 79%  (199) subjects 
were scheduled for the valve 
replacement, with 172 (68%) aortic, 
71 (28%) mitral, and 9 (4%) both 
valves. Out of the subjects, 74 
(24%) were low risk for 
thromboembolic complications after 
the procedure, and 178 (71%) were 
intermediate or high risk. 
 
Inclusion criteria: age 18-75 years 
old and either scheduled for 
implantation of a mechanical 
bileaflet valve in the aortic or mitral 
valve or received a mechanical 
bileaflet mitral valve within 3 
months prior to this study. 
 
Exclusion criteria: prior prosthetic 
valve replacement, aortic surgery, 
endocarditis, complex congenital 
heart anomalies, history of 
hemorrhagic stroke, high bleeding 
risk, uncontrolled hypertension, 
abnormal liver functions >3 times 
the normal limit or active hepatitis, 
creatinine clearance 
<40mL/min, chronic 
anticoagulation for reasons other 
than AF, myocardial infarction 
within the past month, recent 
radiation treatment or cancer, 
pregnancy, scheduled surgery 
within one month, or 
contraindications to warfarin or 
dabigatran. 
The trial ended prematurely after 
increased VTE and bleeding 
events presented in the dabigatran 
group. 
In 52 (32%) of the 162 dabigatran 
patients, dabigatran dose was 
adjusted or discontinued. 
 
Efficacy outcome: Stroke (ischemic 
or unspecified) manifested in 9 (5%) 
of dabigatran subjects compared to 
zero patients in the warfarin group. 
 
Safety outcome: Major bleeding 
(pericardial bleeding) presented in 7 
(4%) subjects of the dabigatran 
group compared to 2 (2%) of the 
warfarin subjects. 
 
Conclusion: Due to the increased 
risk of VTE and bleeding risk in 
patients with mechanical heart 
valves, dabigatran displays 












group, phase 2 study 
comparing four doses of 
edoxaban to warfarin in 
patients with non- 
valvular atrial 
A total of 1,146 subjects were 
randomized to edoxaban (30 mg 
daily, 30 mg twice daily, 60 mg 
daily, or 60 mg twice daily) or 
dose-adjusted warfarin with a 
target INR of 2.0-3.0. The average 
age of subjects was 65 years old 
with 65.4% warfarin naïve. 
Safety outcome: Bleeding occurred 
in 3.2% of subjects in the warfarin 
group, compared to 10.6% in the 
edoxaban 60 mg twice daily group 
(p 
= 0.002) and 7.8% in the edoxaban 
60 mg twice daily group (p = 0.029). 
Bleeding occurred less in the 








measures were bleeding 
events, elevated liver 
enzymes, and elevated 
bilirubin levels. 
 and edoxaban 30 mg daily group 
(3.0%) compared to warfarin. 
 
Labs: Liver enzyme levels and 
bilirubin levels were not significantly 
elevated in any of the edoxaban 
groups. 
 
Conclusions: With comparable 
bleeding risk profiles, edoxaban 30 
mg or 60 mg daily is a safe alternative 
to warfarin in preventing stroke in 
patients with atrial fibrillation. Due to 
the heightened bleeding risk, 
edoxaban 30 mg twice daily or 
edoxaban 60 mg twice daily are not 
recommended. 






with Factor Xa 
Next Generation in 
Atrial Fibrillation) 
 





edoxaban and warfarin 
in patients with atrial 
fibrillation and an 
intermediate to high risk 




warfarin or edoxaban for 
a median of 2.5 years. 
 
This study was 
completed at 1,339 sites 
within 46 countries from 
2008-2010. 
 
The efficacy outcome 
was incidence of stroke 
or systemic embolism. 
The safety outcome was 
major bleeding and 
cardiovascular deaths. 
Out of 21,101 subjects with 
atrial fibrillation were randomly 
assigned to one of three groups: 
1) 7,030 received edoxaban 60 
mg 
daily, 2) 7,034 received edoxaban 
30 mg daily, and 3) 7,037 
received warfarin daily with a 
target INR of 2.0-3.0. The 
average age of subjects was 72 
years old with 38% females per 
group. 
 
Inclusion criteria: >age 21 years 
old, documented AF through an 
EKG within the past year, and 
CHADS2  score >2. 
 
Exclusion criteria: atrial 
fibrillation with a reversible cause, 
a creatinine clearance <30 
mL/min, high risk of bleeding, 
dual antiplatelet therapy, moderate 
to severe mitral stenosis, chronic 
anticoagulation for other reasons, 
acute coronary syndrome, 
coronary revascularization, or 
stroke within 30 days. 
Efficacy Outcome: stroke or 
thromboembolism occurred in 1.50% 
of subjects in the warfarin group 
(therapeutic INR 68.4% of the time), 
compared to 1.18% with edoxaban 60 
mg (HR 0.78; 97. % CI 0.63-0.99; 
p<0.001 for noninferiority) and 
edoxaban 30 mg (HR 1.07; 95% CI 
0.87-1.31; p = 0.005 for 
noninferiority). Edoxaban 60 mg was 
preferred to warfarin for intention-to- 
treat (HR 0.87; 97.5% CI 0.73-1.04; p 
= 0.08). Conversely, warfarin was 
preferred to edoxaban 30 mg in the 




*Subjects on edoxaban 60 mg 
demonstrated less severe bleeding 
annually (3.43%) compared to 
warfarin (2.75%; HR 0.80; 95% CI 
0.71, 0.91), p<0.001]. The same 
results were seen with edoxaban 30 
mg, with 1.61% annual bleeding 
compared to warfarin (HR 0.47; 95% 
CI, 0.41-0.55; p<0.001). The most 
common site of major bleeding was in 
the GI tract: 205 (1.78) with edoxaban 
and 150 (1.27) with warfarin. 
*Annual cardiovascular deaths 
occurred in 3.17% of subjects on 
warfarin compared to 2.74% with 
edoxaban 60 mg (HR 0.86; 95% CI 
0.77-0.97; p=0.01), and 2.71% with 
low dose edoxaban (HR 0.85; 95% CI 
0.76-0.96; p=0.008). 
 
Conclusion: In patients with atrial 
fibrillation, edoxaban 30 mg and 60 
mg were noninferior to warfarin in 
preventing stroke or systemic 
embolism, in addition to decreased 











once daily, oral, 







Embolism Trial in 
Atrial Fibrillation) 
 
(Patel et al., 2011) 
Multi-national double- 
blind, double-dummy, 
event driven study 
comparing rivaroxaban 
to dose-adjusted 





Patients were randomized 
to a study treatment of 
warfarin or rivaroxaban for 
a mean of 590 days. 
 
 
This study was complete at 
1,178 sites within 45 
countries from 2006-2010. 
 
 
Primary efficacy outcomes 
measured the incidence of 
stroke or systemic 
embolism. Safety 
outcomes measured major 
and non-major bleeding 
events. 
A total of 14,264 patients were 
randomized to rivaroxaban (7,131 
subjects) or adjusted-dose 
warfarin (7,133 subjects) with a 
target INR of 2.0-3.0. 
Rivaroxaban was administered 20 
mg daily or 15 mg daily with a 
creatinine clearance of 30-49 
mL/min. The mean age of 
subjects was 71 years, the mean 
CHADS2  score of 3.5, 60% male, 
83% Caucasian, 13% Asian, and 
1.3% Black. 
 
Inclusion criteria: AF had to be 
diagnosed by EKG within 30 
days. Patients were required to 
have the following risk factors: a 
prior stroke (ischemic or unknown 
type), transient ischemic attack, or 
non-CNS systemic embolism. In 
addition, patients were required to 
have 2 or more of the following 
risk factors: age >75 years, 
hypertension, heart failure or left 
ventricular ejection fraction 
<35%, or diabetes mellitus. The 
CHADS2  score had to be >2. 
 
Exclusion criteria: severe mitral 
stenosis, prosthetic heart valve, 
scheduled cardioversion, AF with 
a reversible cause, atrial myxoma, 
endocarditis, active bleeding, high 
bleeding risk, thrombocytopenia 
(<90,000 μ/L), uncontrolled 
hypertension ≥180/100, prior 
stroke or TIA, chronic 
anticoagulation for other reasons, 
current use of antiplatelets, 
chronic NSAID use, use of 
cytochrome P450 3A4 inhibitors 
or inducers, anemia (hemoglobin 
<10 g/dL), pregnancy or 
breastfeeding, HIV positive, liver 
disease, or creatinine clearance 
<30 mL/min 
Efficacy outcomes: 
*Stroke or systemic embolism 
occurred in 188 of the subjects in the 
rivaroxaban group annually (1.7%), 
compared to 241 in the warfarin group 
(2.2%; HR 0.79, 95% CI 0.66-0.96, 
p<0.001 for 
noninferiority). 
*In the intent-to-treat analysis, stroke 
or systemic embolism occurred 
annually in 269 subjects in the 
rivaroxaban group (2.1%) compared to 
306 subjects in the warfarin group 
(2.4%; HR 0.88, 95% CI 0.74-1.03; 
p<0.001 for 
noninferiority; p=0.12 for superiority). 
 
Safety outcomes: 
*Major and non-major bleeding 
occurred in 1,475 patients in the 
rivaroxaban group annually 
(14.9%) and 1,449 in the warfarin 
group annually (14.5%). 
*Intracranial hemorrhage (0.5%) and 
fatal hemorrhage (0.2%; p=0.003) 
occurred less with rivaroxaban than 
warfarin (0.7% intracranial 
hemorrhage and 0.5% fatal 
hemorrhage, p=0.02). 
 
Conclusions: Rivaroxaban was non- 
inferior to warfarin to preventing 
first occurrence of stroke or systemic 
embolism in nonvalvular atrial 
fibrillation [HR (95% CI): 0.88 (0.74, 
1.03)]. Bleeding events was non- 
significant between groups but 
rivaroxaban demonstrated less fatal 





Safety of Once- 
Daily 
Rivaroxaban for 
the Prevention of 
Cardiovascular 






open-label, parallel group 
study comparing safety 
and efficacy of 
rivaroxaban to warfarin in 





This ongoing study will 
be completed in 17 
countries. 
A total of 1,500 patients will be 
randomized into two groups in a 
2:1 ratio of rivaroxaban to 
warfarin. Subjects can be further 
randomized into two groups: 1) 
rivaroxaban or warfarin with 
heparin given 1-5 days prior to 
cardioversion with a 
transesophageal echocardiography 
to assess for atrial thrombi or 2) 
rivaroxaban or warfarin given 21- 
56 days before the cardioversion. 
Rivaroxaban or warfarin will be 
continued 6 weeks after the 
cardioversion. Rivaroxaban 20 mg 
This ongoing trial will assess the 
safety and efficacy of rivaroxaban 
versus warfarin in preventing stroke 
and reducing bleeding risk for non-




(Ezekowitz et al., 
2014) 
The efficacy outcome is 
incidence of strokes, TIA, 
myocardial infarction, 
noncentral nervous system 
systemic emboli, and 
cardiovascular death. The 
safety outcome is the 
incidence of bleeding 
events. 
daily will be the administered 
dose unless the patient has a 
creatinine clearance <30-40 
mL/min, warranting rivaroxaban 
15 mg daily. The target INR for 
warfarin will be 2.0-3.0. 
Inclusion criteria: adults older 
than 18 years old with non- 
valvular atrial fibrillation lasting 
longer than 48 hours and 
hemodynamic stability. These 
patients must be scheduled for 
cardioversion, either electrical or 
pharmacologic. 
 
Exclusion criteria: severe mitral 
stenosis, prosthetic heart valve, 
severe stroke within the past 3 
months, left atrial thrombus, TIA, 
thromboembolus, or myocardial 
infarction within the past 2 weeks, 
high bleeding risk, active 
bleeding, chronic anticoagulation 
for another reason, dual 
antiplatelet therapy or chronic 
aspirin use >100 mg daily, use of 
CYP3A4 and P-gp inhibitors, 
pregnancy or breastfeeding, 
contraindications to rivaroxaban 
or warfarin, hepatic disease, or 
alcoholism. 
 










comparing the safety of 
rivaroxaban and 
warfarin in patients with 
non-valvular atrial 
fibrillation who have 
received percutaneous 
coronary intervention 




measured the incidence 
of thrombolysis in 
myocardial infarction, 
major bleeding, or minor 
bleeding. Patients were 
followed-up for an 
average of 12 months. 
Dual antiplatelet therapy 
is considered aspirin plus 
clopidogrel (or an 
alternative P2Y12 
inhibitor: prasugrel or 
ticagrelor). Triple 
therapy is considered 
dual therapy plus an oral 
anticoagulant. 
A total of 2,100 subjects have 
been enrolled in this study and are 
being randomized to three groups 
(700 subjects per group): 1) 
rivaroxaban 15 mg daily with 
clopidogrel 75 mg daily for 12 
months, 2) rivaroxaban 2.5 mg 
twice daily with dual antiplatelet 
therapy (clopidogrel 75 mg daily 
and aspirin 75-100 mg daily) for a 
predetermined duration of 1, 6, or 
12 months, or 3) dose-adjusted 
warfarin daily (target INR 2.0- 
3.0) with dual antiplatelet therapy 
for a predetermined duration of 1, 
6, or 12 months. If clopidogrel 
was not used, an alternative 
P2Y12 inhibitor could be used in 
its place. 
 
Inclusion criteria: at least 18 
years old with AF diagnosed by 
an EKG and have completed PCI. 
 
Exclusion criteria: active 
bleeding, thrombocytopenia 
(platelets <90,000 µ/L), history of 
intracranial bleed, severe 
gastrointestinal bleed within the 
past year, history of TIA or 
stroke, cardiogenic shock, trauma 
This trial is currently ongoing to 
evaluate bleeding risks between 
warfarin and rivaroxaban in 
patients with non-valvular atrial 




  within 30 days, creatinine 
clearance <30 mL/min, anemia 
(hemoglobin <10 g/dL), liver 
disease, history of HIV, planned 
CABG, contraindications to 
aspirin, warfarin or clopidogrel. 
 

















blind study comparing 
warfarin, aspirin, and 




This study was completed 
from 1985-1988 with a 




measured included stroke, 
transient ischemic attack 
(TIA), embolic 
complications. Death was a 
secondary outcome 
assessed. 
Subjects were randomized to a 
treatment group: warfarin (335), 
aspirin 75 mg daily (336) and 
placebo (336). 
Efficacy outcome: Thromboembolic 
complications and mortality from a 
vascular etiology were decreased in 
the warfarin group (5 patients) 
compared to the placebo (20 patients) 
and aspirin (21 patients) groups. 
 
 
Safety outcome: Bleeding was evident 
in 21 subjects on warfarin, 2 on 
aspirin, and 0 on the placebo. 
 
 
Conclusion: In patients with non- 
valvular atrial fibrillation, warfarin 












investigating the safety and 
efficacy of warfarin in 
preventing stroke in 
patients with nonvalvular 
atrial fibrillation. 
 
Average follow-up time 
was 2.2 years. 
 
The efficacy outcome 
measured was incidence of 
ischemic stroke. The safety 
outcomes measured were 
major and minor bleeding 
events and death. 
Patients were randomized to the 
warfarin group (212 subjects with 
a target prothrombin time ratio of 
1.2-1.5) or the control group (208 
subjects). The control group was 
given the preference of taking 
aspirin. The mean age of subjects 
was 68 years old with 72% men. 
 
Inclusion criteria: adults diagnosed 
with non-rheumatic (valvular) AF 
through at least two separate EKGs. 
With intermittent AF, an EKG must 
document the rhythm within 18 
months of the study. Thyroid 
function must be normal to 
participate. 
 
Exclusion criteria: planned 
cardioversion, transient AF related 
to another diagnosis, cardiac 
thrombus, left ventricular aneurysm, 
severe heart failure, prosthetic heart 
valves, severe stroke within the past 
6 months, TIA, intracranial 
hemorrhage, contraindications to 
anticoagulation (liver disease or 
peptic ulcer disease), recent 
thrombophlebitis, or chronic aspirin 
use. 
Prothrombin time was therapeutic 
in 83% of the subjects. 
Approximately 10% of the subjects 
in the warfarin group chose to stop 
taking warfarin during the study. 
 
 
Efficacy outcome: The annual 
incidence of stroke was 2 (0.41%) in 
the warfarin group compared to 13 
(2.98%) in the control group, 
suggesting warfarin decreases the risk 
of stroke by 86% (95% CI, 0.04-0.49; 





*A total of 37 subjects died during the 
study, with 2.25% annually in the 
warfarin group and 5.97% annually in 
the control group (95% CI, 0.17-0.82; 
p 
= 0.005), with one patient 
succumbing to a severe bleed in each 
group. 
*Bleeding requiring a transfusion or 
hospitalization was comparable in both 
groups. Minor bleeding was higher 
with warfarin (38 subjects) compared 
to the control group (21 subjects). 
Warfarin at lower doses is safe and 
effective in preventing stroke with 
non- valvular atrial fibrillation. 
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comparing aspirin (325 
mg daily) to warfarin 
group with a placebo 
group to prevent stroke 
and systemic embolization 
in patients with atrial 
fibrillation. 
 
1,300 patients were 
followed for an average of 
1.3 years at 16 facilities 
with the United States 
from 1987-1992. 
 
The efficacy outcome 
measured incidence of 
stroke or systemic 
embolization. The safety 
outcome measured 
bleeding events. 
Group 1 was composed of patients 
randomly assigned to the warfarin 
group (210 subjects), aspirin group 
(206 subjects), or placebo group 
(211 subjects). Patients unable to 
take anticoagulation were 
randomized Group 2: either the 
aspirin (346 subjects) or placebo 
group (357 subjects). Out of the 
1,330 subjects, the average age of 
subjects was 67 years old, 71% 
men, 85% Caucasian, 6% 
Black, and 10% 
Asian/Hispanic/other race. 
 
Inclusion criteria: diagnosis 
through an electrocardiogram of 
non-valvular atrial fibrillation 
within the past year. 
 
Exclusion criteria: contraindication 
to aspirin or warfarin, mitral 
stenosis, congestive heart failure 
(New York Heart Association class 
4), myocardial infarction within the 
past three months, coronary bypass 
surgery within the past year, 
unstable angina pectoris within the 
past year, stroke or TIA within the 
past two years, life expectancy less 
than two years, chronic renal 
failure, thrombocytopenia, severe 
alcoholism, other indications for 
chronic warfarin therapy, chronic 
NSAID use. 
 
Exclusion criteria for 
anticoagulation: age greater than 
75 years old, unable to adhere to 
INR monitoring, history of falls, 
positive occult blood in stool, 
chronic alcoholism, uncontrolled 
hypertension, syncope or seizures, 
previous intracranial bleed, poorly 
controlled INR levels, or prior 
bleed while on anticoagulation. 
Efficacy outcomes: 
 
*Patients assigned to the warfarin 
group versus placebo displayed a 
decrease of stroke or systemic 
embolism by 67% annually (2.3% with 
warfarin and 7.4% with placebo, p = 
0.01; 95% confidence interval, 
27.85%). *Patients assigned to the 
aspirin group versus placebo 
demonstrated a 42% reduction of 
stroke or systemic embolism annually 
(3.6% with aspirin and 6.3% with 
placebo, p = 0.02; 95% confidence 
interval, 9-63%). 
*These primary events of stroke or 
systemic embolism, as well as death 
were decreased by 58% with 
warfarin (p = 0.01) and 32% with 
aspirin (p = 0.02) with aspirin. 
 
 
Safety outcome: The annual 
bleeding rates 1.5% with warfarin, 




The risk of stroke and systemic 
embolism in patients with atrial 
fibrillation can be reduced with 
aspirin or warfarin, yet data is not 
conclusive for preferring one drug 
versus the other. 
236 
 











study investigating the use 
of warfarin versus a 
placebo in preventing 





included incidence of 
nonlacunar stroke and 
noncentral nervous 
system embolism. 
Primary safety outcomes 
measured included fatal 
bleed or intracranial bleed 
within 28 days of 
completing the study. 
Patients were randomly assigned to 
the warfarin group with a target 
INR of 2.0-3.0 (187 subjects) or the 
placebo group (191 subjects). 
This trial was stopped prematurely 
because of two similar studies 
displaying superiority in warfarin 
compared to a placebo in 
decreasing stroke risk in patients 
with atrial fibrillation. 
 
Over 26% of subjects stopped warfarin 
prematurely as well as 23% of the 
placebos. An average of 43.7% of the 
subjects maintained the therapeutic 
INR of 2.0-3.0 in the warfarin group. 
 
 
Efficacy outcome: A primary effect 
was noted in 3.5% of the warfarin 
subjects compared to 5.2% of the 
placebo patients, suggesting a 37% 
decrease in stroke risk with warfarin 





*Severe bleeding was present in 
2.5% of the warfarin subjects 
compared to 0.5% in the placebo 
subjects. *Minor bleeding occurred 
in 16% of the warfarin subjects 




Conclusion: Warfarin is superior to a 
placebo in preventing stroke and non- 
central nervous system embolism in 
patients with atrial fibrillation, yet 
displays a high risk of minor and 









study assessing the safety 
and efficacy of 
anticoagulation versus 
aspirin in patients with 
non-valvular atrial 
fibrillation who have 
suffered a minor stroke or 
transient ischemic attack. 
 
This study was completed 
in 108 clinics in 13 
countries, with an average 
follow-up of 2.3 years. 
 
The primary efficacy 
outcomes measured 
included the incidence of 
stroke, myocardial 
infarction, systemic 
embolism, or death from 
In group 1, 669 patients were 
randomized to either open-label 
anticoagulation or a double-blind 
group receiving a placebo or 300 
mg aspirin daily. In group 2, 2,338 
patients were randomized to receive 
aspirin or placebo if they had 
contraindications to warfarin. The 
average age was 73 years old, with 
55-59% men per group. 
 
Inclusion criteria: patients 25 
years or older with non-valvular 
atrial fibrillation and history of a 
minor ischemic stroke or TIA 
within the past 3 months. 
 
Exclusion criteria for the study: 
secondary causes of atrial 
fibrillation such as 
hyperthyroidism, coronary surgery 
Efficacy outcomes: 
 
*Annually, in group 1, primary 
events occurred in 8% of the 
anticoagulant group compared to 
17% in the placebo group (hazard 
ratio [HR] 0.53; 95% confidence 
interval [CI] 0.36-0.79). 
However, the rate of strokes 
decreased annually in group 1 from 
significantly from 12% to 4% (HR 
0.34; 95% CI0.20-0.57). 
 
*If the patient was on aspirin and in 
group 1 or group 2, primary events 
annually occurred in 15% of 
subjects compared to 19% in the 
placebo (HR 0.83; 95% CI 0.65-
1.05). 
*Anticoagulation was determined to 
be superior to aspirin in preventing 
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 a vascular etiology. The 
primary safety outcome 
measured was bleeding 
events. 
scheduled within the next 3 
months 
 
Exclusion criteria for 
randomization to a treatment 
group: concurrent use of 
medications with a high bleeding 
risk (NSAIDS, anti-platelets, or 
oral anticoagulants), mechanical 
valves, cardiac aneurysm, atrial 
myxoma, myocardial infarction 
within the past 3 months, or 
coagulation disorders. The 
acceptable range for the INR for 
the anticoagulant was 2.5-4, with a 
goal of 3. The choice of 




Exclusion criteria for 
anticoagulation: high bleeding 
risk, hypertension >180/100 mm 
Hg, chronic alcoholism, prior 
intracranial bleed, hemorrhagic 
retinopathy, or poor adherence to 
the treatment plan. 




Safety outcome: No intracranial bleeds 
were observed in patients 
anticoagulated, with minor bleeding 
present annually in only 2.8% of 
subjects in the warfarin group and 0.9% 
of the aspirin group. 
 
 
Conclusion: Anticoagulation is 
superior to aspirin for both safety and 
efficacy in patients with non-valvular 
atrial fibrillation who have suffered 
from a recent TIA or stroke. If 
anticoagulation is contraindicated, 
aspirin is a safe alternative for this 
population to prevent stroke. 








Halperin et al., 
1994) 
This study was a 
continuation of SPAF-I to 
better assess through two 
parallel randomized trials 
the efficacy of warfarin 
compared to aspirin in 
reducing stroke in patients 
with atrial fibrillation. The 
focus in this study was the 
incidence of 
thromboembolic events 
with warfarin compared to 
aspirin and to compare the 
effectiveness of 
anticoagulants based on 
patient age. 
 
The goal was to determine 
if warfarin compared to 
aspirin would decrease 
systemic embolism or 
stroke in patients less than 
75 years old by 2% 
decrease this risk by 4% in 
patients older than 75 
years old. The safety 
outcome measured was 
incidence of systemic 
embolism or stroke. 
 
This study took place 
from 1985-1991 at 16 
The first randomized trial 
contained 715 subjects less than 
75 years old and the second 
randomized trial contained 383 
patients over 75 years of age. 
Patients randomized to the 
warfarin group had a goal INR of 
2.0-4.5, while the aspirin group 
was given 325 mg daily. 
 
All 416 patients from SPAF-I were 
who able to take anticoagulation 
continued the therapy they were 
given during this first study. Also 
from SPAF-I, 265 of the patients in 
the placebo group were randomized 
to a group in SPAF-II. The other 
419 patients were new patients who 
did not participate in SPAF-I. 
 
The same inclusion criteria as in 
SPAF-I were utilized. 
Additionally, patients were 
excluded from the study if they 
were less than 60 years old 
without cardiovascular disease, 
mitral stenosis, contraindications 
to warfarin or aspirin, or 
mechanical heart valves. 
Confirmation of atrial fibrillation 
through an electrocardiogram 
within the past year was necessary 
to participate in this study. 
Patients less than 75 years old: 
 
*Warfarin decreased the rate or stroke 
or systemic embolism by 7% per year 
(95% CI; 0.4-1.7). In comparing 
warfarin to aspirin, the rate of stroke or 
systemic embolization was 1.3% 
compared to 1.9% respectively (relative 
risk [RR] 0.67, p = 0.24). 
*In the absence of hypertension, new 
onset heart failure, or a prior 
thromboembolism, stroke or systemic 
embolism occurred in 0.5% of these 
patients annually (95% CI; 0.1-1.9). 
 
 
Patients older than 75 years old: 
 
*Systemic embolism or stroke was 
reduced by 0.5% per year (95% CI, - 
1.7-4.1). In comparing warfarin to 
aspirin, the rate of stroke or systemic 
embolization was 3.6% compared to 
4.8% respectively (relative risk [RR] 
0.73, p = 0.39). 
*The overall rate of hemorrhagic or 
ischemic stroke with deficits was 4.3% 
per year in the aspirin group and 4.6% 
per year in the warfarin group (RR 1.1). 
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 sites within the United 
States. 
 Conclusions: To prevent ischemic 
stroke in patients with atrial 
fibrillation, warfarin is superior to 
aspirin. In the absence of risk 
factors, patients less than 75 years 
old demonstrate a low stroke risk if 
treated with aspirin. In patients older 
than 75 years old, the hemorrhagic 
and ischemic stroke risk is increased, 
despite administration of warfarin or 
aspirin. Selecting the type of 
anticoagulation should be dependent 
on patient age and stroke risk with 
atrial fibrillation. 
 










multicenter study was a 
continuation of SPAF-I 
and SPAF-II. 
 
The goal of this study was 
to compare warfarin to the 
combination of warfarin 
and aspirin to assess 
safety and efficacy of 
anticoagulation in patients 
with atrial fibrillation and 
high risk of stroke. 
 
This study was designed 
to take place over 2 ½ 
years from 1993-1995 in 
20 sites in both the United 
States and Canada. 
 
The primary efficacy 
outcomes measured were 
rates of ischemic stroke 
and systemic embolism. 
Patients were randomly assigned 
to the adjusted-dose warfarin 
(INR 2.0-3.0) group (523 
subjects) or to the low intensity, 
fixed-dose warfarin (INR 1.2-1.5) 
with aspirin (325 mg daily) group 
(521 subjects). 
 
This study was comprised of 1044 
patients with atrial fibrillation and a 
minimum of one risk factor for 
stroke (female sex over 75 years 
old, congestive heart failure, left 
ventricular ejection fraction 
≤25%, prior thromboembolism, or 
systolic blood pressure >160 
mmHg). 
 
The same inclusion and exclusion 
criteria from SPAF-I and SPAF-II 
applied except: subjects who 
participated in the prior trials were 
exempt.  Inclusion  criteria included 
documented AF through an 
electrocardiogram within 6 months, 
no history of mitral stenosis, 
mechanical heart valves or 
pulmonary embolism, and no 
contraindications to warfarin or 
aspirin. Compared to prior trials, 
patients who suffered from an 
ischemic stroke or TIA within 30 
days where included in SPAF-III. 
*In the warfarin patients, the 
average INR in the aspirin with 
warfarin group was 1.3 compared to 
2.4 for the dose adjusted warfarin. 
 
*During the mean follow-up of 1.1 
years, INRs in the aspirin with 
warfarin group were therapeutic 
(1.2-1.5 range) 54% of the time and 
subtherapeutic (<1.2) 34% of the 
time. 
 
*The follow-up period was stopped 
prematurely, as the risk of ischemic 
stroke and systemic embolism was 
significantly higher in the aspirin 
with warfarin group (7.9% annually, 
p = 0.0001), compared to the 
adjusted-dose warfarin (1.9% 
annually, 95% CI (3.4, 
8.6). 
 
*The warfarin with aspirin group 
displayed higher annual rates of 
stroke (5.6%, p = 0.0007) compared 
to warfarin only (1.7%), as well as 
higher rates of death from a vascular 
cause (11.8% in the combination 
group compared to 6.4% with 
warfarin, p = 0.0002). 
*Severe bleeding annually was 
similar between the combination 
group [2.4%, 95% CI 1.4, 4.1)] 





dose warfarin with aspirin is not 
recommended to prevent stroke in 
patients with atrial fibrillation. 
Adjusted-dose warfarin with a 
target INR of 2.0-3.0 has 
demonstrated safety and efficacy in 












(Gullov et al., 
1998) 
This randomized, 
controlled study was a 
continuation of AFASAK-
I to further assess safety 
and efficacy of warfarin to 
aspirin in preventing 
stroke in patients with 
non- valvular atrial 
fibrillation. 
 
Primary efficacy outcomes 
measures included the 





included death, TIA, or 
myocardial infraction. 
The safety outcome 
measured was bleeding 
events. 
 
The trial was designed to 
run for six years starting in 
1993, was but stopped 
prematurely  in  1996 when 
another study (SPAF-II) 
concluded low- intensity 
(minidose) warfarin in 
combination with aspirin is 
less effective compared to 
adjusted dose warfarin. 
A total of 677 subjects were 
randomly assigned to one of four 
groups: 1) minidose warfarin 1.25 
mg/day, 2) warfarin sodium 1.25 
mg/day plus aspirin 300 mg/day, 
3) aspirin 300 mg/day, and 4) 
adjusted dose warfarin with a target 
INR of 2.0-3.0. The average age of 
the subjects was 74 years old and 
35-43% females per group. 
Inclusion criteria: documentation 
of atrial fibrillation through an 
electrocardiogram by at least one 
month, and age 18 or older. 
 
Exclusion criteria: less than age 60 
with atrial fibrillation as a cause of 
heart disease, heart failure, 
hyperthyroidism, or chronic 
obstructive pulmonary disease; 
blood pressure >180/100 mmHg; 
history of stroke or TIA within the 
past 6 months; high bleeding risk; 
patients already on warfarin 
therapy; valvular atrial fibrillation; 




*The incidence of stroke or 
thromboembolism after one year 
on therapy occurred in 5.8% of 
the minidose warfarin group, 
7.2% in the combination aspirin 
and warfarin group, and 2.8% in 
the adjusted-dose warfarin group 
(p = .67). 
*No significant differences were 
noted when comparing treatment 





*Severe bleeding was not 
evident in any of the groups 
after three years. 
 
*Minor bleeding was present in 
24.7% of patients on minidose 
warfarin, 24.4% on combination 
warfarin and aspirin, group, 30.0% 
on aspirin, and 41.1% on adjusted 
dose warfarin. 
 
*With the additional factors of 
allergic reactions and dyspepsia, 
the risk of bleeding with aspirin 




Conclusion: Minidose warfarin did 
not display statistically significance 
in reducing stroke in patients with 
atrial fibrillation, thus adjusted-
dose warfarin with a target INR of 











Randomized control trial 
comparing aspirin to 
warfarin preventing 
thromboembolism in 
patients with non- 
valvular atrial fibrillation. 
 
The average follow-up 
time was 2.7 years. 
 
Efficacy outcomes 
measured included stroke 
or systemic embolism. 
Safety outcomes 
measured included 
vascular death or severe 
bleed. 
729 atrial fibrillation patients in 
Netherland age 60 years old or 
older were randomly assigned to 
standard coumarin therapy (target 
INR of 2.5-3.5), low intensity 
coumarin therapy (target INR of 
1.1-1.6) or aspirin (150 mg daily). 
The average age of patients was 75 
years old, with 32-57% men per 
group. Patients unable to be take 
standard coumarin doses were 
randomized to either the aspirin or 
low intensity coumarin groups. 
 
Inclusion criteria: patients age 60 
or older with atrial fibrillation 
diagnosed through an 
electrocardiogram within the past 
two years. 
 
Exclusion criteria: prior stroke, 
valvular atrial fibrillation, 
Efficacy outcome: In comparing 
low dose anticoagulation to 
aspirin, the hazard ratio for 
stroke or thromboembolism was 
0.91 (0.t1 to 1.36) and 0.78 for 
standard anticoagulation to 





* Out of all three groups, 108 
adverse events occurred (5.5% 
per year), including 13 severe 
bleeds (0.7% annually). 
 
*Death from a non-vascular cause 
was lower in the anticoagulation 
group compared to aspirin [hazard 
ratio 0.41 [0.20 to 0.82]). 
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Trial Design/Method Sample Findings and 
Conclusions 
  myocardial infarction or 
cardiovascular surgery within the 
prior year, cardiomyopathy, heart 
failure, cardiac aneurysm, 
reversible causes of AF, 
pacemaker, contraindications to 
aspirin or coumarin, history of 
systemic embolism, renal 
infarction, prior coumarin use 
within 3 months, life expectancy of 
less than 2 years. 
 
Exclusion criteria for standard 
coumarin doses: age older than 78 
years old, duodenal or gastric ulcer, 
retinopathy, history of a 
genitourinary or gastrointestinal 
bleed, hypertension (systolic blood 
pressure >185 mm Hg and/or 
diastolic blood pressure 
>105 mm Hg). 
*Severe bleeding was 
nonsignificant when comparing the 
three treatment groups. 
 
 
Conclusion: Coumarin therapy (both 
low-intensity and standard therapy) 
has not demonstrating superiority to 
aspirin in preventing 
thromboembolism with no reduction in 
bleeding risk in patients with non-
valvular atrial fibrillation, thus 
aspirin is recommended as first line 




Treatment of the 
Aged Study 
 
(Mant et al., 2007) 
Prospective, randomized, 
open-label, blind 
assessment of end points, 
controlled study 
investigating the bleeding 
versus stroke risk in 
elderly patients on 
warfarin versus aspirin. 
 
Subjects were gathered 
from 260 clinics within 
England and Wales from 
2001-2004. 
Subjects were followed- 
up between 2-7 years. 
 
The primary efficacy and 
safety outcomes measures 
were incidence of ischemic 





A total of 937 subjects age 75 
years age or older were randomly 
assigned to the warfarin group 
(target INR of 2.0-3.0) or aspirin 
(75 mg daily). The average age 
was 81.4 years old with 54-55% 
men per group. 
 
Inclusion criteria: age 75 or older 
with a confirmed diagnosis of atrial 
fibrillation by EKG within the past 
two years. 
 
Exclusion criteria: rheumatic 
(valvular) heart disease, 
intracranial hemorrhage, non- 
traumatic bleed within the past 5 
years, esophageal varices, 
contraindications to warfarin or 
aspirin, terminal illness, surgery 
within the past 3 months, and 
blood pressure >180/110 mm Hg. 
Safety and Efficacy outcomes: 
 
*Throughout the study there was a 
total of 21 strokes, 2 intracranial 
hemorrhages, and 1 systemic 
embolism in the warfarin group 
(annual risk 1.8%). 
 
*In comparison, the aspirin group 
had 44 strokes, 1 intracranial 
hemorrhage, and 3 systemic 
embolisms (annual risk of 3.5%; 
relative risk 0.48, 95% CI 
0.28-0.80, p = 0.003: absolute yearly 
risk reduction 2%, 95% CI 0.7-3.2). 
 
*Regarding extracranial bleeds, 1.4% 
occurred yearly in the warfarin group 
compared to 1.6% in the aspirin 
group (relative risk 0.97, 0.43-1.73; 
absolute 
risk reduction 0.2%-, -0.7 to 1.2). 
 
 
Conclusion: Anticoagulation with 
warfarin is safe and efficacious, thus it 
is recommended over aspirin in 
patients over age 75 years old with 
atrial fibrillation to prevent stroke. 
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(Wang et.al., 2013) 
Open-label, randomized, 
three-treatment, three- 
period, crossover study 
examining a 50-gram 
overdose of apixaban and 
the results of subsequent 
administration of activated 
charcoal. 
 
This study was completed 
from May 6th-17th, 2011. 
 
Activated charcoal was 
ingested at 2 hours or 6 
hours after the overdose of 
apixaban. Serum labs were 
obtained up to 72 hours after 
the administration of 
activated charcoal. 
18 healthy subjects age 18-45 years 
(mean age of 31.8 years), received 
50 grams of activated charcoal 2 
hours OR 6 hours after 
administration of 20 mg apixaban 
PO. The average age of subjects 
was 31.8 years old with 10 males 
and 8 females, 14 Caucasians and 
4 Blacks. 
 
Inclusion criteria: healthy males 
and females age 18-45 years old 
with a body mass index of 18-32 
kg/m2. 
 
Exclusion criteria: relevant acute or 
chronic medical diagnoses, 
pregnancy or breastfeeding, 
gastrointestinal disorders, personal 
history of coagulopathies, family 
history of first degree relatives with 
coagulopathies, or intracranial 
hemorrhage, or smoking greater 
than 10 cigarettes daily. 
 
Five subjected were also excluded 
with emesis 6 hours after 
administration of apixaban or 30 
minutes after ingestion of activated 
charcoal. 
Efficacy outcomes: 
*Apixaban was evident in mean 
plasma concentrations 72 hours 
after ingestion and 48 hours after 
activated charcoal administration, at 
both the 2 and 6 hour intervals post 
apixaban dose. 
*Activated charcoal decreased the 
apixaban exposure (AUC) by 50% 
when administered 2 hours after 
ingestion of 20 mg apixaban and 27% 
when administered 6 hours after the 
20 mg apixaban ingestion. 
*The mean half-life of apixaban 
(13.4 hours) decreased to ~5 hours 
after administration of activated 
charcoal at 2 or 6 hours post-dose. 
 
Safety outcomes: 
*Adverse effects in patients who 
received activated charcoal after 
apixaban overdose included: 
diarrhea, nausea, abdominal pain, 
vomiting, flatulence, and abdominal 
distention (11%). 
*Adverse effects were higher in 
patients who received apixaban 
followed by activated charcoal 2 
hours later (72.2%) and 6 hours later 
(77.8%), compared to patients who 
received only apixaban (16.7%). 
* Adverse effects were mild 
(38.9%) or moderate (44.4%) in 
patients and resolved by the end of 
the study. 
*These adverse effects are 
comparable to known adverse effects 
or activated charcoal. 
 
Conclusion: Activated charcoal can 
help eliminate a 20 mg apixaban 









(Pollack et. al., 
2015) 
Prospective cohort study 
examining safety and 
efficacy of 5 g 
idarucizumab IV to reverse 
the anticoagulant effects of 
dabigatran in the event of 
significant bleeding or 




administered as two 50- mL 
boluses containing 2.5 mg 
of medication each. 
The medications were 
administered intravenously 
less than 15 minutes apart. 
Blood levels of 
idarucizumab were obtained 
at baseline, after 
the first administration of 
A total of 90 subjects group A had 
51 with significant bleeding; group 
B had 39 requiring an urgent 
procedure). Over 68 subjects had an 
elevated dilute thrombin at baseline 
and 81 had an elevated ecarin 
clotting time. The median age of the 
subjects was 76.5 years and 56% 
males, with a median creatinine 
clearance of 58 mL/min. Over 90% 
of subjects were receiving 
dabigatran to prevent stroke related 
to atrial fibrillation. 
 
In group A, the necessity for a 
reversal agent were as follows: 18 
intracranial hemorrhages, 20 
gastrointestinal bleeds, 9 trauma- 
related bleeding, and 11 other 
etiologies of bleeding. 
Efficacy outcomes: 
*The median maximum percentage 
reversal of anticoagulant effects of 
dabigatran was 100% [(CI: 95%: 
100 
(100, 100)]. 
*Test results reached normal levels 
within minutes, in 88-98% of 
subjects. 24 hours later, results of 
unbound dabigatran were <20 ng/mL 
in 79% of subjects. *Hemostasis in 
group A was obtained at a median 
rate of 11.4 hours in 35 patients. 
*Hemostasis in group B was obtained 
intraoperatively in 33 patients, mildly 
abnormal hemostasis in 2 patients, 
and moderately abnormal hemostasis 
in 1 patient. 
*Thrombosis occurred 72 hours 
after idarucizumab in 1 patient 




 idarucizumab, between 10 
to 30 minutes, and at 1, 2, 
4, 12, and 24 hours after the 
second administration. 
 
This study was completed at 
400 sites in 38 countries 
from 2014-2015. Patient 
follow-up was for 1 month 
after the study. 
 
Outcomes measured 
included the dilute 
thrombin time (dTT) or 
ecarin clotting time 




In Group B, the most common 
indications for requiring a reversal 
agent included bone fractures, acute 
cholecystitis, acute renal 
insufficiency with catheter 
placement, acute appendicitis, 
joint/wound infection, and acute 
mesenteric ischemia. 
 
Inclusion criteria: Group A 
subjects required a reversal agent 
for uncontrollable or serious 
bleeding. Group B subjects needed 
surgery or invasive procedures 
which could not be delayed for 8 
hours, the normal time for 
hemostasis. 
 
Exclusion criteria: none. 
Conclusion: Idarucizumab can 
safely and fully reverse the 
anticoagulation effects of 
dabigatran. 








(Siegal et al., 2015) 
Randomized, double-blind 
two-part, placebo- 
controlled study examining 
reversal of apixaban and 
rivaroxaban with andexanet 
alpha in healthy, elderly 
subjects. 
 
The outcome measured was 
the average change in anti-
factor Xa activity 
(inhibition), measured as a 
percentage. 
 
This study was completed 
from 2014-2015: 
ANNEXA-A was 
completed in Arizona and 
ANNEXA-R was 
completed in California. 
 
ANNEXA-A: Andexanet 
alpha antidote administered 
to reverse the anticoagulant 
effects of apixaban 
ANNEXA-R: Andexanet 
alpha antidote administered 
to reverse the anticoagulant 
effects of rivaroxaban 
 
Subjects were observed 
for 8 days after 
administration of the 
antidotes, with safety 
outcomes monitored for 
up to 43 days after 
administration. 
A total of 101 subjects were 
administered apixaban 5 mg twice 
daily for 3.5 days (ANNEXA-A, 48 
subjects) or rivaroxaban 20 mg 
daily for 4 days (ANNEXA-R, 53 
subjects), until therapeutic drug 
levels were achieved. In 
ANNEXA-A, subjects were 
randomized in a 3:1 ratio of 
andexanet to placebo (17 subjects 
received placebo), while in 
ANNEXA-R, subjects were 
randomized in a 2:1 ratio of 
andexanet or placebo (27 subjects). 
 
Subjects also were randomized to a 
part 1 or part 2 portion of the study. 
In part 1 of the study, on day 4, 
andexanet was given as a 400-mg 
bolus in ANNEXA-A and an 800-
mg bolus in ANNEXA-R. In part 2 
of the study, andexanet was given 
as bolus with a 2-hour infusion. 
 
The mean age of the subjects was 
57.9 years old with 39% women. 
 
Inclusion criteria: Subjects were 
healthy and age 50-75 years old. 
 
Exclusion criteria: none 
Apixaban: 
*Anti-factor Xa activity of apixaban 
was inhibited by 94% (24 subjects) 
with the andexanet bolus compared 
to 21% (9 subjects) with the placebo 
(p<0.001). 
*The amount of unbound apixaban 
was decreased 9.3 ng/mL compared 
to 
1.9 ng/mL with the placebo (p<0.001). 
*Thrombin was returned to normal 
levels within 2-5 minutes in 100% 
of the apixaban subjects compared 
to 11% of the placebo (p<0.001). 
 
Rivaroxaban: 
*Anti-factor Xa activity or 
rivaroxaban was inhibited by 92% 
(27 subjects) compared to 18% (14 
subjects) with the placebo (p<0.001). 
*The amount of unbound 
rivaroxaban was decreased 23.4 
ng/mL compared to 4.2 ng/mL with 
the placebo (p<0.001). 
*With both rivaroxaban and 
apixaban, the same results were 
evident with the 2-hour infusion with 
bolus compared to only the bolus. 
 
D-dimer and prothrombin increased 
in 1-2 subjects, yet results 
normalized within 1-3 days. No 
subjects reported any adverse events. 
No thrombotic events occurred. 
 
Conclusion: andexant alpha can 
safely, quickly, and effectively 
reduce the effects of apixaban and 





















trial comparing the 
combination of clopidogrel 
and aspirin to 
anticoagulation in 
preventing vascular events 
in patients with atrial 
fibrillation. 
 
Subjects were assigned to 
one of three ACTIVE trials 
based on eligibility criteria: 
ACTIVE W was for 
patients who could take 
oral anticoagulation, 
ACTIVE A was for 
patients unable to take oral 
anticoagulation, and 
ACTIVE I included 
patients from ACTIVE A 
or ACTIVE W who were 
candidates for irbesartan. 
 
Primary outcomes 
measured included the 
incidence of stroke, non- 
central nervous system 
systemic embolus, 
vascular death, or 
myocardial infarction. 
Subjects were randomly assigned 
to either the oral anticoagulation 
group with a therapeutic INR of 
2.0-3.0 (3,371 subjects), or the 
combination clopidogrel with 
aspirin group (3,335 subjects). The 
daily dose of clopidogrel was 75 
mg and the daily dose of aspirin 
was 75-100 mg. 
The average age of patients was 
70.2 years with 66-67% males per 
group. The average CHADS2 score 
was 2.0 
 
Inclusion criteria: AF confirmed 
by an ECG plus at least one of the 
following stroke risk factors: age 
>75 years old, hypertension, prior 
stroke/TIA/non-central nervous 
system embolism, peripheral 
vascular disease, left ventricular 
ejection fraction <45%, age 55-74 
years old with either diabetes or 
coronary artery disease. 
 
Exclusion criteria: 
contraindications to warfarin or 
clopidogrel, mechanical heart 
valves, peptic ulcer disease within 
the past 6 months, prior 
intracerebral bleed, mitral stenosis, 
or severe 
thrombocytopenia. 
*This  study was  terminated 
prematurely as oral anticoagulation 
displayed superiority to the clopidogrel 
plus aspirin treatment in decreasing 
vascular events (165 events or 3.93% 
annually with anticoagulation 
compared to 234 events or 5.6% 
annually with clopidogrel plus aspirin; 




*The risk of bleeding was reduced in 
patients who were taking oral 
anticoagulation prior to starting this 
study (1.30, 0.94-1.79) compared to 
patients newly initiating oral 
anticoagulation (1.27, 0.85-1.89), plus 
displayed a larger reduction in 
vascular events (relative risk 1.50, 
95% CI 1.19- 
1.80, p = 0.03). 
 
 
Conclusion: in patients with atrial 
fibrillation with a high risk of stroke, 
oral anticoagulation is superior in 
preventing vascular events compared 
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Prevention of 






blind, multicenter study 
examining if the 
combination of clopidogrel 
and aspirin would decrease 
the risk of vascular events 
in patients with atrial 




This study was completed 
at 580 sites within 33 
countries. 
 
The primary outcomes 
measured were the 
incidence of myocardial 
infarction, non-central 
nervous system embolism, 
stroke or death from a 
vascular etiology. 
Out of 7,554 subjects, 3,772 were 
randomly assigned to a clopidogrel 
group (75 mg) and 3,782 were 
randomly assigned to a placebo 
group. The average follow-up time 
was 3.6 years. 
Patients in both groups received 
daily aspirin (75-100 mg). The 
average age of subjects was 70.9- 
71.1 years old and 57-58% males 
per group with an average 
CHADS2  score of 2.0. 
 
Inclusion criteria: the patient was 
currently in AF at the beginning of 
the trial or at least two episodes of 
AF within the past 6 months. At 
least one of the same stroke risk 
factors highlighted in ACTIVE W. 
 
Exclusion criteria: concurrent use 
of warfarin or clopidogrel or high 
bleeding risk factors (peptic ulcer 
disease within the last 6 months, 
history of an intracerebral bleed, 
severe thrombocytopenia, or 
alcoholism). 
*Total vascular events arose in 832 
(6.8% annually) of the clopidogrel 
subjects, compared to 942 placebo 
subjects (relative risk 0.89, 95% CI, 
0.81 to 0.98, p = 0.01). 
 
*Clopidogrel was associated with a 
reduced risk of stroke (296 subjects, 
2.4% annually) compared to the 
placebo (408 subjects, 3.3% annually; 
relative risk 0.72, 95% CI 0.62 to 0.83, 
p <0.001). 
 
*Myocardial infarction presented in 
90 subjects (0.7% annually) of the 
clopidogrel patients compared to 116 
placebo subjects (0.9% per year; 
relative risk 0.78, 95% CI 0.59 to 
1.03, p = 0.08). 
 
*Severe bleeding developed in 251 
clopidogrel subjects (2.0% annually) 
compared to 162 placebo subjects 
(1.3% annually; relative risk 1.57, 
95% CI 1.29 to 1.92, p <0.001). 
244 
 
   Conclusion: clopidogrel with aspirin 
is a suitable alternative to decrease 
the risk of vascular events, especially 
stroke, in patients with atrial 
fibrillation who are unable to take 
warfarin, yet this combination 
augments major bleeding risk. 











examining safety and 
efficacy of WATCHMAN 
(percutaneous closure of 
the left atrial appendage) 
to warfarin in preventing 
embolic stroke in patients 
with non-valvular atrial 
fibrillation. 
 
The study was completed 
at 59 sites within the 
United States and Europe 
from 2005 to 2008. 
 
The efficacy outcome 
measured was the incidence 
of death from a 
cardiovascular cause, 
stroke (ischemic or 
hemorrhagic), or systemic 
embolism. 
 
The safety outcomes 
measured included severe 
bleeding, embolization from 
implantation of the 
WATCHMAN device, and 
pericardial effusion. 
707 subjects were randomly 
assigned in a 2:1 ratio of 
WATCHMAN (473 subjects) or 
dose controlled warfarin with a 
goal INR of 2.0-3.0 (244 subjects). 
Subjects were an average age of 
71.7-72.7 years, 70% males, over 
91% Caucasian, and with a means 
CHADS2 score of 1-2. 
 
For 45 days after implantation of 
the  WATCHMAN  device, patients 
in this group received warfarin and 
aspirin 81 mg daily for 45 days to 
prevent the formation of a thrombus 
while the device endothelializes in 
the heart. Warfarin was 
discontinued once the 
transesophageal echocardiogram 
(completed at 45 days, 6 months, 
and 12 months post procedure) 
demonstrated complete closure 
(seal) of the left atrial appendage, or 
peri-device blood flow of <5 mm 
width was present in the left atrial 
appendage with no thrombus 
present on the device. After 45 days 
and discontinuation of warfarin, 
clopidogrel and aspirin were 
continued for 6 months post- 
implant, followed by aspirin 
administration for life. 
 
Inclusion criteria: adults 18 years 
or older with atrial fibrillation with 
a minimum of one of the following 
factors based on a CHADS2 risk 
score of ≥1: congestive heart 
failure, hypertension, diabetes, ≥75 
years old, or prior stroke or TIA 
 
Exclusion criteria: necessity of 
chronic warfarin use to treat a 
condition other than atrial 
fibrillation, contraindication to 
warfarin, thrombus in the left 
atrial appendage, symptomatic 
carotid artery disease, mobile 
aortic atheroma, and patent 
foramen ovale with atrial septal 
aneurysm and right-to-left shun 
Efficacy outcome: WATCHMAN was 
implanted in 88% (408 out of 463) 
patients. At 1065 patient years of 
follow-up, with an average follow-up 
of 18 months, stroke, systemic emboli, 
or cardiovascular death occurred in 3 
out of 100 patient years (95% credible 
interval [CrI] 1·9–4·5) in the 
WATCHMAN group and 4·9 per 100 
patient-years (2·8–7·1) in the warfarin 
group (rate ratio [RR] 0·62, 95% CrI 
0·35–1·25). Non-inferiority in the 
WATCHMAN group compared to 
warfarin was >99.9%. 
 
 
Safety outcome: Severe bleeding, 
embolization from implantation and 
pericardial effusion were more 
common in the WATCHMAN group 
compared to the warfarin group (7·4 
per 100 patient years, 
 
95% CrI 5·5–9·7, vs 4·4 per 100 
patient-years, 95% CrI 2·5–6·7; 
RR 1·69, 1·01–3·19). 
 
 
Conclusion: Efficacy of 
WATCHMAN is non-inferior to 
warfarin in patients with nonvalvular 
atrial fibrillation to prevent stroke. 
Adverse safety events were more 
common in the WATCHMAN group; 
however, the events were 
predominantly related to the 
procedure itself. The study concluded 
closure of left atrial appendage 
through WATCHMAN is an 
efficacious alternative to long-term 
anticoagulation in patients with non- 
valvular atrial fibrillation, as the 
safety concerns are related to surgery 











(Holmes et al., 
2014) 
This randomized, double- 
blind study is a 
continuation of PROTECT 
AF to further assess the 
safety and efficacy of 
WATCHAN© versus 
warfarin in patients with 
non- valvular atrial 
fibrillation, as early safety 
concerns were discovered 
with WATCHMAN© in 
the prior study. 
 
The efficacy endpoints 
measured were 1) the 
incidence of stroke, 
systemic embolism and 
cardiovascular death and 
2) stroke or systemic 
embolization >7 days after 
randomization to study 
group. 
 
The safety endpoint 
measured was ischemic 
stroke, systemic 
embolization, all-cause 
death, or an adverse event 
related to the procedure or 
device, requiring 
intervention within 7 days 
of the implantation of the 
WATCHMAN© device. 
Complications excluded 
from this safety endpoint 
included pericardial 
effusions drained through 
percutaneous catheter 
drainage, snaring of the 




407 patients were randomly 
assigned in a 2:1 ratio to either the 
WATCHMAN© group (269 
patients) or long-term warfarin 
group (138 patients). The target 
INR for warfarin patients was 2.0- 
3.0. The average age of subjects 
was 74 years old, 67-74% males, 
94% Caucasian, and 45-50% with a 
CHADS2 score of 2. 
 
Transesophageal echocardiograms 
were completed at 45 days, 6 
months, and 12 months, the same as 
in the PROTECT-AF trial. 
Continuing or discontinuing 
warfarin followed the same 
parameters as the PROTECT-AF 
trial. 
 
Inclusion criteria: Adult patients 
with nonvalvular atrial fibrillation 
and a CHADS2 score of ≥2 
(congestive heart failure, 
hypertension, age >75 years old, 
diabetes, or prior stroke/TIA) or 1 
with other risk factors present. 
These high-risk factors include: 
female sex and ≥75 years old, 
baseline ejection fraction ≥30%, 
baseline ejection fraction <35% if 
age 65-74 years old with diabetes 
or coronary artery disease, or age 
≥65 years old and congestive heart 
failure). 
 
Exclusion criteria: necessity of 
chronic warfarin use to treat a 
condition other than atrial 
fibrillation, contraindication to 
warfarin or aspirin, thrombus in the 
left atrial appendage, symptomatic 
carotid artery disease, prior stroke 
or TIA within 90 days of the study, 
patent foramen ovale or atrial septal 
defect necessitating surgery, or 
patients requiring clopidogrel 
therapy. 
Efficacy outcomes: The incidence of 
stroke, systemic embolism or 
cardiovascular death occurred in 
0.064 patients in the 
WATCHMAN© group compared to 
0.063 patients in the warfarin group 
p (rate ratio 1.07 [95% credible 
interval (CrI): 0.57 to 1.89]; non-
inferiority was not discovered for 
WATCHMAN© compared to 
warfarin (95% CrI ≥1.75). Stroke or 
systemic embolization greater than 
7 days after randomization to a 
group occurred in 0.0253 of the 
WATCHMAN© group, compared 
to 0.0200 in the warfarin group 
[95% CrI: –0.0190 to 0.0273]), 
displaying noninferiority 




Safety outcome: Early safety 
events were discovered less in in 
the WATCHMAN© group in 
PREVAIL compared to 
PROTECT-AF (2.2% of subjects). 
Compared to warfarin (8.7%), 
safety events were less with 
WATCHMAN© (4.2%, p = 
0.004). 
Less pericardial effusions requiring 
surgery were noted in 
WATCHMAN© patients in the 
PREVAIL trial (0.4%) compared to 
the PROTECT-AF trial (1.6%, p = 
0.027), as well as reduced rates of 
pericardiocentesis (1.5% compared 
to 2.9%, p = 0.36 respectively) 
 
 
Conclusions: the study concluded 
improved procedural safety of 
WATCHMAN© implantation in 
patients with nonvalvular atrial 
fibrillation to prevent stroke, as long 
at the patient does not have a 
contraindication to using warfarin 
short-term post- procedure. 
WATCHMAN© is non- inferior to 
warfarin to prevent ischemic stroke 
in patients with non-valvular atrial 
fibrillation, as well as preventing 
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Randomized,  double blind 
study investigating whether 
the addition of irbesartan 
to either anticoagulation  
or aspirin with clopidogrel 
would decrease the risk of 
cardiovascular sequelae in 




measures included the 
incidence of stroke, 
myocardial infarction, or 




related to heart failure. 
 
The average follow-up 
period was 4.1 years. 
Subjects for this trial were 
currently partaking in either 
ACTIVE A or ACTIVE W, 
depending on their ability to take 
oral anticoagulation. Subjects 
randomly were administered 
irbesartan 300 mg daily (4,518 
subjects) or a placebo (4,498 
subjects). The average age of 
subjects was 69.5 years old, 60% 
male and with a CHADS2 score of 
2. 
 
Inclusion criteria: risk factors for 
stroke described in ACTIVE A and 
ACTIVE W plus systolic blood 
pressure >110 mmHg. 
 
Exclusion criteria: The same as 
ACTIVE A and ACTIVE W. 
Patients could not be taking any 
other angiotensin receptor 
blockers. 
*Average systolic blood pressure was 
decreased by 2.9 mmHg more in the 
irbesartan group compared to the 
placebo, in addition to a systolic 
blood pressure reduction of 1.9 
mmHg more. 
*Primary vascular events occurred 
in 5.4% per 100 person years in the 
irbesartan and placebo groups (HR 
0.99, 95% CI 0.91-1.09, p = 0.85). 
 
*The secondary outcome of 
hospitalization related to heart failure 
occurred at 7.3% per 100 person 
years in the irbesartan group and 
7.7% per 100 person years in the 
placebo group (HR 0.94%, 95% CI, 
0.87-1.02, p = 
0.12). 
 
*Irbesartan did not prevent any 
hospitalizations for a diagnosis 
of solely atrial fibrillation. 
*Renal impairment (43 subjects) and 
hypotension (127 subjects) were more 
common adverse effects with 
irbesartan than the placebo (24 
subjects and 64 subjects, respectively) 
Conclusion: In patients with atrial 




(What is the 
Optimal 
Antiplatelet 






(Dewilde et al., 
2013). 
Randomized, controlled, 
open-label study assessing 
the safety and efficacy of 
clopidogrel in comparison 
to clopidogrel with aspirin 
in patients who have 
undergone percutaneous 
coronary intervention 
(PCI) for ischemic heart 
disease. Patients with 
mechanical valves and 
atrial fibrillation require 
chronic anticoagulation. 
 
This study was completed 
at 15 clinics within the 
Belgium and the 
Netherlands over a three- 
year period. 
 
The primary safety 
outcome measured 
bleeding within one year 
after the PCI. 
Patients were randomly assigned to 
either double therapy (clopidogrel 
with anticoagulation, 279 subjects) 
or triple therapy (clopidogrel with 
anticoagulation and aspirin, 284 
subjects). The average age of 
patients in the double therapy 
group was 70.3 years and 69.5 
years in the triple therapy group. 
The subjects were 77-82% males 
with an average CHADS2 score of 
1-2. 
 
Inclusion criteria: age 18-80 years 
old, necessity of anticoagulation for 
at least one year, a minimum of 
75% stenosis on angiography or a 
fractional flow reserve lower than 
0.80 and the need for a PCI. 
 
Exclusion criteria: cardiogenic 
shock, history of intracranial 
hemorrhage, peptic ulcer within 
the past 6 months, severe 
thrombocytopenia (platelet count 
<50x109/L), severe bleeding 




*Bleeding occurred in 54 (19.4%) of 
subjects in the double therapy group 
compared to 126 (44.4%) of subjects 
in the triple therapy group; HR 0.36, 
95% CI, 0.26-0.60, p <0.0001). 
 
*Recurrent bleeding occurred 
more often in the triple therapy 
group (34 subjects or 12%) 
compared to the double therapy 
group (6 subjects or 2.2%). 
*Bleeding was severe enough to 
warrant a transfusion in 27 (9.5%) of 
patients in the triple therapy group, 
compared to 11 (3.9%) in the double 
therapy group (odds ratio 0.39, 95% 
CI 0.17-0.84, p = 0.011). 
 
Conclusion: in patients post PCI who 
require anticoagulation, clopidogrel 
without aspirin is recommended due 
to the decrease in bleeding without a 
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Recommendations Classa Levelb 
Recommendations for diagnosis and screening of AF 
ECG documentation is required to establish the diagnosis of AF. I B 
Opportunistic screening for AF is recommended by pulse taking or ECG rhythm strip in patients >65 years of age.  I B 
In patients with TIA or ischaemic stroke, screening for AF is recommended by short-term ECG recording followed by continuous ECG monitoring 
for at least 72 hours. I B 
It is recommended to interrogate pacemakers and ICDs on a regular basis for atrial high rate episodes (AHRE). Patients with AHRE should undergo 
further ECG monitoring to document AF before initiating AF therapy. I B 
Recommendations for general management of AF 
Tailored patient education is recommended in all phases of AF management to support patients’ perception of AF and to improve management. 
I C 
A full cardiovascular evaluation, including an accurate history, careful clinical examination, and assessment of concomitant conditions, is recommended in 
all AF patients. I C 
Use of the modified EHRA symptom scale is recommended in clinical practice and research studies to quantify AF-related symptoms. I C 
Transthoracic echocardiography is recommended in all AF patients to guide management. I C 
The assessment of kidney function by serum creatinine or creatinine clearance is recommended in all AF patients to detect kidney disease and to support 
correct dosing of AF therapy. I A 
Recommendations for stroke prevention in AF 
The CHA2DS2-VASc score is recommended for stroke risk prediction in patients with AF. I A 
Oral anticoagulation therapy to prevent thromboembolism is recommended for all male AF patients with a CHA2DS2-VASc score of 2 or more. 
I A 
Oral anticoagulation therapy to prevent thromboembolism is recommended in all female AF patients with a CHA2DS2-VASc score of 3 or more. 
I A 
When oral anticoagulation is initiated in a patient with AF who is eligible for a non vitamin-K-antagonist oral anticoagulant (apixaban, dabigatran, 
edoxaban, or rivaroxaban), a NOAC is recommended in preference to a Vitamin K antagonist. I A 
Vitamin K antagonist therapy (INR 2.0–3.0 or higher) is recommended for stroke prevention in AF patients with moderate-to- severe mitral 
stenosis or mechanical heart valves. I B 
NOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) are not recommended in patients with mechanical heart valves (Level of evidence B) or 




When patients are treated with a vitamin K antagonist, time in therapeutic range (TTR) should be kept as high as possible and closely monitored. 
I A 





In male or female AF patients without additional stroke risk factors, anticoagulant or antiplatelet therapy is not recommended for stroke prevention. III 
(harm) 
B 
Antiplatelet monotherapy is not recommended for stroke prevention in AF patients, regardless of stroke risk. III 
(harm) 
A 
After surgical occlusion or exclusion of the left atrial appendage, it is recommended to continue anticoagulation in at-risk patients with AF for stroke 
prevention. I B 









In AF patients with severe active bleeding events, it is recommended to interrupt oral anticoagulation therapy until the underlying cause is resolved. 
I C 
NOACs should be avoided in pregnancy and in women planning a pregnancy. III 
(harm) 
C 
For patients with atrial flutter, antithrombotic therapy is recommended according to the same risk profile used for AF. I B 
Management of typical atrial flutter with ablation of the cavotricuspid isthmus is recommended for patients failing antiarrhythmic drug therapy or as 
first-line treatment considering patient preference. 
I B 
Lifelong oral anticoagulation to prevent stroke is recommended in hypertrophic cardiomyopathy patients who develop AF.  I B 
Anticoagulation with heparin or low-molecular-weight heparin immediately after ischaemic stroke is not recommended in AF patients. III 
(harm) 
A 
Systemic thrombolysis with a recombinant tissue plasminogen activator is not recommended if the INR is above 1.7 (or, for patients on dabigatran, if 
















Recommendations Classa Levelb 
Recommendations for rate control of AF 
Beta-blockers, digoxin, diltiazem, or verapamil are recommended to control heart rate in AF patients with LVEF 40%. I B 
Beta-blockers and/or digoxin are recommended to control heart rate in AF patients with LVEF <40%. I B 
In patients with permanent AF (i.e. where no attempt to restore sinus rhythm is planned), antiarrhythmic drugs should not routinely be used for rate control. III 
(harm) 
A 
Recommendations for rhythm control of AF 
Rhythm control therapy is indicated for symptom improvement in patients with AF. I B 
Cardioversion of AF (either electrical or pharmacological) is recommended in symptomatic patients with persistent or long-standing persistent AF as part of rhythm control therapy. 
I B 
In patients with no history of ischaemic or structural heart disease, flecainide, propafenone, or vernakalant are recommended for pharmacological cardioversion  of  new-onset AF. 
I A 
In patients with ischaemic and/or structural heart disease, amiodarone is recommended for cardioversion of AF.  I A 
For cardioversion of AF/atrial flutter, effective anticoagulation is recommended for a minimum of 3 weeks before cardioversion. I B 
Transoesophageal echocardiography (TOE) is recommended to exclude cardiac thrombus as an alternative to preprocedural anticoagulation when early cardioversion is planned. 
I B 
The choice of antiarrhythmic drug needs to be carefully evaluated, taking into account the presence of comorbidities, cardiovascular risk and potential for serious proarrhythmia, extracardiac 
toxic effects, patient preferences, and symptom burden. I A 
Dronedarone, flecainide, propafenone, or sotalol are recommended for prevention of recurrent symptomatic AF in patients with normal left ventricular function and without pathological left 
ventricular hypertrophy. 
I A 
Dronedarone is recommended for prevention of recurrent symptomatic AF in patients with stable coronary artery disease, and without heart failure. 
I A 
Amiodarone is recommended for prevention of recurrent symptomatic AF in patients with heart failure. I B 
Antiarrhythmic drug therapy is not recommended in patients with prolonged QT interval (> 0.5 s) or with significant sinoatrial node disease or atrioventricular node dysfunction who do not 




Catheter ablation of symptomatic paroxysmal AF is recommended to improve AF symptoms in patients who have symptomatic recurrences of AF on antiarrhythmic drug therapy 
(amiodarone, dronedarone, flecainide, propafenone, sotalol) and who prefer further rhythm control therapy, when performed by an electrophysiologist who has received appropriate training 





ACE-Is or ARBs are not recommended for the secondary prevention of paroxysmal AF in patients with little or no underlying heart disease. III 
(no benefit) 
B 
Moderate regular physical activity is recommended to prevent AF, while athletes should be counselled that long-lasting, more intense sports participation can promote AF. 
I A 
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Recommendations                                                                        COR        LOE       References 
 
Hypertrophic cardiomyopathy 
Anticoagulation is indicated in HCM with AF independent of the CHA2DS2-VASc  score I B (169,170) 
Antiarrhythmic drugs can be useful to prevent recurrent AF in HCM.  Amiodarone  or  disopyramide 
combined with a beta blocker or nondihydropyridine calcium channel antagonist are reasonable 
IIa C N/A 
AF catheter ablation can be beneficial for HCM to facilitate a rhythm-control strategy when 
antiarrhythmics fail or are not tolerated 
IIa B (171–174) 
Sotalol, dofetilide, and dronedarone may be considered for a rhythm-control strategy in HCM IIb C (12) 
AF complicating ACS 
Urgent cardioversion of new-onset AF in the setting of ACS is recommended for patients with 
hemodynamic compromise, ongoing ischemia, or inadequate rate control 
I C N/A 
IV  beta blockers are recommended to slow RVR  with ACS and no  HF, hemodynamic 
instability,   or bronchospasm 
I C N/A 
With ACS and AF with CHA2DS2-VASc score $2, anticoagulation with warfarin is recommended 
unless  contraindicated 
I C N/A 
Amiodarone or digoxin may be considered to slow RVR with ACS and AF and severe LV 
dysfunction and HF or hemodynamic instability 
IIb C N/A 
Nondihydropyridine calcium antagonists might be considered to slow RVR with ACS and AF only 
in the absence of significant HF or hemodynamic instability 
IIb C N/A 
Hyperthyroidism 
Beta blockers are recommended to control ventricular rate with AF complicating thyrotoxicosis 
unless contraindicated 
I C N/A 
When beta blockers cannot be used, a nondihydropyridine calcium channel antagonist is 
recommended  to  control  ventricular rate 
I C N/A 
Pulmonary diseases 
A nondihydropyridine calcium channel antagonist is recommended to control ventricular rate with  
AF  and COPD 
I C N/A 
Cardioversion should be attempted for patients with pulmonary disease who become 
hemodynamically  unstable  with  new-onset AF 
I C N/A 
WPW and pre-excitation syndromes 
Cardioversion is recommended for patients with AF, WPW syndrome, and RVR who are 
hemodynamically  compromised 
I C (175) 
IV procainamide or ibutilide to restore sinus rhythm or slow ventricular rate is recommended for patients 
with pre-excited AF and RVR who are not hemodynamically compromised 
I C (175) 
Catheter ablation of the accessory pathway is recommended in symptomatic patients with 
pre-excited AF, especially if the accessory pathway has a short refractory period 








IV amiodarone, adenosine, digoxin, or nondihydropyridine calcium channel antagonists in patients 
with WPW syndrome who have pre-excited AF is potentially harmful 
III: Harm B (176–178) 
Heart failure 
A beta blocker or nondihydropyridine calcium channel  antagonist is  recommended for persistent  
or permanent AF in patients with HFpEF 
I B (95) 
In the absence of preexcitation, an IV beta blocker (or a nondihydropyridine calcium channel 
antagonist with HFpEF) is recommended to slow ventricular response to AF in the acute 
setting, with caution in patients with overt congestion, hypotension, or HFrEF 
I B (179–182) 
In the absence of pre-excitation, IV digoxin or amiodarone is recommended to control heart 
rate acutely 
I B (103,180,183,184) 
Assess heart rate during exercise and adjust pharmacological treatment in symptomatic patients   
during  activity 
I C N/A 
Digoxin is effective to control resting heart rate with HFrEF I C N/A 
A combination of digoxin and beta blocker (or a nondihydropyridine calcium channel antagonist 
with HFpEF) is reasonable to control resting and exercise heart rate with AF 
IIa B (93,180) 
It is reasonable to perform AV node ablation with ventricular pacing to control heart rate when 
pharmacological therapy is insufficient or not tolerated 
IIa B (95,185,186) 
IV amiodarone can be useful to control heart rate with AF when other measures are unsuccessful     
or contraindicated 
IIa C N/A 
With AF and RVR causing or suspected of causing tachycardia-induced cardiomyopathy, it is 
reasonable to achieve rate control by AV nodal blockade or a rhythm-control strategy 
IIa B (187–189) 
 
Recommendations                                                                             COR     LOE References 
In patients with chronic HF who remain symptomatic from AF despite a rate-control strategy, it is 
reasonable to use a rhythm-control strategy 
IIa C N/A 
Amiodarone may be considered when  resting  and  exercise  heart  rate  cannot  be controlled  with  a beta blocker (or  
a nondihydropyridine  calcium  channel  antagonist  with  HFpEF)  or  digoxin,  alone  or  in combination 
IIb C N/A 
AV node ablation may be considered when rate cannot be controlled and tachycardia-mediated cardiomyopathy  
is suspected 
IIb C N/A 
AV node ablation should not be performed without a pharmacological trial to control ventricular rate III: Harm C N/A 
For rate control, IV nondihydropyridine calcium channel antagonists, IV beta blockers,  




Familial (genetic) AF 
For patients with AF and multigenerational family members with AF, referral to a tertiary 
care center for genetic counseling and testing may be considered 
IIb C N/A 
Postoperative cardiac and thoracic surgery 








A nondihydropyridine calcium channel blocker is recommended when a beta blocker is inadequate to 
achieve rate control with postoperative AF 
I B (194) 
Preoperative amiodarone reduces AF with cardiac surgery and is reasonable as prophylactic therapy for 
patients at high risk of postoperative AF 
IIa A (195–197) 
It is reasonable to restore sinus rhythm pharmacologically with ibutilide or direct-current 
cardioversion with postoperative AF 
IIa B (198) 
It is reasonable to administer antiarrhythmic medications to maintain sinus rhythm with recurrent or 
refractory  postoperative AF 
IIa B (194) 
It is reasonable to administer antithrombotic medications for postoperative AF IIa B (199) 
It is reasonable to manage new-onset postoperative AF with rate control and anticoagulation 
with cardioversion if AF does not revert spontaneously to sinus rhythm during  follow-up 
IIa C N/A 
Prophylactic sotalol may be considered for patients with AF risk after cardiac surgery IIb B (193,200) 
Colchicine may be considered postoperatively to reduce AF after cardiac surgery IIb B (201) 
ACS indicates acute coronary syndromes; AF, atrial fibrillation; AV, atrioventricular; CHA2DS2-VASc, Congestive heart failure, Hypertension, Age $75 years (doubled), Diabetes mellitus, Prior Stroke or TIA or thromboembolism (doubled), 
Vascular disease, Age 65 to 74 years, Sex category; COPD, chronic obstructive pulmonary disease; COR, Class of Recommendation; HCM, hypertrophic cardiomyopathy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; 
HFrEF, heart failure with reduced ejection fraction; IV, intravenous; LOE, Level of Evidence; LV, left ventricular; N/A, not applicable; RVR, rapid ventricular response; and WPW, Wolff-Parkinson-White. 
Note: Adapted from “2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: Executive summary,”  C.T. January, L.S. 



























ANTITHROMBOTIC THERAPY FOR ATRIAL FIBRILLATION: 




• Nonrheumatic atrial fibrillation (including paroxysmal) with a CHADS2 score of 0 (low risk of stroke), no treatment is recommended but if 
a patient selects treatment, aspirin is preferred. With a CHADS2 score of 1 (intermediate risk of stroke) or with a CHADS2 score of ≥2 (high 
risk of stroke), oral anticoagulation is recommended. Assessment of stroke risk is assessed through CHADS2 scoring which has been 
validated through research and is easy to use.   
• When selecting oral anticoagulation, dabigatran 150 mg BID is preferred to warfarin (vitamin K antagonist). 
• With a high risk of stroke, oral anticoagulation is the recommended treatment, yet with a low risk of stroke, managed is based on the 
individual patient. 
• Recommendation 2.1.8. For patients with AF, including those with paroxysmal AF, who are at low risk of stroke (eg, CHADS2 [congestive 
heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient attack] score = 0), we suggest no therapy rather than 
antithrombotic therapy (Grade 2B). For patients who do choose antithrombotic therapy, we suggest aspirin (75 mg to 326 mg once daily) 
rather than oral anticoagulation (Grade 2B) or combination therapy with aspirin and clopidogrel (Grade 2B; American College of Chest 
Physicians, 2012, p. e532S). 
• Recommendation 2.1.8.  For patients with AF, including those with paroxysmal AF, who are at low risk of stroke (eg, 
CHADS2 [congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient attack] score = 0), we suggest no 
therapy rather than antithrombotic therapy (Grade 2B). For patients who do choose antithrombotic therapy, we suggest aspirin (75 mg to 
326 mg once daily) rather than oral anticoagulation (Grade 2B) or combination therapy with aspirin and clopidogrel (Grade 2B; American 
College of Chest Physicians, 2012, p. e532S). 
• Recommendation 2.1.9. For patients with AF, including those with paroxysmal AF, who are at intermediate risk of stroke (eg, 
CHADS2 score = 1), we recommend oral anticoagulation rather than no therapy (Grade 1B). We suggest oral anticoagulation rather than 
aspirin (75 mg to 325 mg once daily) (Grade 2B) or combination therapy with aspirin and clopidogrel (Grade 2B). For patients who are 
unsuitable for to choose not to take an oral anticoagulant (for reasons other than concerns about major), we suggest combination therapy 
with aspirin and clopidogrel rather than aspirin (75 mg to 325 mg once daily) (Grade 2B; American College of Chest Physicians, 2012, p. 
e532S).  
• Recommendation 2.1.10. For patients with AF, including whose with AF, including those with paroxysmal AF, who are at high risk of 
stroke (ex. CHADS2 score = 2), we recommend oral anticoagulation rather than no therapy (Grade 1A), aspirin (75 mg to 325 mg once 
daily) (Grade 1B), or combination therapy with aspirin and clopidogrel (Grade 1B). For patients who are unsuitable for or chose not to take 
an oral anticoagulant (for reasons other than concerns about major bleeding), we recommend combination therapy with aspiring and 








• Recommendation 2.1.11. For patients with AF, including those with paroxysmal AF, for recommendations in favor of oral anticoagulation 
(including 2.1.9, 2.1.10, and excluding 2.2, 3.1, 3.2, and 3.3, we suggest dabigatran 150 mg twice daily rather than adjusted-dose vitamin K 
antagonist (VKA) therapy (target INR range, 2.0-3.0) (Grade 2B; American College of Chest Physicians, 2012, p e533S).  
• Recommendation 2.2. For patients with AF and mitral stenosis, we recommend adjusted dose VKA therapy (target INR range, 2.0-3.0) 
rather than no therapy, aspirin (75 mg to 325 mg once daily), or combination therapy with aspirin and clopidogrel (all Grade 1B). For 
patients with AF and mitral stenosis who are unsuitable for or choose not to take adjusted-dose VKA therapy (for reasons other than 
concerns about major bleeding), we recommend combination therapy with aspirin and clopidogrel rather than aspirin (75 mg to 325 mg 
once daily alone (Grade 1B; American College of Chest Physicians, 2012, p e533S). 
• Recommendation 3.1. For patients with AF and stable coronary artery disease (eg, no acute coronary syndrome within the previous year) 
and who choose oral anticoagulation, we suggest adjusted-dose VKA therapy alone (target internationalized normalized ratio [INR] range, 
2.0-3.0) rather than the combination of adjusted-dose VKA therapy and aspirin (Grade 2C; American College of Chest Physicians, 2012, p 
e533S). 
• Recommendation 3.2. For patients with AF at high risk of stroke (eg, CHADS2 score of 2 or greater) during the first month after placement 
of a bare-metal stent or the first 3 to 6 months after placement of a drug-eluting stent, we suggest triple therapy (eg, VKA therapy, aspirin, 
and clopidogrel) rather than dual antiplatelet therapy (eg, aspirin and clopidogrel) (Grade 2C). After this initial period of triple therapy, we 
suggest a VKA (INR 2.0-3.0) plus a single antiplatelet drug rather than VKA alone (Grade 2C). At 12 months after intracoronary stent 
placement, antithrombotic therapy is suggested as for patients with AF and stable coronary artery disease (see section 3.1). For patients with 
AF at low to intermediate risk of stroke (eg, CHADS2 score of 0 or 1 during the first 12 months after placement of an intracoronary stent 
(bare metal or drug eluting), we suggest dual antiplatelet therapy rather than triple therapy (Grade 2C). At 12 months after intracoronary 
stent placement, antithrombotic therapy is suggested as for patients with AF and stable coronary artery disease (see section 3.1; American 
College of Chest Physicians, 2012, p e533S). 
• Recommendation 3.3. For patients with AF at intermediate to high risk of stroke (eg, CHADS2 score of 1 or greater) who experience an 
acute coronary syndrome and do not undergo intracoronary stent placement, we suggest for the first 12 months, adjusted-dose VKA therapy 
(INR 2.0-3.0) plus single antiplatelet therapy rather than dual antiplatelet therapy (eg, aspirin and clopidogrel) or triple therapy (eg, 
warfarin, aspirin, and clopidogrel) (Grade 2C). After the first 12 months, antithrombotic therapy is suggested as for patients with AF and 
stable coronary artery disease (see section 3.1).  
 
For patients with AF at low risk of stroke (eg, CHADS2 score of 0), we suggest dual antiplatelet therapy (eg, aspirin and clopidogrel) rather 
than adjusted-dose VKA therapy (INR 2.0-3.0) plus single antiplatelet therapy or triple therapy (eg, warfarin, aspirin, and clopidogrel) 
(Grade 2C). After the first 12 months, antithrombotic therapy is suggested as for patients with AF and stable coronary artery disease (see 








• Recommendation 3.4. For patients with AF being managed with a rhythm control strategy (pharmacologic or catheter ablation), we suggest 
that antithrombotic therapy decisions follow the general risk-based recommendations for patients with AF in section 2.1, regardless of the 
apparent persistence of normal sinus rhythm (Grade 2C; American College of Cardiology, 2012, p. e534S). 
• Recommendation 3.5: For patients with atrial flutter, we suggest that antithrombotic therapy decisions follow the same risk-based 
recommendations as for AF (American College of Chest Physicians, 2012, p. e534S). 
• Recommendation 4.1.1. For patients with AF of greater than 48 hours or unknown duration undergoing elective electrical or 
pharmacologic conversion, we recommend therapeutic anticoagulation (adjusted-dose VKA therapy, target UBR range 2.0-3.0, low 
molecular weight heparin at full venous thromboembolism treatment doses, or dabigatran) for at least 3 weeks before cardioversion or a 
transesophageal echocardiography (TEE)- guided approach with abbreviated anticoagulation before cardioversion rather than no 
anticoagulation (Grade 1B). We recommend therapeutic anticoagulation for at least 4 weeks after successful cardioversion to sinus rhythm 
rather than no anticoagulation, regardless of the baseline risk of stroke (Grade 1B). Decisions about anticoagulation beyond 4 weeks should 
be made in accordance with our risk-based recommendations for long-term antithrombotic therapy in section 2.1 (American College of 
Chest Physicians, 2012, p. e534S). 
• Recommendation 4.1.2. For patients with AF of documented duration of 48 h or less undergoing elective cardioversion (electrical or 
pharmacologic), we suggest starting anticoagulation at presentation (low-molecular-weight heparin or unfractionated heparin at full venous 
thromboembolism treatment doses) and proceeding to cardioversion for 3 weeks of therapeutic anticoagulation or a TEE-guided approach 
(Grade 2C). After successful cardioversion to sinus rhythm, we recommend therapeutic anticoagulation for at least 4 weeks rather than no 
anticoagulation, regardless of baseline stroke risk (Grade 2C). Decisions about long-term anticoagulation after cardioversion should be 
made in accordance with our risk-based recommendations for long-term antithrombotic therapy in section 2.1 (American College of Chest 
Physicians, 2012, pp. e533S-e534S). 
• Recommendation 4.2. For patients with AF and hemodynamic instability undergoing cardioversion (electrical or pharmacologic), we 
suggest that therapeutic-dose parenteral anticoagulation be started before cardioversion, if possible (Grade 2C), but that initiation of 
anticoagulation must not delay any emergency intervention (Grade 2C). After successful cardioversion to sinus rhythm, we suggest 
therapeutic anticoagulation for at least 4 weeks after successful cardioversion to sinus rhythm rather than no anticoagulation, regardless of 
baseline stroke risk (Grade 2C). Decisions about anticoagulation beyond 4 weeks should be made in accordance with our risk-based 
recommendations for long-term antithrombotic therapy in section 2.1 (American College of Chest Physicians, 2012, p. e534S). 
• Recommendation 4.3: “For patients with atrial flutter undergoing elective or urgent pharmacologic or electrical cardioversion, we suggest 
that the same approach to thromboprophylaxis be used as for patients with atrial fibrillation undergoing cardioversion (American College of 






Note: Adapted from “Antithrombotic Therapy for Atrial Fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest 
Physicians Evidence-Based Clinical Practice Guidelines,” J. J. You, D.E., Singer, P.A. Howard, D.A. Lane, M.H. Eckman, M. C., Fang … G.Y. H. Lip, 2012, 
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• For patients with valvular atrial fibrillation at high risk for stroke, defined as a CHA2DS2- VASc score of 
≥2, and acceptably low risk for hemorrhagic complications, chronic oral anticoagulant therapy with 
warfarin at a target INR of 2.0 to 3.0 is recommended (Class I; Level of Evidence A). 
• For patients with nonvalvular atrial fibrillation, a CHA2DS2-VASc score of ≥2, and acceptably low risk for 
hemorrhagic complications, oral anticoagulants are recommended (Class I). 
• Options include warfarin (INR, 2.0 to 3.0) (Level of Evidence A), dabigatran (Level of Evidence B), apixaban 
(Level of Evidence B), and rivaroxaban (Level of Evidence B). The selection of antithrombotic agent should 
be individualized on the basis of patient risk factors (particularly risk for intracranial hemorrhage), cost, 
tolerability, patient preference, potential for drug interactions, and other clinical characteristics, 
including time INR is in therapeutic range for patients taking warfarin. 
• For patients with nonvalvular atrial fibrillation and CHA2DS2-VASc score of 0, it is reasonable to omit 
antithrombotic therapy (Class IIa; Level of Evidence B). 
• For patients with nonvalvular atrial fibrillation, a CHA2DS2-VASc score of 1, and acceptably low risk 
for hemorrhagic complication, no antithrombotic therapy, anticoagulant therapy, or aspirin therapy may 
be considered (Class IIb; Level of Evidence C). The selection of antithrombotic agent should be 
individualized on the basis of patient risk factors (particularly risk for intracranial hemorrhage), cost, 
tolerability, patient preference, potential for drug interactions, and other clinical characteristics, 
including time INR is in therapeutic range for patients taking warfarin. 
• Closure of the left atrial appendage may be considered for high-risk patients with atrial fibrillation 
who are deemed unsuitable for anticoagulation if performed at a center with low rates of periprocedural 
complications and the patient can tolerate the risk of at least 45 d of postprocedural anticoagulation (Class 
IIb; Level of Evidence B; Meschia et al., 2014, p. 3802). 
Note: Adapted from “Guidelines for the primary prevention of stroke: A statement for healthcare 
professionals from the American Heart Association/American Stroke Association,” J.F. Meschia, C. 
Bushnell, B. Boden-Albala, L.T. Braun, D.M. Bravata, M.A. Creager, . . . J.A. Wilson, 2014, p. 3802. 
























CONSENT FORM FOR HUMAN PARTICIPATION IN RESEARCH 
UNIVERSITY OF NORTHERN COLORADO 
FAMILY PHYSICIANS OF GREELEY 
INFORMED CONSENT – NO SIGNATURE DOCUMENT 
Project Title: Stroke Reduction in Elderly Patients with Atrial Fibrillation 
Through Utilization of an Anticoagulation Toolkit in the Primary Care Setting 
Student Researcher: Rachel J. Mommer, BSN, BS, RN-BC, DNP-S 
Research Advisor: Kathleen N. Dunemn, PhD, APRN, CNM, School of Nursing 
 
Expert Consensus: A Delphi Study 
The purpose of the following Doctor of Nursing Practice Capstone Project is to develop 
an evidence-based anticoagulation toolkit comprised of an algorithm and guideline to 
assist primary care providers on improved diagnosis of atrial fibrillation and enhanced 
initiation and maintenance of oral anticoagulation to reduce the incidence of stroke in 
elderly patients with atrial fibrillation (AF). A summary of the rationale for selecting this 
topic and background information on AF can be forwarded by request. A chart review 
will be completed at Family Physicians of Greeley- Central to evaluate current practice, 
collecting demographics on patients with AF, in addition to diagnosis and treatment of 
AF in the primary care setting. All subjects’ initials within the chart review will be 
assigned a unique numerical value to maintain confidentiality. In addition, providers 
within various primary care and cardiology clinics throughout Northern Colorado will be 
requested to participate in this research.  
 
The evidence-based anticoagulation toolkit for this capstone project will be formulated 
from an extensive and current literature review, including the recommendations from 
national and international guidelines on anticoagulation with AF. Expert consensus will 
be obtained through a series of two surveys in alignment with the Delphi technique, 
striving for group consensus to create and evaluate the anticoagulation guideline with 
algorithm. Since the 1950’s, the Delphi technique has been used as a group 
communication tool to attain controlled, expert consensus for program structuring, needs 
evaluations, policy writing, and resource management.   
For the first round of the Delphi technique, a short survey will discuss expert experience 
and comfort level with diagnosing atrial fibrillation and prescribing anticoagulation for 
this high-risk population. For the second round of the Delphi method an anonymous 
summary of the 70% group consensus from the first round will be attached to a second 
survey assessing the benefits and challenges of this toolkit. In concordance with the 
Delphi technique, feedback to improve this anticoagulation toolkit is essential to improve 
its applicability and relevance to practice. For each round of the Delphi technique, the 
DNP student researcher is requesting the electronic survey be completed and returned to 
her private e-mail account within two weeks. Approximately 10 minutes will be required 
to complete the first round of the Delphi technique and 15-20 minutes for the second 
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round.  After completion of the two rounds of the Delphi technique, the data and 
demographics from the surveys and chart review will be statistically analyzed to compare 
and identify any gaps between evidence and practice. 
The purpose of this e-mail is to invite your participation in this research study. 
Participation is voluntary and all responses and subject identifiers will remain 
confidential and anonymous, including the aggregated group consensus obtained in 
Round 1 and summarized in Round 2. There are no foreseeable risks to the participants. 
All data collected from the chart reviews and Delphi surveys will be statistically analyzed 
and secured on a password protected zip drive, only accessible by the DNP student and 
her advisor. This is a quality improvement project to improve the diagnosis and 
management of atrial fibrillation within the primary are setting. If you have any 
questions, please contact one of the undersigned. 
Participation is voluntary. You may decide not to participate in this study and if you 
begin 
participation you may still decide to stop and withdraw at any time. Your decision will be 
respected and will not result in loss of benefits to which you are otherwise entitled. 
Having read 
the above and having had an opportunity to ask any questions, please electronically sign 
below if you would like to participate in this research. A copy of this form will be given 
to you to retain for future reference. If you have any concerns about your selection or 
treatment as a research participant, please contact Sherry May, IRB Administrator, Office 
of Research, 25 Kepner Hall, University of Northern Colorado Greeley, CO 80639; 970-
351-1910. 
 
If you wish to participate in this study, please access and complete the attached document 
“Phase 1: Delphi Study Round One Survey” and return the completed survey to 
rachel.j.mommer@gmail.com. If you know any colleagues who would be interested in 
participating in this study, please forward this consent form and Delphi survey via e-mail.  
 
Thank you for your time and consideration. 
 
Student Researcher: Rachel J. Mommer, BSN, BA, RN-BC, DNP-S 
E-mail: Rachel.j.mommer@gmail.com 
Phone: (970) 481-5523 
 
Research Advisor: Kathleen N. Dunemn, PhD, APRN, CNM  
E-mail: Kathleen.Dunemn@unco.edu  
Phone: (970) 351-3081/ (303) 649-5581 
 
 

























1) Please fill in the following demographics. 
Title: MD DO NP PA   
Specialty: ________________________ 
Number of years in practice: _______ 
 
2) What patient presentation (symptoms and risk factors) warrants a work-up for 
atrial fibrillation (AF)? 
 





4) Explain your work-up for diagnosing atrial fibrillation.  
 
5) How do you typically treat patients with atrial fibrillation? 
 
6) Which factors influence your decision to initiate anticoagulation in a patient with 
atrial fibrillation, including selection of a particular agent? 
 
7) What is your comfort level with prescribing and managing anticoagulation for 
atrial fibrillation (scale of 0 very uncomfortable to 5 very comfortable).    
 
8) Do you use any screening tools to assess for stroke and bleeding risk with 
anticoagulation and AF (ex. CHADS2, CHA2DS2-VASc, HAS-BLED, etc.)? 
 
9) This question addresses AF guidelines and algoirthms.  
 
a. What guidelines, algorithms, and resources do you reference for 
anticoagulating and treating atrial fibrillation? 
 
b. What would you find most helpful in an AF algorithm or guideline? 
 
 
c. What would you find least helpful in an AF algorithm or guideline? 
 
10) What would help you improve your management of anticoagulation for patients 
with atrial fibrillation (ex. algorithms, community resources, specialists, shared 








































5) Was this toolkit inclusive of current evidence-based practice and guidelines on 




6) What are the benefits of this toolkit?  
 
7) What are the challenges of this toolkit? 
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